thymidine has been researched along with Hepatitis B, Chronic in 330 studies
Hepatitis B, Chronic: INFLAMMATION of the LIVER in humans caused by HEPATITIS B VIRUS lasting six months or more. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the efficacy and safety of treating HBV-positive mothers with telbivudine in early and middle pregnancy to prevent mother-to-infant HBV transmission." | 9.24 | Telbivudine treatment started in early and middle pregnancy completely blocks HBV vertical transmission. ( Hao, A; Li, F; Ma, L; Song, M; Sun, W; Zhao, B; Zhao, S; Zhou, L, 2017) |
| "The purpose of the study was to compare the efficacy and safety of 208-week sequential therapy with telbivudine and entecavir in HBeAg-positive chronic hepatitis B (CHB) patients with suboptimal responses to 24 weeks of Peg-IFNα-2a therapy." | 9.24 | Comparison of 208-week sequential therapy with telbivudine and entecavir in HBeAg-positive chronic hepatitis B patients with suboptimal responses to 24 weeks of Peg-IFNα-2a therapy: An open-labelled, randomized, controlled, "real-life" trial. ( Chen, XF; Chen, XP; Luo, XD; Zhou, Y, 2017) |
| "To explore the effect of Telbivudine (LDT) Tablet combined with Jianpi Bushen Recipe (JBR) on serum hepatitis B virus (HBV) specific cytotoxic T lymphocyte (CTL) and HBeAg seroconversion in chronic hepatitis B (CHB) patients." | 9.22 | [Effect of Telbivudine Tablet Combined Jianpi Bushen Recipe on HBV Specific Cytotoxic T Lymphocyte and HBeAg Seroconversion in Patients with HBeAg Positive Chronic Hepatitis B]. ( Dai, YP; Fu, DC; Guo, XY; Hua, Z; Li, YG; Tu, KW; Xu, W, 2016) |
| "To investigate the efficacy and safety of 104-week sequential therapy with telbivudine or entecavir in HBeAg-positive chronic hepatitis B (CHB) patients with suboptimal responses to 24-week pegylated interferon-α-2a (PEG-IFN-α-2a) therapy." | 9.22 | [Efficacy of 104-week sequential therapy with telbivudine or entecavir in HBeAg-positive chronic hepatitis B patients with suboptimal responses to 24-week therapy with pegylated interferon-α-2a]. ( Chen, R; Chen, XF; Chen, XP; Huang, J; Luo, XD, 2016) |
| "This study investigated the antiviral efficacy and safety of telbivudine in combination with pegylated interferon (PegIFN) alpha-2a in chronic hepatitis B (CHB) patients." | 9.20 | Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy. ( Avila, C; Bao, W; Chuang, WL; Fainboim, H; Foster, GR; Gane, E; Lau, G; Lim, SG; Manns, M; Marcellin, P; Naoumov, N; Peng, CY; Rizzetto, M; Safadi, R; Trylesinski, A; Wedemeyer, H; Wursthorn, K, 2015) |
| "The purpose of this study was to analyze the cost-effectiveness of lamivudine (LMV), telbivudine (LdT), and entecavir (ETV) in treatment of chronic hepatitis B with adefovir dipivoxil (ADV) resistance." | 9.20 | Cost-effectiveness analysis of lamivudine, telbivudine, and entecavir in treatment of chronic hepatitis B with adefovir dipivoxil resistance. ( Liu, Y; Qiu, P; Wang, G; Wen, J; Wen, P; Xiao, X; Xu, L; Zhou, SF, 2015) |
| " The aim of this study was to assess whether prolonged telbivudine treatment improves liver inflammation and fibrosis." | 9.20 | Long-Term Telbivudine Treatment Results in Resolution of Liver Inflammation and Fibrosis in Patients with Chronic Hepatitis B. ( Bao, W; Chen, C; Dong, Y; Goodman, Z; Hou, JL; Jia, J; Naoumov, NV; Niu, J; Ren, H; Shi, G; Tan, D; Trylesinski, A; Wan, M; Wang, Q; Wang, Y; Wei, L; Xie, Q; Xu, D, 2015) |
| "We used serum creatinine-based equations (ie, Cockcroft-Gault, Modification of Diet in Renal Disease, and Chronic Kidney Disease Epidemiology Collaboration) to estimate GFR (eGFR) in adults with chronic hepatitis B virus infection and compensated liver disease who participated in a phase III, randomized, double-blind study comparing the efficacy and safety of telbivudine (600 mg/d) and lamivudine (100 mg/d) for 2 years (the GLOBE study) and in long-term extension studies (4-6 years), as well as in patients with decompensated cirrhosis (2 years)." | 9.19 | Telbivudine improves renal function in patients with chronic hepatitis B. ( Bosset, S; Buti, M; Deray, G; Di Bisceglie, A; Gane, EJ; Lai, CL; Liaw, YF; Lim, SG; Papatheodoridis, G; Rasenack, J; Samuel, D; Trylesinski, A; Uddin, A; Wang, Y, 2014) |
| "To prospectively observe the long-term antiviral efficacy and safety of telbivudine (LDT) administered as a monotherapy and as a combination therapy with adefovir dipivoxil (ADV) in patients diagnosed with chronic hepatitis B (CHB) and positivity for hepatitis B e antigen (HBeAg)." | 9.19 | [Long-term efficacy and safety of telbivudine as monotherapy and as combination therapy with adefovir dipivoxil in HBeAg-positive chronic hepatitis B patients]. ( Chang, L; Du, Y; Jia, T; Li, H; Li, W; Liu, L; Liu, Y; Peng, D, 2014) |
| "Little observational data exist describing telbivudine (LdT) or lamivudine (LAM) use in late pregnancy for preventing hepatitis B mother-to-child transmission (MTCT) in real-world settings." | 9.19 | Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice. ( Liu, X; Pan, CQ; Pang, Q; Tian, R; Yan, M; Zhang, H, 2014) |
| "To observe the long-term efficacy and safety of telbivudine (LdT) for pregnant women with chronic hepatitis B (CHB) and their children born from the treatment period." | 9.19 | [Long-term efficacy and safety of telbivudine in the treatment of childbearing patients with chronic hepatitis B]. ( Lu, C; Pan, H; Zheng, J; Zhou, Y, 2014) |
| "The objective of this study was to compare the efficacy and safety of two rescue strategies for hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) patients with resistance to adefovir dipivoxil (ADV)." | 9.17 | Efficacy and safety of telbivudine plus adefovir dipivoxil combination therapy and entecavir monotherapy for HBeAg-positive chronic hepatitis B patients with resistance to adefovir dipivoxil. ( Chen, EQ; Liu, K; Lu, JJ; Ma, YJ; Tang, H; Wang, J, 2013) |
| "Telbivudine (LdT) has demonstrated potent antiviral activity in nucleos(t)ide analogue (NA)-naïve chronic hepatitis B patients (CHB), but data on its efficacy in NA-experienced patients are limited." | 9.17 | Efficacy of telbivudine treatment for hepatitis B e antigen-positive chronic hepatitis B patients with poor response to adefovir dipivoxil. ( Bai, XF; Li, Y; Lian, JQ; Wang, JP; Zhang, Y, 2013) |
| "The aim of this study was to investigate the efficacy of sequential use of telbivudine in hepatitis B e antigen (HBeAg)-positive chronic hepatitis B patients with partial responses to pegylated interferon." | 9.17 | Efficacy of sequential use of telbivudine in hepatitis B e antigen-positive chronic hepatitis B patients with partial responses to pegylated interferon: a pilot study. ( Deng, H; Gao, Z; Huang, Z; Lin, C; Peng, L; Zhao, Z; Zheng, Y, 2013) |
| " In recent years, there have been gradually increasing reports on the safety of telbivudine (LdT) treatment for chronic hepatitis B virus (HBV) infection in the third trimester of pregnancy to block mother-to-infant transmission (MTIT) of HBV; however, the safety of LdT treatment for chronic HBV infection for the entire pregnancy has not been reported." | 9.17 | Safety of telbivudine treatment for chronic hepatitis B for the entire pregnancy. ( Cai, H; Liu, M; Yi, W, 2013) |
| "In the phase-III GLOBE/015 studies, telbivudine demonstrated superior efficacy vs lamivudine during 2-year treatment in HBeAg-positive and HBeAg-negative chronic hepatitis B (CHB)." | 9.17 | Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B. ( Bao, W; Chan, HL; Gane, EJ; Hou, J; Jia, J; Liaw, YF; Naoumov, NV; Niu, J; Papatheodoridis, G; Thongsawat, S; Trylesinski, A; Wan, M; Wang, Y, 2013) |
| "Telbivudine is a nucleoside analogue that has been approved for the treatment of chronic hepatitis B virus (HBV) infection in adults at 600 mg/day." | 9.17 | Phase I, open-label, single-dose study to evaluate the pharmacokinetics and safety of telbivudine in children and adolescents with chronic hepatitis B. ( Bosheva, M; Ke, J; Praestgaard, J; Qi, Y; Stein, DS; Uy, G, 2013) |
| "The objective of this study was to evaluate the short-term efficacy and safety of telbivudine therapy as compared to lamivudine therapy in liver failure patients with chronic hepatitis B virus (HBV) infection." | 9.17 | Efficacy and safety of telbivudine therapy in liver failure patients with chronic hepatitis B virus infection. ( Chen, H; Fan, C; Gong, Z; Wang, L, 2013) |
| "To investigate the therapeutic benefit of sequential interferon alpha-1b (IFNa-1b) in patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) who showed early complete response to telbivudine (LdT) treatment, and to explore the clinical value of serum hepatitis B surface antigen (HBsAg) for predicting sustained virological response (SVR)." | 9.17 | [Clinical observations of sequential interferon therapy following complete response to telbivudine treatment in chronic hepatitis B patients]. ( Guo, SH; Sandeep, KK; Zhang, DZ; Zhang, QF; Zhang, W, 2013) |
| "Telbivudine therapy with tenofovir intensification at Week 24, where indicated by the Roadmap strategy, appears effective and well tolerated for the treatment of chronic hepatitis B." | 9.17 | 52-week efficacy and safety of telbivudine with conditional tenofovir intensification at week 24 in HBeAg-positive chronic hepatitis B. ( Bessone, F; Chan, HL; Cheinquer, H; Daruich, J; Dong, Y; Fassio, E; Komolmit, P; Ono, SK; Pathan, R; Pessôa, MG; Piratvisuth, T; Sukeepaisarnjaroen, W; Tanwandee, T; Trylesinski, A; Zeuzem, S, 2013) |
| "Telbivudine reduces hepatitis B virus (HBV) DNA and normalizes levels of alanine aminotransferase (ALT) in patients with chronic hepatitis B (CHB)." | 9.16 | Telbivudine prevents vertical transmission from HBeAg-positive women with chronic hepatitis B. ( Cao, MK; Han, GR; Jiang, HX; Pan, CQ; Wang, CM; Wang, GJ; Yue, X; Zhao, W, 2012) |
| "To study the influences of warming kidney prescription on antiviral therapeutic efficacy and creatine kinase (CK) level in telbivudine-treated HBeAg-positive chronic hepatitis B patients with kidney yang deficiency syndrome." | 9.16 | [Influences of warming kidney prescription on antiviral therapeutic efficacy and creatine kinase in telbivudine-treated HBeAg-positive chronic hepatitis B patients]. ( Fan, XJ; Hu, XY; Liu, GW; Nie, HM; Zhang, Y; Zhong, S, 2012) |
| "The present phase IIIb, randomized, double-blind, multicentre global trial assessed the antiviral efficacy and safety of telbivudine switch in chronic hepatitis B (CHB) patients who exhibited persistent viraemia under lamivudine therapy." | 9.15 | Efficacy of switching to telbivudine in chronic hepatitis B patients treated previously with lamivudine. ( Chen, Y; Hwang, SG; Jia, JD; Lopez, P; Safadi, R; Wei, L; Xie, Q; Yin, YK; Zuckerman, E, 2011) |
| "In the GLOBE trial, telbivudine demonstrated superior efficacy to lamivudine at 2 years in patients with chronic hepatitis B (CHB)." | 9.15 | Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis B. ( Avila, C; Bao, W; Chao, YC; Gane, EJ; Hou, J; Hsu, CW; Jia, J; Leung, N; Liaw, YF; Lopez, P; Moon, YM; Niu, J; Samuel, D; Thongsawat, S; Wan, M; Wang, Y, 2011) |
| "To investigate the efficacy of Telbivudine and Entecavir for therapy of HBeAg positive chronic hepatitis B for 52 weeks." | 9.15 | [Study on the efficacy and HBeAg seroconversion related factors of telbivudine and entecavir therapy in HBeAg positive chronic hepatitis B patients]. ( Chen, R; Chen, WL; Chen, XF; Chen, XP; Huang, J; Luo, XD; Ma, XJ, 2011) |
| "Telbivudine used during pregnancy in CHB HBeAg+highly viremic mothers can safely reduce perinatal HBV transmission." | 9.15 | A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. ( Bai, SF; Cao, MK; Fang, ZX; Han, GR; Jiang, HX; Tang, X; Wang, CM; Wang, GJ; Yue, X; Zhao, W, 2011) |
| "The GLOBE trial has compared the efficacy and safety of telbivudine versus lamivudine treatment over 2 years in patients with chronic hepatitis B." | 9.14 | 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. ( Albanis, E; Brown, NA; Bzowej, N; Cakaloglu, Y; Chen, Y; Galil, K; Gane, E; Han, SH; Heathcote, EJ; Hwang, SG; Lai, CL; Leung, N; Liaw, YF; Manns, M; Naoumov, NV; Niu, J; Papatheodoridis, G; Tong, MJ; Wang, Y; Zeuzem, S, 2009) |
| "To study the therapeutic efficacy of 48-week telbivudine treatment on cirrhosis resulting from chronic hepatitis B." | 9.14 | [Telbivudine treatment on cirrhosis resulting from chronic hepatitis B]. ( Han, T; Liang, J; Xiao, SX, 2009) |
| "61 pregnant chronic hepatitis B (CHB) patients were enrolled and 31 patients were treated by telbivudine 600 mg once daily, 30 patients in the control group were not received antiviral treatment." | 9.14 | [Blocking intrauterine infection by telbivudine in pregnant chronic hepatitis B patients]. ( Wang, L; Zhang, LJ, 2009) |
| "We characterized the early viral kinetic profiles of telbivudine and entecavir and the effects of these potent nucleoside analogs on hepatitis B virus (HBV) DNA and alanine aminotransferase levels in adults with hepatitis B e antigen-positive compensated chronic hepatitis B." | 9.14 | Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B. ( Avila, C; Bao, W; Herrmann, E; Kim, JH; Lee, HC; Lee, HJ; Lee, MS; Lee, YJ; Lee, YS; Lopez, P; Suh, DJ; Um, SH; Zeuzem, S, 2010) |
| "The aim of this work was to compare the early antiviral effectiveness of telbivudine and entecavir in the treatment of patients with hepatitis B e antigen (HBeAg)-positive HBV." | 9.14 | A 24-week, parallel-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients. ( Chen, YP; Dai, ZJ; Shi, KQ; Ye, C; Zheng, MH, 2010) |
| "To analyze antiviral effects of telbivudine in patients with chronic hepatitis B." | 9.14 | [Clinical antiviral effects of telbivudine in patients with chronic hepatitis B]. ( Guo, HH; Ji, SW; Jiao, J; Li, Y; Siqingtu, NL; Wang, JB; Xu, Y; Zhang, YG; Zhao, P; Zhou, CY, 2010) |
| "To evaluate the efficacy and safety of telbivudine (LDT) in hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) patients who have high baseline alanine aminotransferase (ALT) levels between 10 and 20 times the upper limit of normal." | 9.14 | Efficacy of telbivudine in HBeAg-positive chronic hepatitis B patients with high baseline ALT levels. ( Jin, X; Lv, GC; Ma, WJ; Yang, YD; Ying, LJ; Zheng, L, 2010) |
| "To evaluate the efficacy and safety of telbivudine (LDT) versus entecavir treatments in hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) patients." | 9.13 | [Short-term results of telbivudine versus entecavir treatments in HBeAg-positive chronic hepatitis B patients in China]. ( Guo, SH; He, H; Ren, H; Shi, KQ; Shi, XF; Wang, ZY; Zeng, WQ; Zhang, DZ, 2008) |
| "In Chinese patients with chronic hepatitis B, telbivudine treatment for 52 weeks provided greater antiviral and clinical efficacy than lamivudine, with less resistance." | 9.13 | Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial. ( Brown, NA; Chao, G; Chen, C; Chen, Y; Constance, BF; Harb, G; He, Y; Hou, J; Jia, J; Niu, J; Ren, H; Tan, D; Wan, M; Wang, Q; Wang, Y; Wei, L; Wu, S; Xu, D; Xu, J; Yin, YK; Zhou, X; Zhu, L, 2008) |
| "The pharmacokinetics of telbivudine were evaluated in adult patients with chronic hepatitis B virus (HBV) infection following once-daily oral administration at escalating doses of 25, 50, 100, 200, 400, and 800 mg/day for 4 weeks." | 9.12 | Pharmacokinetics of telbivudine following oral administration of escalating single and multiple doses in patients with chronic hepatitis B virus infection: pharmacodynamic implications. ( Brown, NA; Chao, GC; Lai, CL; Lim, SG; Lloyd, DM; Zhou, XJ, 2006) |
| "In this double-blind, phase 3 trial, 1370 patients with chronic hepatitis B were randomly assigned to receive 600 mg of telbivudine or 100 mg of lamivudine once daily." | 9.12 | Telbivudine versus lamivudine in patients with chronic hepatitis B. ( Brown, NA; Bzowej, N; Chao, G; Chen, Y; Constance, BF; Di Bisceglie, AM; Gane, E; Goodman, Z; Heathcote, EJ; Hsu, CW; Lai, CL; Liaw, YF; Moon, YM; Naoumov, NV; Rasenack, J; Thongsawat, S; Wang, Y; Zeuzem, S, 2007) |
| "This randomized, double-blind, multicenter trial evaluated the efficacy and safety of telbivudine 400 or 600 mg/day and telbivudine 400 or 600 mg/day plus lamivudine 100 mg/day (Comb400 and Comb600) compared with lamivudine 100 mg/day in hepatitis B e antigen (HBeAg)-positive adults with compensated chronic hepatitis B." | 9.11 | A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. ( Brown, NA; Chao, G; Han, S; Hann, HW; Lai, CL; Leung, N; Lloyd, D; Myers, M; Poynard, T; Teo, EK; Tong, M; Wong, F, 2005) |
| " The antiviral efficacy and safety of telbivudine (LdT) have been shown in patients with CHB infection, and LdT is approved as a class B drug for pregnancy." | 8.95 | Telbivudine therapy for gravidas with chronic hepatitis B infection and patients at risk of renal impairment. ( Chen, T; Liu, J; Zhao, Y, 2017) |
| "Telbivudine can cause severe side effects, including myositis, neuritis, rhabdomyolysis, and lactic acidosis." | 8.95 | Rhabdomyolysis, lactic acidosis, and multiple organ failure during telbivudine treatment for hepatitis B: a case report and review of the literature. ( Chen, Z; Deng, M; Deng, Q; Deng, X; Li, D; Qiu, X; Yu, Z; Zheng, J, 2017) |
| "Although there have been reports on telbivudine-induced myopathy and creatine kinase (CK) elevation, few reports focus on its effect on hyperlactatemia in patients with chronic hepatitis B (CHB)." | 8.91 | Continuous venovenous hemodiafiltration for hyperlactatemia caused by telbivudine in a patient with chronic hepatitis B: a case report and update review. ( Liu, H; Wang, YH; Wu, BQ, 2015) |
| "A meta-analysis to compare the efficacy and safety of telbivudine (TBV) and lamivudine (LAM) in patients with chronic hepatitis B (CHB), assessed via changes in serum alanine aminotransferase (ALT) levels." | 8.91 | Changes in serum alanine aminotransferase levels in telbivudine versus lamivudine treatment for chronic hepatitis B: a meta-analysis. ( Dai, M; Li, YM; Wang, FL; Xiao, GM; Yang, HZ; Zhang, JS, 2015) |
| "We performed a meta-analysis to compare the efficacies of entecavir and telbivudine in treatment-naive hepatitis B e-antigen (HBeAg)-positive Asian patients with chronic hepatitis B (CHB)." | 8.90 | Telbivudine versus entecavir for nucleos(t)ide-naive HBeAg-positive chronic hepatitis B: a meta-analysis. ( Liu, H; Wan, G; Wang, X; Yang, Z; Zeng, H, 2014) |
| "Telbivudine, one of the oral anti-hepatitis B virus (HBV) nucleoside analogues, has been used for more than 5 years to treat HBeAg-positive and -negative chronic hepatitis B (CHB) patients." | 8.89 | Telbivudine treatment in chronic hepatitis B: experience from China. ( Jia, J; You, H, 2013) |
| "All oral nucleoside analogues against hepatitis B virus, with an exception of telbivudine, have been reported causing lactic acidosis (LA)." | 8.89 | Lactic acidosis during telbivudine treatment for HBV: a case report and literature review. ( Hu, P; Huang, XY; Jin, JL; Lu, JH; Luo, SS; Weng, XH; Zhang, JM, 2013) |
| "Telbivudine and entecavir are two pharmacologic agents recommended and also widely used for the treatment of chronic hepatitis B in most Asian countries." | 8.89 | Comparison of the forty-eight week efficacy between telbivudine and entecavir in HBeAg-positive Asian patients with chronic hepatitis B: A meta-analysis. ( Feng, Q; Hu, HD; Hu, P; Liu, Q; Ren, H; Sun, H; Wang, N, 2013) |
| "The purpose of this study was to evaluate the efficacy of lamivudine (LAM) versus telbivudine (LdT) in the treatment of chronic hepatitis B (CHB)." | 8.89 | Lamivudine versus telbivudine in the treatment of chronic hepatitis B: a systematic review and meta-analysis. ( Jiang, H; Wang, J; Zhao, W, 2013) |
| "To compare the effects of telbivudine (LDT) and entecavir (ETV) in treatment of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B by meta-analysis." | 8.88 | Effects of telbivudine and entecavir for HBeAg-positive chronic hepatitis B: a meta-analysis. ( Su, QM; Ye, XG, 2012) |
| " Currently, several drugs, such as lamivudine and telbivudine, are recommended for treatment of patients with chronic hepatitis B." | 8.86 | Comparison of the efficacy of lamivudine and telbivudine in the treatment of chronic hepatitis B: a systematic review. ( Chen, L; Dai, X; Fan, X; Tang, L; Zhao, S; Zhou, R, 2010) |
| "This paper presents a summary of the evidence review group (ERG) report into the clinical effectiveness and cost-effectiveness of telbivudine for the treatment of chronic hepatitis B (CHB) in adults based upon a review of the manufacturer's submission to the National Institute for Health and Clinical Excellence (NICE) as part of the single technology appraisal (STA) process." | 8.85 | Telbivudine for the treatment of chronic hepatitis B infection. ( Cooper, K; Harris, P; Hartwell, D; Jones, J, 2009) |
| "Clinical trials demonstrated telbivudine to be a safe and potent antiviral agent for treatment of chronic hepatitis B." | 8.84 | A review of telbivudine for the management of chronic hepatitis B virus infection. ( Chan, HL; Lui, YY, 2008) |
| "Telbivudine is a novel, orally administered nucleoside analog under development for use in the treatment of chronic hepatitis B." | 8.83 | Telbivudine: a novel nucleoside analog for chronic hepatitis B. ( Kim, JW; Louie, SG; Park, SH, 2006) |
| "To investigate postpartum hepatic flares and associated factors in highly viremic pregnant patients in the immune tolerance phase who adopted telbivudine (LdT) treatment in the last trimester to reduce vertical transmission of hepatitis B virus." | 8.02 | Clinical and Immunological Factors Associated with Postpartum Hepatic Flares in Immune-Tolerant Pregnant Women with Hepatitis B Virus Infection Treated with Telbivudine. ( Chen, X; Hu, Z; Lu, J; Ma, L; Wang, X; Zheng, S; Zhu, Y, 2021) |
| "Treatment with lamivudine or telbivudine for active CHB in early pregnancy appears to be safe and effective for controlling maternal disease as well as interrupting MTCT." | 7.88 | Safety and efficacy of lamivudine or telbivudine started in early pregnancy for mothers with active chronic hepatitis B. ( Bai, Y; Cai, H; He, T; Jia, J; Liu, M; Ou, X; Yi, W, 2018) |
| "To estimate long-term outcomes after treatment modification in patients with chronic hepatitis B (CHB) treated with entecavir (ETV) and telbivudine (LdT)." | 7.88 | Real World Experience of Telbivudine Versus Entecavir in Patients with Chronic Hepatitis B, Including Long-Term Outcomes after Treatment Modification. ( Cho, YS; Choi, JW; Jeon, HH; Kim, SH; Lee, CK; Lee, YK; Park, BK; Seo, JH; Won, SY, 2018) |
| "9% of patients on telbivudine treatment were reported to develop severe elevation of serum creatine phosphokinase (CPK) levels, but related clinical disease, like lactic acidosis (LA) and rhabdomyolysis (RM) were rare." | 7.88 | Case report: lactic acidosis and rhabdomyolysis during telbivudine and tenofovir treatment for chronic hepatitis B. ( Hu, YK; Huang, YX; Jin, JL; Ying, Y; Zhang, JM; Zhang, WH, 2018) |
| "The aim of this study was to evaluate clinical efficacy of telbivudine in treatment of hepatitis B virus-associated glomerulonephritis (HBV-GN)." | 7.88 | Effectiveness of telbivudine antiviral treatment in patients with hepatitis B virus-associated glomerulonephritis: A 104-week pilot study. ( Gou, W; Qiao, B; Wang, Y; Yan, Z; Zhang, H, 2018) |
| " In this study, we reported a CHB patient with decompensated cirrhosis showing a significant improvement in massive proteinuria along with elevation of estimated glomerular filtration rate (eGFR) after 1 year treatment with telbivudine." | 7.85 | Improvement of telbivudine on renal function and massive proteinuria: A case report. ( Liu, J; Yao, N; Zhao, Y, 2017) |
| "Chronic hepatitis B virus-infected women who received telbivudine beginning at week 24 or 28 of gestation were enrolled and then followed up to 52 weeks postpartum." | 7.85 | Hepatic flare after telbivudine withdrawal and efficacy of postpartum antiviral therapy for pregnancies with chronic hepatitis B virus. ( Cao, F; Chen, T; Feng, W; Guo, D; Jin, D; Jin, L; Liu, J; Qi, C; Tian, Z; Wang, J; Yan, T; Yuan, N; Zhang, S; Zhao, Y, 2017) |
| "Thirty patients with chronic hepatitis B were enrolled and serum samples were collected at multiple time points during treatment with telbivudine (LdT)." | 7.85 | Small surface antigen variants of HBV associated with responses to telbivudine treatment in chronic hepatitis B patients. ( Dong, H; He, Y; Hou, J; Jin, W; Kang, H; Shen, Y; Sun, J; Wang, S; Zhao, G; Zhou, B; Zhu, Y, 2017) |
| "Telbivudine, an FDA pregnancy category B drug, has been found to reduce hepatitis B virus (HBV) perinatal transmission with no safety concerns in infants aged up to 1 year." | 7.85 | Long-term safety and efficacy of telbivudine in infants born to mothers treated during the second or third trimesters of pregnancy. ( Ding, Y; Han, GR; Jiang, HX; Wang, CM; Wang, GJ; Yue, X; Zhao, W; Zhou, L, 2017) |
| "A subgroup analysis of a GLOBE study identified subgroups of chronic hepatitis B (CHB) patients with excellent outcomes to telbivudine (LdT) treatment." | 7.83 | Efficacy and resistance to telbivudine treatment in chronic hepatitis B patients with favorable predictors: a multicenter study in Taiwan. ( Chen, TM; Hsieh, TY; Hsu, YC; Kao, JH; Lin, CL; Peng, CY; Su, TH; Tseng, KC; Wang, CC; Yang, SS, 2016) |
| "Telbivudine is a relatively novel oral nucleoside analogue with favourable efficacy and tolerability in treatment-naïve chronic hepatitis B virus (HBV) infection, but its data in kidney transplant recipients (KTRs) was lacking." | 7.83 | Use of telbivudine in kidney transplant recipients with chronic hepatitis B virus infection: A preliminary experience. ( Chan, TM; Yap, DY, 2016) |
| "Data comparing the clinical outcomes of telbivudine (LdT) and entecavir (ETV) in elderly patients with chronic hepatitis B are limited." | 7.83 | Comparison of efficacy and renal safety of telbivudine and entecavir in treatment-naive elderly patients with chronic hepatitis B. ( Law, ST; Lee, MK; Li, KK; Mok, CK, 2016) |
| "To investigate serum interleukin (IL)-38 level and its clinical role in predicting virological response (VR) to telbivudine (LdT) in patients with chronic hepatitis B (CHB)." | 7.83 | Elevated serum interleukin-38 level at baseline predicts virological response in telbivudine-treated patients with chronic hepatitis B. ( Gao, PJ; Jiang, YF; Wang, HJ; Wang, XR; Zhang, ML, 2016) |
| "Tenofovir disoproxil fumarate (TDF) is newly available for treatment of chronic hepatitis B patients in China." | 7.83 | Cost-effectiveness analysis of tenofovir disoproxil fumarate for treatment of chronic hepatitis B in China. ( Gao, Y; Ke, W; Liu, L; Yang, Y; Yao, Z; Ye, X; Zhang, C; Zhou, S, 2016) |
| "Thirty-six HBeAg-positive patients with chronic hepatitis B (CHB) were enrolled for 52-week telbivudine monotherapy and were followed at treatment week (TW)-0, 4, 12, 24 and 52." | 7.81 | Telbivudine therapy may shape CD4(+) T-cell response to prevent liver fibrosis in patients with chronic hepatitis B. ( Jia, M; Jiang, W; Li, J; Li, L; Liu, Y; She, W; Wang, J, 2015) |
| "We studied the growth and development of children prenatally exposed to telbivudine used to treat chronic hepatitis B virus (HBV) infection in their mothers." | 7.81 | Growth and development of children prenatally exposed to telbivudine administered for the treatment of chronic hepatitis B in their mothers. ( Cai, H; Shen, Y; Wang, Y; Zeng, H, 2015) |
| " These pregnant females developed lamivudine (LAM)- or telbivudine (LdT)-resistant chronic hepatitis B and received tenofovir (TDF) therapy (300 mg/d), and its curative effect, maternal and perinatal adverse events, fetal growth and development, and neonatal prognosis were evaluated." | 7.81 | Tenofovir rescue therapy in pregnant females with chronic hepatitis B. ( Cai, HD; Cao, YJ; Hu, YH; Liu, M; Yi, W, 2015) |
| "To explore the antiviral efficacy, safety and protective ability against mother-to-infant transmission of telbivudine in pregnant patients with chronic hepatitis B (CHB) during the first trimester." | 7.81 | [Clinical observation of telbivudine's antiviral efficacy and protection against mother-to-infant transmission of chronic hepatitis B during the first trimester of pregnancy]. ( Chen, C; Chen, F; Cheng, Q; Dai, Y; Gong, F; Lin, X; Tu, X, 2015) |
| "This study was aimed to evaluate the long-term effects of telbivudine (LdT) in the treatment of chronic hepatitis B (CHB) and HBV-related liver cirrhosis (LC) and to observe the changes of immunological responses during LdT treatment." | 7.81 | Efficacy of telbivudine in the treatment of chronic hepatitis b and liver cirrhosis and its effect on immunological responses. ( Gao, X; Liu, P; Lu, XD; Lu, YQ; Meng, N; Tang, WX; Wang, M; Yan, W; Zhang, SJ, 2015) |
| "The aim of this study was to evaluate the estimated glomerular filtration rate (eGFR) during telbivudine (LdT) versus entecavir (ETV) treatment in chronic hepatitis B (CHB) patients with underlying comorbidities such as diabetes mellitus (DM), hypertension, and cirrhosis." | 7.81 | Comparison of the Effects of Telbivudine and Entecavir Treatment on Estimated Glomerular Filtration Rate in Patients with Chronic Hepatitis B. ( Ahn, SH; Han, KH; Kim, BK; Kim, DY; Kim, SU; Ku, HJ; Lee, S; Park, JY; Song, K, 2015) |
| "To compare the efficacy of telbivudine monotherapy and telbivudine combination therapy with adefovir in patients with nucleos(t)ide-naive chronic hepatitis B, high-level hepatitis B virus (HBV) load and hepatitis B e antigen (HBeAg)-positivity, and to explore the relationship between treatment regimen adherence and treatment outcomes." | 7.81 | [Efficacy and safety of telbivudine alone and combined with adefovir for the treatment of nucleos(t)ide-naive chronic hepatitis B in patients with high-level hepatitis B virus load]. ( Dang, B; Kang, W; Liu, Q; Sun, Y; Wang, C; Yao, N; Yu, Z; Zhao, K, 2015) |
| "To compare renal function in chronic hepatitis B (CHB) patients before and after antiviral treatment with either telbivudine or entecavir administered as monotherapy,as well as to assess the impact of these antivirals on renal function in patients with mild renal impairment and to provide evidence for optimizing each as an antiviral treatment of CHB." | 7.81 | [Influence of monotherapy with telbivudine or entecavir on renal function in patients with chronic hepatitis B]. ( Li, W; Zhang, D, 2015) |
| "Previous studies have demonstrated that the treatment of chronic hepatitis B (CHB) infection with adefovir (ADV) can impair renal function." | 7.80 | Telbivudine protects renal function in patients with chronic hepatitis B infection in conjunction with adefovir-based combination therapy. ( Kim, HY; Kim, YJ; Lee, HJ; Lee, HS; Lee, JH; Lee, M; Oh, S; Yeum, TS; Yoon, JH; Yu, SJ, 2014) |
| "Telbivudine therapy is generally safe and well tolerated among adult Indonesian patients with chronic hepatitis B." | 7.80 | An observational study to evaluate the safety and efficacy of telbivudine in adults with chronic hepatitis B. ( Lesmana, LA; Sulaiman, A, 2014) |
| "This study aimed to investigate the antiviral efficacy of telbivudine concurrent with initiation of chemotherapy in HBsAg-positive patients with lymphoma." | 7.80 | Antiviral efficacy analysis of telbivudine concurrent with the first cycle of chemotherapy in HBsAg-positive lymphoma patients. ( Guo, H; Huang, L; Li, W; Liang, Z; Wei, X, 2014) |
| "There is very limited experience in the management of telbivudine (LdT)-associated virological breakthrough (VBT) and resistance in the treatment of chronic hepatitis B (CHB) patients, and the guideline recommendations are primitively based on the general principles of rescue therapy to nucleos(t)ide analog resistance." | 7.79 | Telbivudine plus adefovir therapy for chronic hepatitis B patients with virological breakthrough or genotypic resistance to telbivudine. ( Bai, XF; Huang, CX; Li, Y; Lian, JQ; Wang, JP; Zhang, Y, 2013) |
| "The roadmap concept suggests the use of on-treatment HBV DNA to guide treatment strategy of chronic hepatitis B patients treated by telbivudine." | 7.79 | Efficacy of entecavir switch therapy in chronic hepatitis B patients with incomplete virological response to telbivudine. ( Chan, HL; Chan, HY; Cheung, CM; Lo, AO; Wong, GL; Wong, VW, 2013) |
| "We recruited 161 patients of chronic hepatitis B (CHB) on telbivudine between January 2009 and September 2011 in Macau, China." | 7.79 | Serum HBV DNA level at week 12 is superior to viral response at week 24 in predicting long-term treatment outcome of telbivudine for chronic hepatitis B patients. ( Fan, HW; Fan, YM; Li, T; Liu, XQ; Liu, ZY; Lü, W; Mui, C; Ng, H; Yang, HH; Zhang, LF; Zhou, BT, 2013) |
| " Telbivudine therapy has been proved to inhibit HBV replication effectively and to improve clinical outcome of chronic hepatitis B (CHB)." | 7.79 | Kinetics of Th17 cytokines during telbivudine therapy in patients with chronic hepatitis B. ( Bai, X; Hao, C; Jia, Z; Kang, W; Lian, J; Ma, L; Peng, M; Wang, J; Xie, Y; Zhou, Y, 2013) |
| "The aim of our study was to validate the roadmap concept in the treatment of chronic hepatitis B, and to investigate the virologic efficacy and kinetics of quantitative hepatitis B surface antigen (qHBsAg) during telbivudine therapy in a real-world setting." | 7.79 | Real-world application of the roadmap model in chronic hepatitis B patients with telbivudine therapy. ( Hsu, PI; Lai, KH; Lin, KH; Tsai, TJ; Tsay, FW; Wang, HM; Yu, HC, 2013) |
| "To investigate the efficacy and safety ofTelbivudine +Tenofovir combination therapy in chronic hepatitis B patients, over a period of 52 weeks, in real life clinical settings." | 7.79 | Telbivudine plus tenofovir in combination therapy in patients with chronic hepatitis B infection--an Indian experience. ( Panda, C, 2013) |
| "We propose an explorative evaluation of treatment of MC HBV-related with telbivudine (LdT) in a small group of patients affected by chronic hepatitis B (CHB)." | 7.79 | Telbivudine in the treatment of hepatitis B-associated cryoglobulinemia. ( Boglione, L; Cariti, G; D'Avolio, A; Di Perri, G, 2013) |
| " This study was aimed at investigating the impact of treatment with telbivudine (LDT) on T and NK cell immunity in patients with chronic hepatitis B (CHB)." | 7.79 | Treatment with telbivudine positively regulates antiviral immune profiles in Chinese patients with chronic hepatitis B. ( Cai, YJ; Feng, JY; Jiang, YF; Li, C; Ma, L; Niu, JQ; Wang, J; Yu, L, 2013) |
| " In this study, we investigated the frequencies, functions and PD-1 expression of peripheral iNKT cells from HBeAg-positive chronic hepatitis B (CHB) patients during antiviral treatment with Telbivudine." | 7.78 | Effects of antiviral therapy with Telbivudine on peripheral iNKT cells in HBeAg(+) chronic hepatitis B patients. ( Chen, CB; Chen, M; Ren, H; Shi, TD; Sun, H; Wang, XF; Zhang, JM, 2012) |
| "To evaluate the efficacy of telbivudine and entecavir in chronic hepatitis B (CHB) patients over a 1 year period." | 7.78 | A comparison of telbivudine and entecavir for chronic hepatitis B in real-world clinical practice. ( Chang, KC; Chen, CH; Chiu, KW; Hu, TH; Hung, CH; Lee, CM; Lu, SN; Tsai, MC; Tseng, PL; Tung, WC; Wang, JH; Yen, YH, 2012) |
| "To evaluate the changes in the renal function of patients with chronic hepatitis B (CHB) receiving adefovir dipivoxil (ADV) or telbivudine (L-DT) monotherapy." | 7.78 | [Influence of adefovir dipivoxil or telbivudine monotherapy on renal function of patients with chronic hepatitis B]. ( Fan, R; Guo, Y; Hou, J; Li, X; Peng, J; Sun, J; Yang, S; Zhong, C, 2012) |
| "To evaluate the occurrence and prognosis of telbivudine (LdT) therapy-associated elevations in creatine kinase (CK) in chronic hepatitis B (CHB) patients." | 7.78 | [Telbivudine-associated creatine kinase elevation in chronic hepatitis B patients]. ( Jia, JD; Li, HY; Ma, H; Ren, JB; Sun, SJ; Wang, Y, 2012) |
| " Several lines of experimental evidence suggest that treatment with telbivudine increases the rate of HBV e antigen (HBeAg) loss, undetectable HBV DNA, and normalization of serum alanine aminotransferase (ALT) in chronic hepatitis B patients (CHB)." | 7.77 | Effect of telbivudine therapy on the cellular immune response in chronic hepatitis B. ( Cao, H; Chen, B; Chen, Y; Li, L; Li, X; Pan, X; Wu, W; Yang, X; Ye, B, 2011) |
| "To investigate the dynamic changes of Th1/Th2 type cytokines in peripheral blood of patients with hepatitis B e antigen-positive chronic hepatitis B treated with telbivudine (LDT)." | 7.75 | [Dynamic changes of Th1/Th2 type cytokines in peripheral blood of patients with hepatitis B e antigen-positive chronic hepatitis B treated with telbivudine]. ( Chen, M; Guo, SH; He, H; Zhang, DZ; Zhang, L, 2009) |
| "To investigate the effect of telbivudine on peripheral blood regulatory T cells and its significance in patients with chronic hepatitis B (CHB)." | 7.74 | [The effect of telbivudine on peripheral blood CD4+CD25+ regulatory T cells and its significance in patients with chronic hepatitis B]. ( Chen, M; Pan, XC; Yang, F, 2008) |
| "There is no standard management of chronic hepatitis B (CHB) patients with suboptimal response to nucleoside/nucleotide analogues (NAs)." | 6.77 | Lamivudine plus adefovir or telbivudine plus adefovir for chronic hepatitis B patients with suboptimal response to adefovir. ( Bai, L; Chen, EQ; Liang, LB; Tang, H; Wang, JR; Yan, LB; Zhou, TY, 2012) |
| "Telbivudine is an L-nucleoside analogue with potent antiviral activity against hepatitis B virus (HBV)." | 6.73 | [The efficacy and safety of telbivudine in korean patients with chronic hepatitis B]. ( Ahn, SH; Cho, M; Choi, HS; Han, JY; Hwang, SG; Kim, BS; Kim, DJ; Kim, YS; Moon, YM; Rim, KS, 2007) |
| "Telbivudine has potent antiviral activity against hepatitis B virus (HBV) in vitro and in the woodchuck model and has a promising preclinical safety profile." | 6.71 | A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection. ( Brown, NA; Chao, GC; Lai, CL; Lee, YM; Lim, SG; Lloyd, DM; Myers, MW; Yuen, MF; Zhou, XJ, 2004) |
| "Telbivudine was also superior to lamivudine in ALT normalization and to adefovir and lamivudine in suppressing HBV DNA levels." | 6.53 | Effect of Telbivudine Versus Other Nucleos(t)ide Analogs on HBeAg Seroconversion and Other Outcomes in Patients with Chronic Hepatitis B: A Network Meta-Analysis. ( Fan, R; Gupta, S; Hamed, K; Liang, X; Shaikh, J; Sun, J; Taneja, A, 2016) |
| "Telbivudine is a synthetic thymidine nucleoside analogue with activity against HBV." | 6.48 | The effects of telbivudine in late pregnancy to prevent intrauterine transmission of the hepatitis B virus: a systematic review and meta-analysis. ( Chen, HZ; Deng, M; Gao, S; Ruan, B; Wang, B; Yang, SG; Zhou, X, 2012) |
| "Telbivudine has a resistance rate lower than that of LAM and higher than that of entecavir or tenofovir." | 6.46 | Telbivudine: an effective anti-HBV drug for chronic hepatitis B patients with early on-treatment responses. ( Hann, HW, 2010) |
| "Telbivudine is a potent antiviral that provides effective and sustained viral suppression in patients with compensated CHB." | 6.46 | Telbivudine: a review of its use in compensated chronic hepatitis B. ( Keam, SJ; McKeage, K, 2010) |
| "Telbivudine is an L-nucleoside that is structurally related to lamivudine and has recently been approved for use in patients with chronic HBV infection." | 6.45 | Telbivudine in the treatment of chronic hepatitis B. ( Nash, K, 2009) |
| "Telbivudine was also proved to be superior to lamivudine and adefovir dipivoxil." | 6.45 | Treatment of chronic hepatitis B: focus on telbivudine. ( Chan, HL; Lui, YY, 2009) |
| "Treatment of chronic hepatitis B with oral nucleos(t)ide analogs is evolving rapidly with newer compounds gaining approval." | 6.44 | Telbivudine in the treatment of chronic hepatitis B. ( Hadziyannis, SJ; Vassilopoulos, D, 2008) |
| "Six drugs have been approved for the treatment of chronic hepatitis B: interferon-alpha(2b), pegylated interferon-alpha(2a), lamivudine, adefovir, entecavir and telbivudine." | 6.44 | Telbivudine: a new option for the treatment of chronic hepatitis B. ( Ruiz-Sancho, A; Sheldon, J; Soriano, V, 2007) |
| "Telbivudine is a novel, orally administered nucleoside analogue for use in the treatment of chronic hepatitis B." | 6.44 | Telbivudine: a new treatment for chronic hepatitis B. ( Amarapurkar, DN, 2007) |
| "Telbivudine (LdT) is an L-nucleoside that is structurally related to lamivudine." | 6.44 | Telbivudine for the management of chronic hepatitis B virus infection. ( Matthews, SJ, 2007) |
| "Telbivudine was well tolerated with no identified safety issues." | 6.43 | Telbivudine: a new nucleoside analogue for the treatment of chronic hepatitis B. ( Han, SH, 2005) |
| "Telbivudine (LdT) is an orally L-nucleoside with potent and specific antihepatitis B virus (HBV) activity." | 5.46 | Relationship of Treg/Th17 balance with HBeAg change in HBeAg-positive chronic hepatitis B patients receiving telbivudine antiviral treatment: A longitudinal observational study. ( Gao, M; Li, J; Liu, J; Lu, W; Yang, X; Zhou, L, 2017) |
| " In addition, adverse events regarding infants at delivery and HBV vaccination outcomes were recorded." | 5.46 | Safety and efficacy of telbivudine for chronic hepatitis B during the entire pregnancy: Long-term follow-up. ( Bai, L; Liu, K; Shang, J; Tang, H; Wang, CC; Wen, Q, 2017) |
| "This study indicates that newer antivirals are effective and safe in HTR with CHB." | 5.43 | Efficacy and safety of tenofovir, entecavir, and telbivudine for chronic hepatitis B in heart transplant recipients. ( Andini, R; Durante-Mangoni, E; Falco, E; Iossa, D; Maiello, C; Parrella, A; Ragone, E; Utili, R; Vitrone, M; Zampino, R, 2016) |
| "Both telbivudine and entecavir were associated with eGFR improvement, especially in patients with renal insufficiency." | 5.40 | A comparison of efficacy and safety of 2-year telbivudine and entecavir treatment in patients with chronic hepatitis B: a match-control study. ( Chang, KC; Chen, CH; Chiu, KW; Hu, TH; Hung, CH; Lee, CM; Lu, SN; Tsai, MC; Tseng, PL; Wang, JH; Yen, YH, 2014) |
| "Telbivudine is an L-nucleoside analogue with potent antiviral activity against hepatitis B virus (HBV)." | 5.39 | Two cases of telbivudine-induced myopathy in siblings with chronic hepatitis B. ( Ahn, SH; Han, KH; Kim, EH; Kim, SM; Lee, KH; Park, H, 2013) |
| "Effective management of chronic hepatitis B infection is still very challenging, despite decades of clinical research." | 5.36 | On-treatment serum HBsAg level is predictive of sustained off-treatment virologic response to telbivudine in HBeAg-positive chronic hepatitis B patients. ( An, B; Bao, S; Cai, W; Gu, R; Guo, Q; Wang, H; Xie, Q; Zhao, G; Zhou, X, 2010) |
| "Telbivudine is a potent inhibitor of hepatitis B virus (HBV) replication without anti-HIV type-1 (HIV-1) activity demonstrated in vitro; however, very few clinical data on HIV-1-infected patients are available at present." | 5.35 | Telbivudine in the treatment of chronic hepatitis B: experience in HIV type-1-infected patients naive for antiretroviral therapy. ( Balotta, C; Caramma, I; Cesari, M; De Maddalena, C; Galli, M; Lai, A; Milazzo, L; Violin, M, 2009) |
| "To evaluate the efficacy and safety of treating HBV-positive mothers with telbivudine in early and middle pregnancy to prevent mother-to-infant HBV transmission." | 5.24 | Telbivudine treatment started in early and middle pregnancy completely blocks HBV vertical transmission. ( Hao, A; Li, F; Ma, L; Song, M; Sun, W; Zhao, B; Zhao, S; Zhou, L, 2017) |
| "The purpose of the study was to compare the efficacy and safety of 208-week sequential therapy with telbivudine and entecavir in HBeAg-positive chronic hepatitis B (CHB) patients with suboptimal responses to 24 weeks of Peg-IFNα-2a therapy." | 5.24 | Comparison of 208-week sequential therapy with telbivudine and entecavir in HBeAg-positive chronic hepatitis B patients with suboptimal responses to 24 weeks of Peg-IFNα-2a therapy: An open-labelled, randomized, controlled, "real-life" trial. ( Chen, XF; Chen, XP; Luo, XD; Zhou, Y, 2017) |
| "To explore the effect of Telbivudine (LDT) Tablet combined with Jianpi Bushen Recipe (JBR) on serum hepatitis B virus (HBV) specific cytotoxic T lymphocyte (CTL) and HBeAg seroconversion in chronic hepatitis B (CHB) patients." | 5.22 | [Effect of Telbivudine Tablet Combined Jianpi Bushen Recipe on HBV Specific Cytotoxic T Lymphocyte and HBeAg Seroconversion in Patients with HBeAg Positive Chronic Hepatitis B]. ( Dai, YP; Fu, DC; Guo, XY; Hua, Z; Li, YG; Tu, KW; Xu, W, 2016) |
| "To investigate the efficacy and safety of 104-week sequential therapy with telbivudine or entecavir in HBeAg-positive chronic hepatitis B (CHB) patients with suboptimal responses to 24-week pegylated interferon-α-2a (PEG-IFN-α-2a) therapy." | 5.22 | [Efficacy of 104-week sequential therapy with telbivudine or entecavir in HBeAg-positive chronic hepatitis B patients with suboptimal responses to 24-week therapy with pegylated interferon-α-2a]. ( Chen, R; Chen, XF; Chen, XP; Huang, J; Luo, XD, 2016) |
| "This study investigated the antiviral efficacy and safety of telbivudine in combination with pegylated interferon (PegIFN) alpha-2a in chronic hepatitis B (CHB) patients." | 5.20 | Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy. ( Avila, C; Bao, W; Chuang, WL; Fainboim, H; Foster, GR; Gane, E; Lau, G; Lim, SG; Manns, M; Marcellin, P; Naoumov, N; Peng, CY; Rizzetto, M; Safadi, R; Trylesinski, A; Wedemeyer, H; Wursthorn, K, 2015) |
| "The purpose of this study was to analyze the cost-effectiveness of lamivudine (LMV), telbivudine (LdT), and entecavir (ETV) in treatment of chronic hepatitis B with adefovir dipivoxil (ADV) resistance." | 5.20 | Cost-effectiveness analysis of lamivudine, telbivudine, and entecavir in treatment of chronic hepatitis B with adefovir dipivoxil resistance. ( Liu, Y; Qiu, P; Wang, G; Wen, J; Wen, P; Xiao, X; Xu, L; Zhou, SF, 2015) |
| " The aim of this study was to assess whether prolonged telbivudine treatment improves liver inflammation and fibrosis." | 5.20 | Long-Term Telbivudine Treatment Results in Resolution of Liver Inflammation and Fibrosis in Patients with Chronic Hepatitis B. ( Bao, W; Chen, C; Dong, Y; Goodman, Z; Hou, JL; Jia, J; Naoumov, NV; Niu, J; Ren, H; Shi, G; Tan, D; Trylesinski, A; Wan, M; Wang, Q; Wang, Y; Wei, L; Xie, Q; Xu, D, 2015) |
| "We used serum creatinine-based equations (ie, Cockcroft-Gault, Modification of Diet in Renal Disease, and Chronic Kidney Disease Epidemiology Collaboration) to estimate GFR (eGFR) in adults with chronic hepatitis B virus infection and compensated liver disease who participated in a phase III, randomized, double-blind study comparing the efficacy and safety of telbivudine (600 mg/d) and lamivudine (100 mg/d) for 2 years (the GLOBE study) and in long-term extension studies (4-6 years), as well as in patients with decompensated cirrhosis (2 years)." | 5.19 | Telbivudine improves renal function in patients with chronic hepatitis B. ( Bosset, S; Buti, M; Deray, G; Di Bisceglie, A; Gane, EJ; Lai, CL; Liaw, YF; Lim, SG; Papatheodoridis, G; Rasenack, J; Samuel, D; Trylesinski, A; Uddin, A; Wang, Y, 2014) |
| "To prospectively observe the long-term antiviral efficacy and safety of telbivudine (LDT) administered as a monotherapy and as a combination therapy with adefovir dipivoxil (ADV) in patients diagnosed with chronic hepatitis B (CHB) and positivity for hepatitis B e antigen (HBeAg)." | 5.19 | [Long-term efficacy and safety of telbivudine as monotherapy and as combination therapy with adefovir dipivoxil in HBeAg-positive chronic hepatitis B patients]. ( Chang, L; Du, Y; Jia, T; Li, H; Li, W; Liu, L; Liu, Y; Peng, D, 2014) |
| "Little observational data exist describing telbivudine (LdT) or lamivudine (LAM) use in late pregnancy for preventing hepatitis B mother-to-child transmission (MTCT) in real-world settings." | 5.19 | Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice. ( Liu, X; Pan, CQ; Pang, Q; Tian, R; Yan, M; Zhang, H, 2014) |
| "To observe the long-term efficacy and safety of telbivudine (LdT) for pregnant women with chronic hepatitis B (CHB) and their children born from the treatment period." | 5.19 | [Long-term efficacy and safety of telbivudine in the treatment of childbearing patients with chronic hepatitis B]. ( Lu, C; Pan, H; Zheng, J; Zhou, Y, 2014) |
| " Because previous studies showed that long-term telbivudine treatment improved renal function in chronic hepatitis B virus (HBV) infected patients, we conducted a case-control study to evaluate the clinical outcome of telbivudine preemptive therapy in HBV-related advanced HCC patients treated by combination chemotherapy comprising 5-fluorouracil, mitoxantrone and cisplatin (FMP)." | 5.19 | Significant renoprotective effect of telbivudine during preemptive antiviral therapy in advanced liver cancer patients receiving cisplatin-based chemotherapy: a case-control study. ( Chang, ML; Chen, YC; Chien, RN; Hsu, CW; Lin, CL; Yeh, C; Yeh, CT, 2014) |
| "The objective of this study was to compare the efficacy and safety of two rescue strategies for hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) patients with resistance to adefovir dipivoxil (ADV)." | 5.17 | Efficacy and safety of telbivudine plus adefovir dipivoxil combination therapy and entecavir monotherapy for HBeAg-positive chronic hepatitis B patients with resistance to adefovir dipivoxil. ( Chen, EQ; Liu, K; Lu, JJ; Ma, YJ; Tang, H; Wang, J, 2013) |
| "Telbivudine (LdT) has demonstrated potent antiviral activity in nucleos(t)ide analogue (NA)-naïve chronic hepatitis B patients (CHB), but data on its efficacy in NA-experienced patients are limited." | 5.17 | Efficacy of telbivudine treatment for hepatitis B e antigen-positive chronic hepatitis B patients with poor response to adefovir dipivoxil. ( Bai, XF; Li, Y; Lian, JQ; Wang, JP; Zhang, Y, 2013) |
| "The aim of this study was to investigate the efficacy of sequential use of telbivudine in hepatitis B e antigen (HBeAg)-positive chronic hepatitis B patients with partial responses to pegylated interferon." | 5.17 | Efficacy of sequential use of telbivudine in hepatitis B e antigen-positive chronic hepatitis B patients with partial responses to pegylated interferon: a pilot study. ( Deng, H; Gao, Z; Huang, Z; Lin, C; Peng, L; Zhao, Z; Zheng, Y, 2013) |
| " In recent years, there have been gradually increasing reports on the safety of telbivudine (LdT) treatment for chronic hepatitis B virus (HBV) infection in the third trimester of pregnancy to block mother-to-infant transmission (MTIT) of HBV; however, the safety of LdT treatment for chronic HBV infection for the entire pregnancy has not been reported." | 5.17 | Safety of telbivudine treatment for chronic hepatitis B for the entire pregnancy. ( Cai, H; Liu, M; Yi, W, 2013) |
| "In the phase-III GLOBE/015 studies, telbivudine demonstrated superior efficacy vs lamivudine during 2-year treatment in HBeAg-positive and HBeAg-negative chronic hepatitis B (CHB)." | 5.17 | Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B. ( Bao, W; Chan, HL; Gane, EJ; Hou, J; Jia, J; Liaw, YF; Naoumov, NV; Niu, J; Papatheodoridis, G; Thongsawat, S; Trylesinski, A; Wan, M; Wang, Y, 2013) |
| "Telbivudine is a nucleoside analogue that has been approved for the treatment of chronic hepatitis B virus (HBV) infection in adults at 600 mg/day." | 5.17 | Phase I, open-label, single-dose study to evaluate the pharmacokinetics and safety of telbivudine in children and adolescents with chronic hepatitis B. ( Bosheva, M; Ke, J; Praestgaard, J; Qi, Y; Stein, DS; Uy, G, 2013) |
| "The objective of this study was to evaluate the short-term efficacy and safety of telbivudine therapy as compared to lamivudine therapy in liver failure patients with chronic hepatitis B virus (HBV) infection." | 5.17 | Efficacy and safety of telbivudine therapy in liver failure patients with chronic hepatitis B virus infection. ( Chen, H; Fan, C; Gong, Z; Wang, L, 2013) |
| "To investigate the therapeutic benefit of sequential interferon alpha-1b (IFNa-1b) in patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) who showed early complete response to telbivudine (LdT) treatment, and to explore the clinical value of serum hepatitis B surface antigen (HBsAg) for predicting sustained virological response (SVR)." | 5.17 | [Clinical observations of sequential interferon therapy following complete response to telbivudine treatment in chronic hepatitis B patients]. ( Guo, SH; Sandeep, KK; Zhang, DZ; Zhang, QF; Zhang, W, 2013) |
| "To examine the efficacy of telbivudine (LdT) + adefovir (ADV) vs continuation of lamivudine (LAM) + ADV in patients with LAM-resistant chronic hepatitis B (CHB) who show a suboptimal response to LAM + ADV." | 5.17 | Efficacy of switching to telbivudine plus adefovir in suboptimal responders to lamivudine plus adefovir. ( Ahn, SH; Chon, CY; Han, KH; Kim, DY; Kim, SU; Park, H; Park, JY, 2013) |
| "Telbivudine therapy with tenofovir intensification at Week 24, where indicated by the Roadmap strategy, appears effective and well tolerated for the treatment of chronic hepatitis B." | 5.17 | 52-week efficacy and safety of telbivudine with conditional tenofovir intensification at week 24 in HBeAg-positive chronic hepatitis B. ( Bessone, F; Chan, HL; Cheinquer, H; Daruich, J; Dong, Y; Fassio, E; Komolmit, P; Ono, SK; Pathan, R; Pessôa, MG; Piratvisuth, T; Sukeepaisarnjaroen, W; Tanwandee, T; Trylesinski, A; Zeuzem, S, 2013) |
| "Serum IL-21 levels were measured by enzyme immunoassay in 75 HBeAg-positive chronic hepatitis B (CHB) patients undergoing telbivudine treatment." | 5.16 | High serum IL-21 levels after 12 weeks of antiviral therapy predict HBeAg seroconversion in chronic hepatitis B. ( Abbott, WG; Dong, YH; Hou, JL; Huang, X; Jiang, XT; Li, YY; Liu, ZH; Ma, SW; Naoumov, NV; Sun, J; Sun, XF; Tang, LB; Zhang, YX, 2012) |
| "Telbivudine reduces hepatitis B virus (HBV) DNA and normalizes levels of alanine aminotransferase (ALT) in patients with chronic hepatitis B (CHB)." | 5.16 | Telbivudine prevents vertical transmission from HBeAg-positive women with chronic hepatitis B. ( Cao, MK; Han, GR; Jiang, HX; Pan, CQ; Wang, CM; Wang, GJ; Yue, X; Zhao, W, 2012) |
| "To study the influences of warming kidney prescription on antiviral therapeutic efficacy and creatine kinase (CK) level in telbivudine-treated HBeAg-positive chronic hepatitis B patients with kidney yang deficiency syndrome." | 5.16 | [Influences of warming kidney prescription on antiviral therapeutic efficacy and creatine kinase in telbivudine-treated HBeAg-positive chronic hepatitis B patients]. ( Fan, XJ; Hu, XY; Liu, GW; Nie, HM; Zhang, Y; Zhong, S, 2012) |
| "The present phase IIIb, randomized, double-blind, multicentre global trial assessed the antiviral efficacy and safety of telbivudine switch in chronic hepatitis B (CHB) patients who exhibited persistent viraemia under lamivudine therapy." | 5.15 | Efficacy of switching to telbivudine in chronic hepatitis B patients treated previously with lamivudine. ( Chen, Y; Hwang, SG; Jia, JD; Lopez, P; Safadi, R; Wei, L; Xie, Q; Yin, YK; Zuckerman, E, 2011) |
| "In the GLOBE trial, telbivudine demonstrated superior efficacy to lamivudine at 2 years in patients with chronic hepatitis B (CHB)." | 5.15 | Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis B. ( Avila, C; Bao, W; Chao, YC; Gane, EJ; Hou, J; Hsu, CW; Jia, J; Leung, N; Liaw, YF; Lopez, P; Moon, YM; Niu, J; Samuel, D; Thongsawat, S; Wan, M; Wang, Y, 2011) |
| "To investigate the efficacy of Telbivudine and Entecavir for therapy of HBeAg positive chronic hepatitis B for 52 weeks." | 5.15 | [Study on the efficacy and HBeAg seroconversion related factors of telbivudine and entecavir therapy in HBeAg positive chronic hepatitis B patients]. ( Chen, R; Chen, WL; Chen, XF; Chen, XP; Huang, J; Luo, XD; Ma, XJ, 2011) |
| "Telbivudine used during pregnancy in CHB HBeAg+highly viremic mothers can safely reduce perinatal HBV transmission." | 5.15 | A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. ( Bai, SF; Cao, MK; Fang, ZX; Han, GR; Jiang, HX; Tang, X; Wang, CM; Wang, GJ; Yue, X; Zhao, W, 2011) |
| "The GLOBE trial has compared the efficacy and safety of telbivudine versus lamivudine treatment over 2 years in patients with chronic hepatitis B." | 5.14 | 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. ( Albanis, E; Brown, NA; Bzowej, N; Cakaloglu, Y; Chen, Y; Galil, K; Gane, E; Han, SH; Heathcote, EJ; Hwang, SG; Lai, CL; Leung, N; Liaw, YF; Manns, M; Naoumov, NV; Niu, J; Papatheodoridis, G; Tong, MJ; Wang, Y; Zeuzem, S, 2009) |
| "To study the therapeutic efficacy of 48-week telbivudine treatment on cirrhosis resulting from chronic hepatitis B." | 5.14 | [Telbivudine treatment on cirrhosis resulting from chronic hepatitis B]. ( Han, T; Liang, J; Xiao, SX, 2009) |
| "61 pregnant chronic hepatitis B (CHB) patients were enrolled and 31 patients were treated by telbivudine 600 mg once daily, 30 patients in the control group were not received antiviral treatment." | 5.14 | [Blocking intrauterine infection by telbivudine in pregnant chronic hepatitis B patients]. ( Wang, L; Zhang, LJ, 2009) |
| "We characterized the early viral kinetic profiles of telbivudine and entecavir and the effects of these potent nucleoside analogs on hepatitis B virus (HBV) DNA and alanine aminotransferase levels in adults with hepatitis B e antigen-positive compensated chronic hepatitis B." | 5.14 | Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B. ( Avila, C; Bao, W; Herrmann, E; Kim, JH; Lee, HC; Lee, HJ; Lee, MS; Lee, YJ; Lee, YS; Lopez, P; Suh, DJ; Um, SH; Zeuzem, S, 2010) |
| "The aim of this work was to compare the early antiviral effectiveness of telbivudine and entecavir in the treatment of patients with hepatitis B e antigen (HBeAg)-positive HBV." | 5.14 | A 24-week, parallel-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients. ( Chen, YP; Dai, ZJ; Shi, KQ; Ye, C; Zheng, MH, 2010) |
| "To analyze antiviral effects of telbivudine in patients with chronic hepatitis B." | 5.14 | [Clinical antiviral effects of telbivudine in patients with chronic hepatitis B]. ( Guo, HH; Ji, SW; Jiao, J; Li, Y; Siqingtu, NL; Wang, JB; Xu, Y; Zhang, YG; Zhao, P; Zhou, CY, 2010) |
| "To evaluate the efficacy and safety of telbivudine (LDT) in hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) patients who have high baseline alanine aminotransferase (ALT) levels between 10 and 20 times the upper limit of normal." | 5.14 | Efficacy of telbivudine in HBeAg-positive chronic hepatitis B patients with high baseline ALT levels. ( Jin, X; Lv, GC; Ma, WJ; Yang, YD; Ying, LJ; Zheng, L, 2010) |
| "To evaluate the efficacy and safety of telbivudine (LDT) versus entecavir treatments in hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) patients." | 5.13 | [Short-term results of telbivudine versus entecavir treatments in HBeAg-positive chronic hepatitis B patients in China]. ( Guo, SH; He, H; Ren, H; Shi, KQ; Shi, XF; Wang, ZY; Zeng, WQ; Zhang, DZ, 2008) |
| "In Chinese patients with chronic hepatitis B, telbivudine treatment for 52 weeks provided greater antiviral and clinical efficacy than lamivudine, with less resistance." | 5.13 | Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial. ( Brown, NA; Chao, G; Chen, C; Chen, Y; Constance, BF; Harb, G; He, Y; Hou, J; Jia, J; Niu, J; Ren, H; Tan, D; Wan, M; Wang, Q; Wang, Y; Wei, L; Wu, S; Xu, D; Xu, J; Yin, YK; Zhou, X; Zhu, L, 2008) |
| "The pharmacokinetics of telbivudine were evaluated in adult patients with chronic hepatitis B virus (HBV) infection following once-daily oral administration at escalating doses of 25, 50, 100, 200, 400, and 800 mg/day for 4 weeks." | 5.12 | Pharmacokinetics of telbivudine following oral administration of escalating single and multiple doses in patients with chronic hepatitis B virus infection: pharmacodynamic implications. ( Brown, NA; Chao, GC; Lai, CL; Lim, SG; Lloyd, DM; Zhou, XJ, 2006) |
| "In this phase III, double-blind, multicenter trial, we compared the efficacy of telbivudine treatment with lamivudine treatment in 332 Chinese compensated chronic hepatitis B patients." | 5.12 | [The degree of HBV suppression with 24 week telbivudine- or lamivudine-treatment in hepatitis B patients predicts the efficacy of the treatment at week 52]. ( Chen, CW; Chen, YG; He, YW; Hou, JL; Jia, JD; Ma, H; Niu, JQ; Ren, H; Tan, DM; Wan, MB; Wang, QH; Wang, YM; Wei, L; Wu, SM; Xu, DZ; Xu, JZ; Yin, YK; Zhou, XQ; Zhu, LM, 2007) |
| "To compare the antiviral efficacy of telbivudine and adefovir dipivoxil, and the effects of switching from adefovir to telbivudine, in hepatitis B e antigen (HBeAg)-positive patients with chronic hepatitis B." | 5.12 | Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. ( Brown, NA; Bzowej, N; Chan, HL; Chao, YC; Cho, M; Harb, G; Heathcote, EJ; Jeffers, L; Kaiser, R; Lai, CL; Marcellin, P; Minuk, GY; Moon, YM; Myers, RP; Qiao, XJ; Sievert, W, 2007) |
| "In this double-blind, phase 3 trial, 1370 patients with chronic hepatitis B were randomly assigned to receive 600 mg of telbivudine or 100 mg of lamivudine once daily." | 5.12 | Telbivudine versus lamivudine in patients with chronic hepatitis B. ( Brown, NA; Bzowej, N; Chao, G; Chen, Y; Constance, BF; Di Bisceglie, AM; Gane, E; Goodman, Z; Heathcote, EJ; Hsu, CW; Lai, CL; Liaw, YF; Moon, YM; Naoumov, NV; Rasenack, J; Thongsawat, S; Wang, Y; Zeuzem, S, 2007) |
| "This randomized, double-blind, multicenter trial evaluated the efficacy and safety of telbivudine 400 or 600 mg/day and telbivudine 400 or 600 mg/day plus lamivudine 100 mg/day (Comb400 and Comb600) compared with lamivudine 100 mg/day in hepatitis B e antigen (HBeAg)-positive adults with compensated chronic hepatitis B." | 5.11 | A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. ( Brown, NA; Chao, G; Han, S; Hann, HW; Lai, CL; Leung, N; Lloyd, D; Myers, M; Poynard, T; Teo, EK; Tong, M; Wong, F, 2005) |
| "We aimed to evaluate the efficacy of five oral nucleos(t)ide analogues (NAs), including lamivudine, entecavir, adefovir, telbivudine and tenofovir, for the prevention of hepatitis B virus (HBV) reactivation and HBV-related complications in chronic hepatitis B virus (CHB) infected patients with hematological malignancies receiving chemotherapy or hematopoietic stem cell transplantation (HSCT) by network meta-analysis." | 4.95 | Nucleos(t)ide analogues for preventing HBV reactivation in immunosuppressed patients with hematological malignancies: a network meta-analysis. ( Chen, FY; Cheng, Z; Huang, HH; Shi, KQ; Van Poucke, S; Zhang, MY; Zheng, JN; Zheng, MH; Zhu, GQ, 2017) |
| " US FDA pregnancy category B agents such as tenofovir and telbivudine are allowed through all trimesters of pregnancy." | 4.95 | Hepatitis B During Pregnancy in Endemic Areas: Screening, Treatment, and Prevention of Mother-to-Child Transmission. ( Chamroonkul, N; Piratvisuth, T, 2017) |
| " The antiviral efficacy and safety of telbivudine (LdT) have been shown in patients with CHB infection, and LdT is approved as a class B drug for pregnancy." | 4.95 | Telbivudine therapy for gravidas with chronic hepatitis B infection and patients at risk of renal impairment. ( Chen, T; Liu, J; Zhao, Y, 2017) |
| "Telbivudine can cause severe side effects, including myositis, neuritis, rhabdomyolysis, and lactic acidosis." | 4.95 | Rhabdomyolysis, lactic acidosis, and multiple organ failure during telbivudine treatment for hepatitis B: a case report and review of the literature. ( Chen, Z; Deng, M; Deng, Q; Deng, X; Li, D; Qiu, X; Yu, Z; Zheng, J, 2017) |
| "To assess the potential effects of telbivudine (LdT) and entecavir (ETV) on renal function in patients with chronic hepatitis B (CHB), we performed a meta-analysis of the relevant data available on these agents to evaluate their effects on the estimated glomerular filtration rate (eGFR) during treatment." | 4.93 | Potential effects of telbivudine and entecavir on renal function: a systematic review and meta-analysis. ( Cai, S; Li, Z; Peng, J; Wu, X; Xue, X; Zeng, J; Zheng, C, 2016) |
| "Although there have been reports on telbivudine-induced myopathy and creatine kinase (CK) elevation, few reports focus on its effect on hyperlactatemia in patients with chronic hepatitis B (CHB)." | 4.91 | Continuous venovenous hemodiafiltration for hyperlactatemia caused by telbivudine in a patient with chronic hepatitis B: a case report and update review. ( Liu, H; Wang, YH; Wu, BQ, 2015) |
| "A meta-analysis to compare the efficacy and safety of telbivudine (TBV) and lamivudine (LAM) in patients with chronic hepatitis B (CHB), assessed via changes in serum alanine aminotransferase (ALT) levels." | 4.91 | Changes in serum alanine aminotransferase levels in telbivudine versus lamivudine treatment for chronic hepatitis B: a meta-analysis. ( Dai, M; Li, YM; Wang, FL; Xiao, GM; Yang, HZ; Zhang, JS, 2015) |
| "We performed a meta-analysis to compare the efficacies of entecavir and telbivudine in treatment-naive hepatitis B e-antigen (HBeAg)-positive Asian patients with chronic hepatitis B (CHB)." | 4.90 | Telbivudine versus entecavir for nucleos(t)ide-naive HBeAg-positive chronic hepatitis B: a meta-analysis. ( Liu, H; Wan, G; Wang, X; Yang, Z; Zeng, H, 2014) |
| "The treatment of chronic hepatitis B (CHB) in patients with chronic kidney disease (CKD) is based on nucleoside (lamivudine, telbivudine, entecavir) or nucleotide (adefovir, tenofovir) analogues (NAs), but it may be complex and the information is scarce." | 4.90 | Review article: nucleos(t)ide analogues in patients with chronic hepatitis B virus infection and chronic kidney disease. ( Cholongitas, E; Papatheodoridis, G; Pipili, C, 2014) |
| "Telbivudine, one of the oral anti-hepatitis B virus (HBV) nucleoside analogues, has been used for more than 5 years to treat HBeAg-positive and -negative chronic hepatitis B (CHB) patients." | 4.89 | Telbivudine treatment in chronic hepatitis B: experience from China. ( Jia, J; You, H, 2013) |
| "All oral nucleoside analogues against hepatitis B virus, with an exception of telbivudine, have been reported causing lactic acidosis (LA)." | 4.89 | Lactic acidosis during telbivudine treatment for HBV: a case report and literature review. ( Hu, P; Huang, XY; Jin, JL; Lu, JH; Luo, SS; Weng, XH; Zhang, JM, 2013) |
| "Telbivudine and entecavir are two pharmacologic agents recommended and also widely used for the treatment of chronic hepatitis B in most Asian countries." | 4.89 | Comparison of the forty-eight week efficacy between telbivudine and entecavir in HBeAg-positive Asian patients with chronic hepatitis B: A meta-analysis. ( Feng, Q; Hu, HD; Hu, P; Liu, Q; Ren, H; Sun, H; Wang, N, 2013) |
| "The purpose of this study was to evaluate the efficacy of lamivudine (LAM) versus telbivudine (LdT) in the treatment of chronic hepatitis B (CHB)." | 4.89 | Lamivudine versus telbivudine in the treatment of chronic hepatitis B: a systematic review and meta-analysis. ( Jiang, H; Wang, J; Zhao, W, 2013) |
| "To compare the effects of telbivudine (LDT) and entecavir (ETV) in treatment of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B by meta-analysis." | 4.88 | Effects of telbivudine and entecavir for HBeAg-positive chronic hepatitis B: a meta-analysis. ( Su, QM; Ye, XG, 2012) |
| "To evaluate the efficacy and safety of telbivudine treatment in pregnant patients with chronic hepatitis B to block mother-to-child transmission of hepatitis B virus (HBV)." | 4.88 | [Efficacy and safety of telbivudine treatment to block mother-to-child transmission of hepatitis B virus: a meta-analysis]. ( Chen, Y; Liu, XX; Wang, LJ; Wu, YP; Xu, HX; Xu, YF; Yu, YX, 2012) |
| " Combination therapy with Interferon-α and ribavirin remains the backbone treatment for chronic hepatitis C; the addition of serine protease inhibitors improves the treatment outcome of patients infected with hepatitis C virus genotype 1." | 4.87 | Antiviral drugs for viruses other than human immunodeficiency virus. ( Razonable, RR, 2011) |
| " Currently, several drugs, such as lamivudine and telbivudine, are recommended for treatment of patients with chronic hepatitis B." | 4.86 | Comparison of the efficacy of lamivudine and telbivudine in the treatment of chronic hepatitis B: a systematic review. ( Chen, L; Dai, X; Fan, X; Tang, L; Zhao, S; Zhou, R, 2010) |
| "This paper presents a summary of the evidence review group (ERG) report into the clinical effectiveness and cost-effectiveness of telbivudine for the treatment of chronic hepatitis B (CHB) in adults based upon a review of the manufacturer's submission to the National Institute for Health and Clinical Excellence (NICE) as part of the single technology appraisal (STA) process." | 4.85 | Telbivudine for the treatment of chronic hepatitis B infection. ( Cooper, K; Harris, P; Hartwell, D; Jones, J, 2009) |
| "Clinical trials demonstrated telbivudine to be a safe and potent antiviral agent for treatment of chronic hepatitis B." | 4.84 | A review of telbivudine for the management of chronic hepatitis B virus infection. ( Chan, HL; Lui, YY, 2008) |
| " In the last few years the therapeutic options in chronic hepatitis B have increased and currently six treatments are authorized: standard interferon (IFN)-alpha, pegylated interferon-alpha (PEG-IFNalpha), lamivudine, adefovir, entecavir, and telbivudine." | 4.84 | [Interferon in hepatitis B]. ( García Buey, L; González Mateos, F; Moreno Otero, R, 2008) |
| "At least 4 nucleos(t)ide analogs have been approved for the treatment of chronic hepatitis B: lamivudine, adefovir dipivoxil, entecavir, and telbivudine." | 4.84 | [Nucleoside and nucleotide analogs in the treatment of chronic hepatitis B]. ( Buti, M, 2008) |
| "The practising clinician is currently faced with a number of effective treatment options for chronic hepatitis B, including two formulations of interferon (standard IFN and pegylated IFN) and five nucleos(t)ide analogues (lamivudine, adefovir, entecavir, telbivudine and tenofovir)." | 4.84 | Peginterferon for the treatment of chronic hepatitis B in the era of nucleos(t)ide analogues. ( Buster, EH; Janssen, HL; Schalm, SW, 2008) |
| "Among the six drugs licensed for the treatment of chronic hepatitis B in the US, the preferred agents in 2008 will include entecavir, peginterferon alfa-2a, possibly telbivudine, and tenofovir following licensure." | 4.84 | Review article: current antiviral therapy of chronic hepatitis B. ( Ayoub, WS; Keeffe, EB, 2008) |
| "Telbivudine is a novel, orally administered nucleoside analog under development for use in the treatment of chronic hepatitis B." | 4.83 | Telbivudine: a novel nucleoside analog for chronic hepatitis B. ( Kim, JW; Louie, SG; Park, SH, 2006) |
| "To investigate postpartum hepatic flares and associated factors in highly viremic pregnant patients in the immune tolerance phase who adopted telbivudine (LdT) treatment in the last trimester to reduce vertical transmission of hepatitis B virus." | 4.02 | Clinical and Immunological Factors Associated with Postpartum Hepatic Flares in Immune-Tolerant Pregnant Women with Hepatitis B Virus Infection Treated with Telbivudine. ( Chen, X; Hu, Z; Lu, J; Ma, L; Wang, X; Zheng, S; Zhu, Y, 2021) |
| "Treatment with lamivudine or telbivudine for active CHB in early pregnancy appears to be safe and effective for controlling maternal disease as well as interrupting MTCT." | 3.88 | Safety and efficacy of lamivudine or telbivudine started in early pregnancy for mothers with active chronic hepatitis B. ( Bai, Y; Cai, H; He, T; Jia, J; Liu, M; Ou, X; Yi, W, 2018) |
| "To estimate long-term outcomes after treatment modification in patients with chronic hepatitis B (CHB) treated with entecavir (ETV) and telbivudine (LdT)." | 3.88 | Real World Experience of Telbivudine Versus Entecavir in Patients with Chronic Hepatitis B, Including Long-Term Outcomes after Treatment Modification. ( Cho, YS; Choi, JW; Jeon, HH; Kim, SH; Lee, CK; Lee, YK; Park, BK; Seo, JH; Won, SY, 2018) |
| "9% of patients on telbivudine treatment were reported to develop severe elevation of serum creatine phosphokinase (CPK) levels, but related clinical disease, like lactic acidosis (LA) and rhabdomyolysis (RM) were rare." | 3.88 | Case report: lactic acidosis and rhabdomyolysis during telbivudine and tenofovir treatment for chronic hepatitis B. ( Hu, YK; Huang, YX; Jin, JL; Ying, Y; Zhang, JM; Zhang, WH, 2018) |
| "The aim of this study was to evaluate clinical efficacy of telbivudine in treatment of hepatitis B virus-associated glomerulonephritis (HBV-GN)." | 3.88 | Effectiveness of telbivudine antiviral treatment in patients with hepatitis B virus-associated glomerulonephritis: A 104-week pilot study. ( Gou, W; Qiao, B; Wang, Y; Yan, Z; Zhang, H, 2018) |
| " In this study, we reported a CHB patient with decompensated cirrhosis showing a significant improvement in massive proteinuria along with elevation of estimated glomerular filtration rate (eGFR) after 1 year treatment with telbivudine." | 3.85 | Improvement of telbivudine on renal function and massive proteinuria: A case report. ( Liu, J; Yao, N; Zhao, Y, 2017) |
| "Chronic hepatitis B virus-infected women who received telbivudine beginning at week 24 or 28 of gestation were enrolled and then followed up to 52 weeks postpartum." | 3.85 | Hepatic flare after telbivudine withdrawal and efficacy of postpartum antiviral therapy for pregnancies with chronic hepatitis B virus. ( Cao, F; Chen, T; Feng, W; Guo, D; Jin, D; Jin, L; Liu, J; Qi, C; Tian, Z; Wang, J; Yan, T; Yuan, N; Zhang, S; Zhao, Y, 2017) |
| "Thirty patients with chronic hepatitis B were enrolled and serum samples were collected at multiple time points during treatment with telbivudine (LdT)." | 3.85 | Small surface antigen variants of HBV associated with responses to telbivudine treatment in chronic hepatitis B patients. ( Dong, H; He, Y; Hou, J; Jin, W; Kang, H; Shen, Y; Sun, J; Wang, S; Zhao, G; Zhou, B; Zhu, Y, 2017) |
| "A total of 546 consecutive cirrhotic patients treated with entecavir (n = 359), telbivudine (n = 104), or tenofovir (n = 83) for chronic hepatitis B were enrolled." | 3.85 | Long-term outcomes of hepatitis B virus-related cirrhosis treated with nucleos(t)ide analogs. ( Chen, CH; Hu, TH; Hung, CH; Lee, CM; Lu, SN; Tsai, MC; Wang, JH, 2017) |
| "Telbivudine, an FDA pregnancy category B drug, has been found to reduce hepatitis B virus (HBV) perinatal transmission with no safety concerns in infants aged up to 1 year." | 3.85 | Long-term safety and efficacy of telbivudine in infants born to mothers treated during the second or third trimesters of pregnancy. ( Ding, Y; Han, GR; Jiang, HX; Wang, CM; Wang, GJ; Yue, X; Zhao, W; Zhou, L, 2017) |
| "A subgroup analysis of a GLOBE study identified subgroups of chronic hepatitis B (CHB) patients with excellent outcomes to telbivudine (LdT) treatment." | 3.83 | Efficacy and resistance to telbivudine treatment in chronic hepatitis B patients with favorable predictors: a multicenter study in Taiwan. ( Chen, TM; Hsieh, TY; Hsu, YC; Kao, JH; Lin, CL; Peng, CY; Su, TH; Tseng, KC; Wang, CC; Yang, SS, 2016) |
| "Telbivudine is a relatively novel oral nucleoside analogue with favourable efficacy and tolerability in treatment-naïve chronic hepatitis B virus (HBV) infection, but its data in kidney transplant recipients (KTRs) was lacking." | 3.83 | Use of telbivudine in kidney transplant recipients with chronic hepatitis B virus infection: A preliminary experience. ( Chan, TM; Yap, DY, 2016) |
| "In this observational study, patients with chronic hepatitis B receiving telbivudine therapy between July 2008 and December 2013 were enrolled." | 3.83 | Cumulative incidence and risk factors of creatine kinase elevation associated with telbivudine. ( Chen, B; Chen, L; Cheng, C; Wang, B; Zhang, J; Zhao, Y, 2016) |
| "Data comparing the clinical outcomes of telbivudine (LdT) and entecavir (ETV) in elderly patients with chronic hepatitis B are limited." | 3.83 | Comparison of efficacy and renal safety of telbivudine and entecavir in treatment-naive elderly patients with chronic hepatitis B. ( Law, ST; Lee, MK; Li, KK; Mok, CK, 2016) |
| "Lamivudine, telbivudine, and entecavir are the first-line drugs covered by the Taiwan National Health Insurance as 3-year treatments for patients with chronic hepatitis B virus (HBV), but the optimal treatment duration of each remains unclear." | 3.83 | Off-treatment efficacy of 3-year nucleos(t)ide analogues in chronic hepatitis B patients. ( Bair, MJ; Chang, CW; Chen, CJ; Chen, MJ; Chu, CH; Hu, KC; Lee, KH; Lin, CC; Lin, SC; Liou, TC; Liu, CY; Shih, SC; Wang, HY; Wang, TE, 2016) |
| "To investigate serum interleukin (IL)-38 level and its clinical role in predicting virological response (VR) to telbivudine (LdT) in patients with chronic hepatitis B (CHB)." | 3.83 | Elevated serum interleukin-38 level at baseline predicts virological response in telbivudine-treated patients with chronic hepatitis B. ( Gao, PJ; Jiang, YF; Wang, HJ; Wang, XR; Zhang, ML, 2016) |
| "Tenofovir disoproxil fumarate (TDF) is newly available for treatment of chronic hepatitis B patients in China." | 3.83 | Cost-effectiveness analysis of tenofovir disoproxil fumarate for treatment of chronic hepatitis B in China. ( Gao, Y; Ke, W; Liu, L; Yang, Y; Yao, Z; Ye, X; Zhang, C; Zhou, S, 2016) |
| "Thirty-six HBeAg-positive patients with chronic hepatitis B (CHB) were enrolled for 52-week telbivudine monotherapy and were followed at treatment week (TW)-0, 4, 12, 24 and 52." | 3.81 | Telbivudine therapy may shape CD4(+) T-cell response to prevent liver fibrosis in patients with chronic hepatitis B. ( Jia, M; Jiang, W; Li, J; Li, L; Liu, Y; She, W; Wang, J, 2015) |
| "Entecavir (ETV) is effective in the treatment of chronic hepatitis B virus (HBV) infections, even in patients with underlying cirrhosis." | 3.81 | Efficacy of telbivudine compared with entecavir in hepatitis B virus-related cirrhosis: 2 year follow-up data. ( Byun, KS; Hyun, JJ; Kang, S; Kim, HR; Kim, JH; Kim, SY; Koo, JS; Lee, SW; Seo, YS; Suh, SJ; Um, SH; Yeon, JE; Yim, HJ, 2015) |
| "Chronic hepatitis B pregnant women with normal levels of ALT and high levels of HBV DNA were treated with Telbivudine during the third trimester of their pregnancy." | 3.81 | Effect of Peg-interferon α-2a combined with Adefovir in HBV postpartum women with normal levels of ALT and high levels of HBV DNA. ( Chen, X; Chen, Y; Du, X; Liu, Y; Lu, J; Ma, L; Ren, S; Shen, C; Zhang, H; Zhang, S, 2015) |
| "We studied the growth and development of children prenatally exposed to telbivudine used to treat chronic hepatitis B virus (HBV) infection in their mothers." | 3.81 | Growth and development of children prenatally exposed to telbivudine administered for the treatment of chronic hepatitis B in their mothers. ( Cai, H; Shen, Y; Wang, Y; Zeng, H, 2015) |
| " These pregnant females developed lamivudine (LAM)- or telbivudine (LdT)-resistant chronic hepatitis B and received tenofovir (TDF) therapy (300 mg/d), and its curative effect, maternal and perinatal adverse events, fetal growth and development, and neonatal prognosis were evaluated." | 3.81 | Tenofovir rescue therapy in pregnant females with chronic hepatitis B. ( Cai, HD; Cao, YJ; Hu, YH; Liu, M; Yi, W, 2015) |
| "To explore the antiviral efficacy, safety and protective ability against mother-to-infant transmission of telbivudine in pregnant patients with chronic hepatitis B (CHB) during the first trimester." | 3.81 | [Clinical observation of telbivudine's antiviral efficacy and protection against mother-to-infant transmission of chronic hepatitis B during the first trimester of pregnancy]. ( Chen, C; Chen, F; Cheng, Q; Dai, Y; Gong, F; Lin, X; Tu, X, 2015) |
| "This study was aimed to evaluate the long-term effects of telbivudine (LdT) in the treatment of chronic hepatitis B (CHB) and HBV-related liver cirrhosis (LC) and to observe the changes of immunological responses during LdT treatment." | 3.81 | Efficacy of telbivudine in the treatment of chronic hepatitis b and liver cirrhosis and its effect on immunological responses. ( Gao, X; Liu, P; Lu, XD; Lu, YQ; Meng, N; Tang, WX; Wang, M; Yan, W; Zhang, SJ, 2015) |
| "The aim of this study was to evaluate the estimated glomerular filtration rate (eGFR) during telbivudine (LdT) versus entecavir (ETV) treatment in chronic hepatitis B (CHB) patients with underlying comorbidities such as diabetes mellitus (DM), hypertension, and cirrhosis." | 3.81 | Comparison of the Effects of Telbivudine and Entecavir Treatment on Estimated Glomerular Filtration Rate in Patients with Chronic Hepatitis B. ( Ahn, SH; Han, KH; Kim, BK; Kim, DY; Kim, SU; Ku, HJ; Lee, S; Park, JY; Song, K, 2015) |
| "To compare the efficacy of telbivudine monotherapy and telbivudine combination therapy with adefovir in patients with nucleos(t)ide-naive chronic hepatitis B, high-level hepatitis B virus (HBV) load and hepatitis B e antigen (HBeAg)-positivity, and to explore the relationship between treatment regimen adherence and treatment outcomes." | 3.81 | [Efficacy and safety of telbivudine alone and combined with adefovir for the treatment of nucleos(t)ide-naive chronic hepatitis B in patients with high-level hepatitis B virus load]. ( Dang, B; Kang, W; Liu, Q; Sun, Y; Wang, C; Yao, N; Yu, Z; Zhao, K, 2015) |
| "To compare renal function in chronic hepatitis B (CHB) patients before and after antiviral treatment with either telbivudine or entecavir administered as monotherapy,as well as to assess the impact of these antivirals on renal function in patients with mild renal impairment and to provide evidence for optimizing each as an antiviral treatment of CHB." | 3.81 | [Influence of monotherapy with telbivudine or entecavir on renal function in patients with chronic hepatitis B]. ( Li, W; Zhang, D, 2015) |
| "Use of telbivudine antiviral therapy during late pregnancy in women with high-load HBV DNA can significantly reduce level of HBV DNA in maternal peripheral blood, block HBV intrauterine transmission, and provide good short-term efficacy, with good tolerability and safety." | 3.81 | [The safety of telbivudine in preventing mother-to-infant transmission of hepatitis B virus in pregnant women after discontinuation]. ( Deng, Y; Hu, P; Kang, J; Wu, W; Yang, Y; Zeng, W; Zhang, D, 2015) |
| "To observe the clinical efficacy of combination therapy with peg-IFNalpha and adefovir (CPIA) in women who were hepatfis B virus (HBV) carriers and had just given birth and received telbivudine (LdT) during pregnancy for prevention of mother-to-child transmission." | 3.81 | [Efficacy of combination antiviral therapy following childbirth in pregnant HBV carriers receiving telbivudine for prevention of mother-to-child transmission]. ( Cao, ZH; Chen, XY; He, ZM; Jin, Y; Liu, YL; Lu, JF; Ma, LN; Zhang, SB, 2015) |
| "Previous studies have demonstrated that the treatment of chronic hepatitis B (CHB) infection with adefovir (ADV) can impair renal function." | 3.80 | Telbivudine protects renal function in patients with chronic hepatitis B infection in conjunction with adefovir-based combination therapy. ( Kim, HY; Kim, YJ; Lee, HJ; Lee, HS; Lee, JH; Lee, M; Oh, S; Yeum, TS; Yoon, JH; Yu, SJ, 2014) |
| " To examine changes in phosphorylated Smad3 signalling before and after anti-HBV therapies, we chose 27 patients with chronic hepatitis B who underwent baseline and follow-up biopsies at 52 weeks from the start of nucleoside analogue treatments (Lamivudine 100 mg daily or Telbivudine 600 mg daily)." | 3.80 | Reversible phospho-Smad3 signalling between tumour suppression and fibrocarcinogenesis in chronic hepatitis B infection. ( Deng, YR; Jin, QL; Lian, ZX; Matsuzaki, K; Moritoki, Y; Murata, M; Niu, JQ; Tsuneyama, K; Yamaguchi, T; Yoshida, K, 2014) |
| "Telbivudine therapy is generally safe and well tolerated among adult Indonesian patients with chronic hepatitis B." | 3.80 | An observational study to evaluate the safety and efficacy of telbivudine in adults with chronic hepatitis B. ( Lesmana, LA; Sulaiman, A, 2014) |
| "Since the licensing of lamivudine in 1999, the treatment of chronic hepatitis B has been revolutionized by the introduction of oral nucleoside and nucleotide analogues (NAs), which act as inhibitors of the HBV polymerase." | 3.80 | Antiviral therapy of chronic hepatitis B. ( Berg, T; van Bömmel, F, 2014) |
| "This study aimed to investigate the antiviral efficacy of telbivudine concurrent with initiation of chemotherapy in HBsAg-positive patients with lymphoma." | 3.80 | Antiviral efficacy analysis of telbivudine concurrent with the first cycle of chemotherapy in HBsAg-positive lymphoma patients. ( Guo, H; Huang, L; Li, W; Liang, Z; Wei, X, 2014) |
| "There were 136 patients of chronic hepatitis B treated with entecavir (68) or telbivudine (68)." | 3.80 | [Effect of human concentration nucleoside transporters 1 and multi-drug resistance protein 4 gene polymorphism on response of chronic hepatitis B to nucleoside analogues treatment]. ( He, M; Li, DJ; Liu, C; Lu, JJ; Lu, LX; Tang, H; Wang, LC; Wang, WZ, 2014) |
| "There is very limited experience in the management of telbivudine (LdT)-associated virological breakthrough (VBT) and resistance in the treatment of chronic hepatitis B (CHB) patients, and the guideline recommendations are primitively based on the general principles of rescue therapy to nucleos(t)ide analog resistance." | 3.79 | Telbivudine plus adefovir therapy for chronic hepatitis B patients with virological breakthrough or genotypic resistance to telbivudine. ( Bai, XF; Huang, CX; Li, Y; Lian, JQ; Wang, JP; Zhang, Y, 2013) |
| "The roadmap concept suggests the use of on-treatment HBV DNA to guide treatment strategy of chronic hepatitis B patients treated by telbivudine." | 3.79 | Efficacy of entecavir switch therapy in chronic hepatitis B patients with incomplete virological response to telbivudine. ( Chan, HL; Chan, HY; Cheung, CM; Lo, AO; Wong, GL; Wong, VW, 2013) |
| " Fifteen chronic hepatitis B patients (men, 10; mean age, 34; HBeAg positive, 6) who received lamivudine or telbivudine for at least 52 weeks were included." | 3.79 | Dynamics of hepatitis B virus quasispecies heterogeneity and virologic response in patients receiving low-to-moderate genetic barrier nucleoside analogs. ( Farnik, H; Herrmann, E; Hofmann, WP; Kronenberger, B; Peveling-Oberhag, J; Sarrazin, C; Susser, S; Zeuzem, S, 2013) |
| " This study aimed at determining serum IL-37 concentrations and HBeAg seroconversion in chronic hepatitis B virus (HBV) patients during Telbivudine (LDT) treatment." | 3.79 | Serum interleukin-37 concentrations and HBeAg seroconversion in chronic HBV patients during telbivudine treatment. ( Ayana, DA; Cai, Y; Ji, H; Jiang, Y; Li, C; Liu, M; Lv, P, 2013) |
| "We recruited 161 patients of chronic hepatitis B (CHB) on telbivudine between January 2009 and September 2011 in Macau, China." | 3.79 | Serum HBV DNA level at week 12 is superior to viral response at week 24 in predicting long-term treatment outcome of telbivudine for chronic hepatitis B patients. ( Fan, HW; Fan, YM; Li, T; Liu, XQ; Liu, ZY; Lü, W; Mui, C; Ng, H; Yang, HH; Zhang, LF; Zhou, BT, 2013) |
| "Twenty-one consecutive chronic hepatitis B patients experiencing severe acute exacerbation were treated with either telbivudine or entecavir." | 3.79 | On-treatment mortality predictors in chronic hepatitis B patients experiencing severe acute exacerbation: a prospective observational study. ( Chang, MY; Chen, YC; Hsu, CW; Yeh, CT, 2013) |
| " Telbivudine therapy has been proved to inhibit HBV replication effectively and to improve clinical outcome of chronic hepatitis B (CHB)." | 3.79 | Kinetics of Th17 cytokines during telbivudine therapy in patients with chronic hepatitis B. ( Bai, X; Hao, C; Jia, Z; Kang, W; Lian, J; Ma, L; Peng, M; Wang, J; Xie, Y; Zhou, Y, 2013) |
| "The aim of our study was to validate the roadmap concept in the treatment of chronic hepatitis B, and to investigate the virologic efficacy and kinetics of quantitative hepatitis B surface antigen (qHBsAg) during telbivudine therapy in a real-world setting." | 3.79 | Real-world application of the roadmap model in chronic hepatitis B patients with telbivudine therapy. ( Hsu, PI; Lai, KH; Lin, KH; Tsai, TJ; Tsay, FW; Wang, HM; Yu, HC, 2013) |
| "To investigate the efficacy and safety ofTelbivudine +Tenofovir combination therapy in chronic hepatitis B patients, over a period of 52 weeks, in real life clinical settings." | 3.79 | Telbivudine plus tenofovir in combination therapy in patients with chronic hepatitis B infection--an Indian experience. ( Panda, C, 2013) |
| "We propose an explorative evaluation of treatment of MC HBV-related with telbivudine (LdT) in a small group of patients affected by chronic hepatitis B (CHB)." | 3.79 | Telbivudine in the treatment of hepatitis B-associated cryoglobulinemia. ( Boglione, L; Cariti, G; D'Avolio, A; Di Perri, G, 2013) |
| " This study was aimed at investigating the impact of treatment with telbivudine (LDT) on T and NK cell immunity in patients with chronic hepatitis B (CHB)." | 3.79 | Treatment with telbivudine positively regulates antiviral immune profiles in Chinese patients with chronic hepatitis B. ( Cai, YJ; Feng, JY; Jiang, YF; Li, C; Ma, L; Niu, JQ; Wang, J; Yu, L, 2013) |
| " In this study, we investigated the frequencies, functions and PD-1 expression of peripheral iNKT cells from HBeAg-positive chronic hepatitis B (CHB) patients during antiviral treatment with Telbivudine." | 3.78 | Effects of antiviral therapy with Telbivudine on peripheral iNKT cells in HBeAg(+) chronic hepatitis B patients. ( Chen, CB; Chen, M; Ren, H; Shi, TD; Sun, H; Wang, XF; Zhang, JM, 2012) |
| "To evaluate the efficacy of telbivudine and entecavir in chronic hepatitis B (CHB) patients over a 1 year period." | 3.78 | A comparison of telbivudine and entecavir for chronic hepatitis B in real-world clinical practice. ( Chang, KC; Chen, CH; Chiu, KW; Hu, TH; Hung, CH; Lee, CM; Lu, SN; Tsai, MC; Tseng, PL; Tung, WC; Wang, JH; Yen, YH, 2012) |
| "To evaluate the changes in the renal function of patients with chronic hepatitis B (CHB) receiving adefovir dipivoxil (ADV) or telbivudine (L-DT) monotherapy." | 3.78 | [Influence of adefovir dipivoxil or telbivudine monotherapy on renal function of patients with chronic hepatitis B]. ( Fan, R; Guo, Y; Hou, J; Li, X; Peng, J; Sun, J; Yang, S; Zhong, C, 2012) |
| "To evaluate the occurrence and prognosis of telbivudine (LdT) therapy-associated elevations in creatine kinase (CK) in chronic hepatitis B (CHB) patients." | 3.78 | [Telbivudine-associated creatine kinase elevation in chronic hepatitis B patients]. ( Jia, JD; Li, HY; Ma, H; Ren, JB; Sun, SJ; Wang, Y, 2012) |
| "We determined the cumulative rates of HBeAg seroconversion, ALT normalization, HBV DNA suppression (<12IU/ml) and telbivudine resistant mutations (using the highly sensitive line probe assay) for 117 treatment-native chronic hepatitis B (CHB) patients (61." | 3.77 | Significance of HBV DNA levels at 12 weeks of telbivudine treatment and the 3 years treatment outcome. ( Fung, J; Hung, IF; Lai, CL; Seto, WK; Wong, DK; Yuen, JC; Yuen, MF, 2011) |
| " Several lines of experimental evidence suggest that treatment with telbivudine increases the rate of HBV e antigen (HBeAg) loss, undetectable HBV DNA, and normalization of serum alanine aminotransferase (ALT) in chronic hepatitis B patients (CHB)." | 3.77 | Effect of telbivudine therapy on the cellular immune response in chronic hepatitis B. ( Cao, H; Chen, B; Chen, Y; Li, L; Li, X; Pan, X; Wu, W; Yang, X; Ye, B, 2011) |
| "To study PD-1 and PD-L1 expressions during 24 weeks telbivudine antiviral treatment in patients with chronic hepatitis B (CHB) and to explore the relationship between PD-1 expression and HBeAg/HBeAb seroconversion." | 3.76 | [Programmed death-1 (PD-1) and PD-L1 expression during antiviral treatment of chronic hepatitis B]. ( Chen, FJ; Chong, YT; Deng, H; Gao, ZL; Lin, BL; Xie, DY; Zhang, XH, 2010) |
| "To investigate the dynamic changes of Th1/Th2 type cytokines in peripheral blood of patients with hepatitis B e antigen-positive chronic hepatitis B treated with telbivudine (LDT)." | 3.75 | [Dynamic changes of Th1/Th2 type cytokines in peripheral blood of patients with hepatitis B e antigen-positive chronic hepatitis B treated with telbivudine]. ( Chen, M; Guo, SH; He, H; Zhang, DZ; Zhang, L, 2009) |
| " We studied longitudinally 18 hepatitis B e antigen (HBeAg)-positive patients undergoing treatment with direct antivirals (telbivudine or lamivudine) to determine the relationship between treatment-induced viremia reduction and HBeAg seroconversion with respect to PD-1 levels and T-cell reactivity." | 3.74 | Programmed death 1 expression during antiviral treatment of chronic hepatitis B: Impact of hepatitis B e-antigen seroconversion. ( Brett, S; Chokshi, S; Cooksley, H; Evans, A; Naoumov, NV; Nathwani, A; Phillips, S; Puranik, S; Riva, A, 2008) |
| "To investigate the effect of telbivudine on peripheral blood regulatory T cells and its significance in patients with chronic hepatitis B (CHB)." | 3.74 | [The effect of telbivudine on peripheral blood CD4+CD25+ regulatory T cells and its significance in patients with chronic hepatitis B]. ( Chen, M; Pan, XC; Yang, F, 2008) |
| "Telbivudine is a novel nucleoside drug recently approved for the treatment of patients with chronic hepatitis B." | 3.74 | Nonclinical safety profile of telbivudine, a novel potent antiviral agent for treatment of hepatitis B. ( Bridges, EG; Luo, S; Selden, JR, 2008) |
| "Twenty-six HBeAg-positive chronic hepatitis B patients were treated with LDT for a period of 104 weeks and were characterized as 16 responders, six partial responders and four viral breakthrough patients based on hepatitis B virus (HBV) DNA levels." | 2.80 | Resistant mutations and quasispecies complexity of hepatitis B virus during telbivudine treatment. ( Deng, F; Du, R; Fang, W; Han, M; Hu, Z; Liu, J; Ning, Q; Rayner, S; Wang, H; Wang, M; Wu, C; Wu, Z; Yin, F, 2015) |
| "Adefovir + telbivudine treatment resulted in a significant reduction in HBV DNA levels." | 2.79 | Telbivudine and adefovir combination therapy for patients with chronic lamivudine-resistant hepatitis B virus infections. ( Chang, KC; Chiu, KW; Chou, YP; Hsu, YC; Hu, TH; Lin, MT; Tsai, MC; Tseng, PL; Yen, YH; Yu, HC, 2014) |
| "Patients with hepatitis B virus-related hepatocellular carcinoma undergoing liver resection were screened." | 2.78 | Antiviral therapy decreases viral reactivation in patients with hepatitis B virus-related hepatocellular carcinoma undergoing hepatectomy: a randomized controlled trial. ( Huang, L; Li, J; Sun, J; Wu, M; Yan, J; Yan, Y; Zhang, X, 2013) |
| "Telbivudine treatment has significantly improved the clinical outcome of chronic HBV infection." | 2.77 | Inhibition of viral replication downregulates CD4(+)CD25(high) regulatory T cells and programmed death-ligand 1 in chronic hepatitis B. ( Bai, XF; Li, Y; Lian, JQ; Nan, XP; Peng, MJ; Su, WJ; Sun, RL; Wang, JP; Yu, HT; Zhang, Y, 2012) |
| "There is no standard management of chronic hepatitis B (CHB) patients with suboptimal response to nucleoside/nucleotide analogues (NAs)." | 2.77 | Lamivudine plus adefovir or telbivudine plus adefovir for chronic hepatitis B patients with suboptimal response to adefovir. ( Bai, L; Chen, EQ; Liang, LB; Tang, H; Wang, JR; Yan, LB; Zhou, TY, 2012) |
| "Telbivudine treatment was an independent predictive factor for HBV DNA <300 copies/mL and ALT normalization (P = 0." | 2.77 | Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-naïve patients with HBV-related decompensated cirrhosis. ( Avila, C; Bao, W; Chan, HL; Chen, YC; Choudhuri, G; Chutaputti, A; Gane, EJ; Hwang, SG; Piratvisuth, T; Prabhakar, B; Safadi, R; Sarin, SK; Suh, DJ; Tanwandee, T; Trylesinski, A; Yurdaydin, C, 2012) |
| "352 patients with acute-on-chronic hepatitis B liver failure including 175 cases of low HBV viral load and 177 cases of high HBV viral load were enrolled into this study." | 2.75 | [Efficacy of antiviral treatment on patients with acute-on-chronic hepatitis B liver failure with low viral load]. ( Cao, H; Chen, LB; Chen, N; Li, G; Shu, X; Xu, QH; Zhang, K; Zhang, YF, 2010) |
| "Telbivudine is an L-nucleoside analogue with potent antiviral activity against hepatitis B virus (HBV)." | 2.73 | [The efficacy and safety of telbivudine in korean patients with chronic hepatitis B]. ( Ahn, SH; Cho, M; Choi, HS; Han, JY; Hwang, SG; Kim, BS; Kim, DJ; Kim, YS; Moon, YM; Rim, KS, 2007) |
| "Telbivudine has potent antiviral activity against hepatitis B virus (HBV) in vitro and in the woodchuck model and has a promising preclinical safety profile." | 2.71 | A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection. ( Brown, NA; Chao, GC; Lai, CL; Lee, YM; Lim, SG; Lloyd, DM; Myers, MW; Yuen, MF; Zhou, XJ, 2004) |
| "Telbivudine treatment, whether short term or long term, is associated with higher HBeAg seroconversion compared with the other NAs." | 2.55 | HBeAg Seroconversion in HBeAg-Positive Chronic Hepatitis B Patients Receiving Long-Term Nucleos(t)ide Analog Treatment: A Systematic Review and Network Meta-Analysis. ( Cao, L; Xing, T; Xu, H; Ye, M, 2017) |
| "Telbivudine was also superior to lamivudine in ALT normalization and to adefovir and lamivudine in suppressing HBV DNA levels." | 2.53 | Effect of Telbivudine Versus Other Nucleos(t)ide Analogs on HBeAg Seroconversion and Other Outcomes in Patients with Chronic Hepatitis B: A Network Meta-Analysis. ( Fan, R; Gupta, S; Hamed, K; Liang, X; Shaikh, J; Sun, J; Taneja, A, 2016) |
| "Because the course of chronic hepatitis B is determined by an ongoing interaction between the virus and the host immune system, immunomodulation may be the most logical approach in attempting to accomplish control or even cure of chronic hepatitis B." | 2.52 | How to achieve immune control in chronic hepatitis B? ( Janssen, HL; van Campenhout, MJ, 2015) |
| "Hepatitis B is a major cause of hepatocellular carcinoma and liver cirrhosis." | 2.52 | Hepatitis B: encouraging the use of interferon. ( Krishnamoorthy, TL; Mutimer, D, 2015) |
| " Long-term use of NUCs with maintained viral suppression results in a decrease in liver-related complications." | 2.52 | Monotherapy for hepatitis B infection: a review of treatment options. ( Demirhan, YE; Gultekin, G; Isal, B; Khodor, H; Ozaras, R; Unal, UK; Yetim, N, 2015) |
| "Increased risk of lactic acidosis has also been described for those with impaired liver and renal function taking entecavir." | 2.50 | Extrahepatic effects of nucleoside and nucleotide analogues in chronic hepatitis B treatment. ( Fung, J; Lai, CL; Seto, WK; Yuen, MF, 2014) |
| "NAs are used in most HBeAg-positive chronic hepatitis B patients for several reasons." | 2.50 | HBeAg-positive chronic hepatitis B: why do i treat my patients with Nucleos(t)ide analogs? ( Buti, M, 2014) |
| "There are five approved drugs for the treatment of chronic hepatitis B(lamivudine, adefovir dipivoxil [ADV], entecavir [ETV], as well as pegylated and standard interferon) in Japan." | 2.48 | [New drugs of treatment of patients with chronic hepatitis B]. ( Suzuki, F, 2012) |
| "Telbivudine is a synthetic thymidine nucleoside analogue with activity against HBV." | 2.48 | The effects of telbivudine in late pregnancy to prevent intrauterine transmission of the hepatitis B virus: a systematic review and meta-analysis. ( Chen, HZ; Deng, M; Gao, S; Ruan, B; Wang, B; Yang, SG; Zhou, X, 2012) |
| "Treatment of chronic hepatitis B (CHB) with nucleos(t)ide analogs is often required over a prolonged period to achieve durable virologic suppression." | 2.48 | Considerations for the long-term treatment of chronic hepatitis B with nucleos(t)ide analogs. ( Buti, M; Petersen, J, 2012) |
| "In the natural history of chronic hepatitis B infection, HBeAg marks the first two of the four phases, namely the immune tolerant phase and the immune clearance phase, and is associated with highly replicative activity of the hepatitis B virus (HBV)." | 2.47 | Treatment of HBeAg-positive chronic hepatitis B with nucleos(t)ide analogues. ( Leung, N, 2011) |
| "Major progress in the treatment of chronic hepatitis B (CHB) has been made during the last decade with the development of antivirals that inhibit viral polymerase activity." | 2.47 | Hepatitis B virus resistance to antiviral drugs: where are we going? ( Zoulim, F, 2011) |
| "Treatment of chronic hepatitis B is still challenging." | 2.47 | [Interferon-based versus direct antiviral therapy in patients with chronic hepatitis B]. ( Tornai, I, 2011) |
| "Successful treatment of chronic hepatitis B (CHB) often requires long-term oral nucleoside/nucleotide agents which can be associated with viral resistance, patient non-compliance and adverse effects." | 2.46 | Safety evaluation of telbivudine. ( But, DY; Fung, J; Lai, CL; Yuen, MF, 2010) |
| "Telbivudine has a resistance rate lower than that of LAM and higher than that of entecavir or tenofovir." | 2.46 | Telbivudine: an effective anti-HBV drug for chronic hepatitis B patients with early on-treatment responses. ( Hann, HW, 2010) |
| "Telbivudine is a potent antiviral that provides effective and sustained viral suppression in patients with compensated CHB." | 2.46 | Telbivudine: a review of its use in compensated chronic hepatitis B. ( Keam, SJ; McKeage, K, 2010) |
| "Antiviral therapy is aimed to persistently suppress hepatitis B virus (HBV) to prevent liver complications and improve survival and long-term administration of nucleos(t)ide analogues represents an attractive treatment strategy." | 2.45 | HBeAg-negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues. ( Colombo, M; Lampertico, P, 2009) |
| "Telbivudine is an L-nucleoside that is structurally related to lamivudine and has recently been approved for use in patients with chronic HBV infection." | 2.45 | Telbivudine in the treatment of chronic hepatitis B. ( Nash, K, 2009) |
| "Telbivudine was also proved to be superior to lamivudine and adefovir dipivoxil." | 2.45 | Treatment of chronic hepatitis B: focus on telbivudine. ( Chan, HL; Lui, YY, 2009) |
| "Telbivudine has also been reported to be associated with myopathy and neuropathy, particularly when used in combination with pegylated interferon." | 2.45 | Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B. ( Fleischer, RD; Lok, AS, 2009) |
| "Chronic hepatitis B is a serious disease both worldwide and in the United States." | 2.45 | Current status of nucleoside antivirals in chronic hepatitis B. ( Duong, A; Mousa, SA, 2009) |
| "Treatment of chronic hepatitis B with oral nucleos(t)ide analogs is evolving rapidly with newer compounds gaining approval." | 2.44 | Telbivudine in the treatment of chronic hepatitis B. ( Hadziyannis, SJ; Vassilopoulos, D, 2008) |
| "Chronic hepatitis B is still a major public health problem, aggravated by the growing phenomenon of immigration from areas with a high prevalence of infection with this virus." | 2.44 | [Clinical management of patients with chronic hepatitis B virus infection]. ( González-Diéguez, ML; Rodríguez, M, 2008) |
| "Six drugs have been approved for the treatment of chronic hepatitis B: interferon-alpha(2b), pegylated interferon-alpha(2a), lamivudine, adefovir, entecavir and telbivudine." | 2.44 | Telbivudine: a new option for the treatment of chronic hepatitis B. ( Ruiz-Sancho, A; Sheldon, J; Soriano, V, 2007) |
| "Telbivudine was generally well tolerated and most adverse events were of mild or moderate severity." | 2.44 | Telbivudine. ( Keam, SJ, 2007) |
| "Telbivudine is a novel, orally administered nucleoside analogue for use in the treatment of chronic hepatitis B." | 2.44 | Telbivudine: a new treatment for chronic hepatitis B. ( Amarapurkar, DN, 2007) |
| "Telbivudine (LdT) is an L-nucleoside that is structurally related to lamivudine." | 2.44 | Telbivudine for the management of chronic hepatitis B virus infection. ( Matthews, SJ, 2007) |
| " The incidence of HCC correlated with serum HBV DNA level at entry in a dose-response relationship." | 2.44 | Active antiviral therapy for chronic hepatitis B and hepatocellular carcinoma. ( Hann, HW, 2008) |
| "Telbivudine was well tolerated with no identified safety issues." | 2.43 | Telbivudine: a new nucleoside analogue for the treatment of chronic hepatitis B. ( Han, SH, 2005) |
| "To summarize, the future of chronic hepatitis B therapy seems to be the combination of different drugs." | 2.42 | Entecavir, FTC, L-FMAU, LdT and others. ( Buti, M; Esteban, R, 2003) |
| "Currently approved treatments for chronic hepatitis B are limited by low rates of sustained response, side effects, or drug resistance." | 2.42 | New treatment of chronic hepatitis B. ( Lok, AS, 2004) |
| " All LdT-treated mothers were well tolerated and no LdT-related adverse events in infants were reported." | 1.91 | Efficacy and Long-term Safety of Telbivudine Usage During Second or Third Trimester in Hepatitis B Surface Antigen Positive Mothers With High Viral Load: A 10-year Prospective Study. ( Chen, C; Han, G; Jiang, H; Ye, X; Zhou, G, 2023) |
| "Telbivudine is an orally nucleoside analog with potent and specific antihepatitis B virus (HBV) activity, and it has been reported to block mother-to-infant transmission." | 1.48 | Motor development delay in offspring is associated with prenatal telbivudine exposure. ( Hou, M; Huang, HF; Jin, L; Miao, M; Sheng, J; Wang, H; Yang, Q; Yang, X; Yu, Y; Zhang, F; Zhou, C, 2018) |
| "Telbivudine (LdT) is an orally L-nucleoside with potent and specific antihepatitis B virus (HBV) activity." | 1.46 | Relationship of Treg/Th17 balance with HBeAg change in HBeAg-positive chronic hepatitis B patients receiving telbivudine antiviral treatment: A longitudinal observational study. ( Gao, M; Li, J; Liu, J; Lu, W; Yang, X; Zhou, L, 2017) |
| " In addition, adverse events regarding infants at delivery and HBV vaccination outcomes were recorded." | 1.46 | Safety and efficacy of telbivudine for chronic hepatitis B during the entire pregnancy: Long-term follow-up. ( Bai, L; Liu, K; Shang, J; Tang, H; Wang, CC; Wen, Q, 2017) |
| "Mortality and complications including hepatocellular carcinoma are associated primarily with cirrhosis and age, but not with HBeAg status or viral load probably because modern therapies considerably reduce viral replication in almost all patients." | 1.43 | Long-term follow-up of HBsAg-positive patients in Germany. ( Amani, A; Niederau, C; Thiel, A, 2016) |
| "This study indicates that newer antivirals are effective and safe in HTR with CHB." | 1.43 | Efficacy and safety of tenofovir, entecavir, and telbivudine for chronic hepatitis B in heart transplant recipients. ( Andini, R; Durante-Mangoni, E; Falco, E; Iossa, D; Maiello, C; Parrella, A; Ragone, E; Utili, R; Vitrone, M; Zampino, R, 2016) |
| "Both telbivudine and entecavir were associated with eGFR improvement, especially in patients with renal insufficiency." | 1.40 | A comparison of efficacy and safety of 2-year telbivudine and entecavir treatment in patients with chronic hepatitis B: a match-control study. ( Chang, KC; Chen, CH; Chiu, KW; Hu, TH; Hung, CH; Lee, CM; Lu, SN; Tsai, MC; Tseng, PL; Wang, JH; Yen, YH, 2014) |
| " Antiviral treatments were withdrawn in patients who met all of the following 7 criteria: (i) no clinical and histologic evidence of cirrhosis, (ii) normal liver biochemistry, (iii) negative for both HBV DNA and hepatitis B envelope antigen (HBeAg), (iv) no resistance to antiviral agent, (v) antiviral therapy > 9 months, (vi) maintenance dosage of immunosuppressant for > 3 months, and (vii) no history of acute rejection during recent 6 months." | 1.40 | Successful withdrawal of antiviral treatment in kidney transplant recipients with chronic hepatitis B viral infection. ( Cho, JH; Choi, JY; Huh, S; Kang, YJ; Kim, CD; Kim, HK; Kim, JS; Kim, YL; Kwon, O; Lim, JH; Park, GY; Park, SH, 2014) |
| "Telbivudine is an L-nucleoside analogue with potent antiviral activity against hepatitis B virus (HBV)." | 1.39 | Two cases of telbivudine-induced myopathy in siblings with chronic hepatitis B. ( Ahn, SH; Han, KH; Kim, EH; Kim, SM; Lee, KH; Park, H, 2013) |
| "In patients affected by chronic hepatitis because of HBV infection, long-term suppressive therapy with nucleos(t)ides analogues in the HBeAg- patients has shown low effects on HBsAg titre (qHBsAg) decrease, and HBsAg loss is difficult to achieve." | 1.39 | Kinetics and prediction of HBsAg loss during therapy with analogues in patients affected by chronic hepatitis B HBeAg negative and genotype D. ( Baietto, L; Boglione, L; Burdino, E; Cariti, G; Cusato, J; D'Avolio, A; De Rosa, FG; Di Perri, G; Ghisetti, V; Gregori, G, 2013) |
| "New insights into the treatment of chronic hepatitis B with relevance for clinical practice have been adopted in these concise, revised guidelines." | 1.38 | The 2012 revised Dutch national guidelines for the treatment of chronic hepatitis B virus infection. ( Baak, BC; Bakker, CM; Beuers, UH; Brouwer, JT; Buster, EH; Drenth, JP; Honkoop, P; Janssen, HL; Kerbert-Dreteler, MJ; Koek, GH; Tan, AC; van der Spek, BW; van Erpecum, KJ; van Hoek, B; van Nieuwkerk, KM; van Soest, H; Vrolijk, JM, 2012) |
| "Current agents used in the treatment of chronic hepatitis B (CHB) can be classified into interferons-α (IFN-α: standard or pegylated) and nucleos(t)ide analogues (NUCs)." | 1.37 | Treatment of HBeAg-negative chronic hepatitis B patients with nucleos(t)ide analogues. ( Papatheodoridis, GV, 2011) |
| "In this study, 35 chronic hepatitis B (CHB) patients, 25 inactive carriers (IC) and 36 healthy controls (HC) were enrolled and the proportions of circulating iNKT cells in fresh isolated peripheral blood mononuclear cells (PBMC) were detected by flow cytometry." | 1.37 | Restored circulating invariant NKT cells are associated with viral control in patients with chronic hepatitis B. ( Abbott, WG; Hou, J; Huang, X; Jiang, X; Lai, Q; Li, Y; Ma, S; Sun, J; Zhang, M, 2011) |
| "Effective management of chronic hepatitis B infection is still very challenging, despite decades of clinical research." | 1.36 | On-treatment serum HBsAg level is predictive of sustained off-treatment virologic response to telbivudine in HBeAg-positive chronic hepatitis B patients. ( An, B; Bao, S; Cai, W; Gu, R; Guo, Q; Wang, H; Xie, Q; Zhao, G; Zhou, X, 2010) |
| "Telbivudine treatment progressively reduced serum HBsAg levels (mean ± SD) from baseline (3." | 1.36 | Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients. ( Bao, W; Goodman, ZD; Jung, M; Lopez, P; Manns, MP; Naoumov, NV; Riva, A; Wedemeyer, H; Wursthorn, K, 2010) |
| "Serum samples of 199 chronic hepatitis B patients undergoing NA treatment from five hospitals in four northern cities of China were obtained between January 2007 and July 2009." | 1.36 | Profile of HBV antiviral resistance mutations with distinct evolutionary pathways against nucleoside/nucleotide analogue treatment among Chinese chronic hepatitis B patients. ( Abuduheilili, X; Dong, JP; Hou, CS; Jiao, XJ; Li, T; Li, XG; Liu, BM; Sun, XW; Wang, YH; Xu, J; Yan, CH; Yan, L; Yang, JX; Zhuang, H, 2010) |
| "This was accompanied by cardiac arrhythmia in one patient, and nervous symptoms in three." | 1.35 | Clinical features of adverse reactions associated with telbivudine. ( Jin, R; Tao, ML; Zhang, SB; Zhang, XS, 2008) |
| "Long-term management of some chronic hepatitis B patients might require combination therapy using drugs with distinct resistance profiles to sustain viral suppression and to reduce the resistance-associated failure." | 1.35 | Anti-hepatitis B virus activity in vitro of combinations of tenofovir with nucleoside/nucleotide analogues. ( Borroto-Esoda, K; Curtis, M; Miller, MD; Qi, X; Zhu, Y, 2009) |
| "A total of 170 naïve HBeAg-positive chronic hepatitis B patients were treated with a nucleoside/nucleotide analogues (NA), either lamivudine, adefovir, entecavir, or telbivudine, for at least 2 years and followed up for 1 more year." | 1.35 | Different models of HBeAg seroconversion predicated by on-treatment ALT and HBV DNA profiles. ( Cong, M; Jia, J; Li, H; Liu, T; Ma, H; Ou, X; Ren, J; Wang, B; Wang, P; Wang, X; You, H, 2009) |
| "Chronic hepatitis B affects 5-10% of HIV patients in Western countries." | 1.35 | Hepatitis B in HIV patients: what is the current treatment and what are the challenges? ( Barreiro, P; Fernández, JV; Labarga, P; Medrano, J; Soriano, V; Tuma, P; Vispo, E, 2009) |
| "Telbivudine is a potent inhibitor of hepatitis B virus (HBV) replication without anti-HIV type-1 (HIV-1) activity demonstrated in vitro; however, very few clinical data on HIV-1-infected patients are available at present." | 1.35 | Telbivudine in the treatment of chronic hepatitis B: experience in HIV type-1-infected patients naive for antiretroviral therapy. ( Balotta, C; Caramma, I; Cesari, M; De Maddalena, C; Galli, M; Lai, A; Milazzo, L; Violin, M, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 78 (23.64) | 29.6817 |
| 2010's | 250 (75.76) | 24.3611 |
| 2020's | 2 (0.61) | 2.80 |
| Authors | Studies |
|---|---|
| Jiang, H | 2 |
| Ye, X | 2 |
| Chen, C | 6 |
| Zhou, G | 1 |
| Han, G | 1 |
| Lu, J | 2 |
| Wang, X | 5 |
| Zhu, Y | 3 |
| Ma, L | 5 |
| Zheng, S | 1 |
| Hu, Z | 2 |
| Chen, X | 5 |
| Zhang, MY | 1 |
| Zhu, GQ | 1 |
| Zheng, JN | 1 |
| Cheng, Z | 1 |
| Van Poucke, S | 1 |
| Shi, KQ | 3 |
| Huang, HH | 1 |
| Chen, FY | 1 |
| Zheng, MH | 2 |
| Kim, DH | 1 |
| Choi, JW | 2 |
| Seo, JH | 2 |
| Cho, YS | 2 |
| Won, SY | 2 |
| Park, BK | 2 |
| Jeon, HH | 2 |
| Shin, SY | 1 |
| Lee, CK | 2 |
| Kader, C | 1 |
| Sunbul, M | 1 |
| Das, YK | 1 |
| Yarim, M | 1 |
| Bedir, A | 1 |
| Karaca, E | 1 |
| Celikbilek, M | 1 |
| Ozaras, R | 2 |
| He, L | 1 |
| Liu, X | 3 |
| Zhao, Y | 5 |
| Zhang, S | 4 |
| Jiang, Y | 2 |
| Yang, Z | 2 |
| Sun, W | 1 |
| Zhao, S | 2 |
| Hao, A | 1 |
| Zhao, B | 1 |
| Zhou, L | 3 |
| Li, F | 1 |
| Song, M | 1 |
| Chamroonkul, N | 1 |
| Piratvisuth, T | 4 |
| Su, TH | 2 |
| Liu, CJ | 1 |
| Cai, S | 2 |
| Cao, J | 1 |
| Yu, T | 1 |
| Xia, M | 1 |
| Peng, J | 3 |
| Yang, X | 3 |
| Li, J | 4 |
| Liu, J | 6 |
| Gao, M | 1 |
| Lu, W | 3 |
| Liang, X | 2 |
| Xie, Q | 6 |
| Tan, D | 4 |
| Ning, Q | 3 |
| Niu, J | 7 |
| Bai, X | 3 |
| Chen, S | 3 |
| Cheng, J | 2 |
| Yu, Y | 3 |
| Wang, H | 5 |
| Xu, M | 2 |
| Shi, G | 3 |
| Wan, M | 6 |
| Tang, H | 7 |
| Sheng, J | 3 |
| Dou, X | 2 |
| Shi, J | 2 |
| Ren, H | 9 |
| Wang, M | 8 |
| Zhang, H | 5 |
| Gao, Z | 4 |
| Ma, H | 6 |
| Chen, Y | 10 |
| Fan, R | 5 |
| Sun, J | 14 |
| Jia, J | 14 |
| Hou, J | 14 |
| Shang, J | 1 |
| Wen, Q | 1 |
| Wang, CC | 2 |
| Liu, K | 3 |
| Bai, L | 2 |
| Yao, N | 2 |
| Luo, XD | 3 |
| Chen, XF | 3 |
| Zhou, Y | 3 |
| Chen, XP | 3 |
| Chen, T | 2 |
| Chen, B | 3 |
| Chen, L | 5 |
| Cheng, C | 3 |
| Zhong, M | 1 |
| Shi, X | 1 |
| Zhang, J | 4 |
| Wang, B | 5 |
| Zheng, J | 2 |
| Deng, M | 2 |
| Qiu, X | 1 |
| Chen, Z | 1 |
| Li, D | 1 |
| Deng, X | 1 |
| Deng, Q | 1 |
| Yu, Z | 2 |
| He, T | 1 |
| Bai, Y | 1 |
| Cai, H | 4 |
| Ou, X | 3 |
| Liu, M | 6 |
| Yi, W | 3 |
| Zhou, C | 1 |
| Yang, Q | 1 |
| Hou, M | 1 |
| Jin, L | 3 |
| Zhang, F | 1 |
| Miao, M | 1 |
| Huang, HF | 1 |
| Kim, SH | 1 |
| Lee, YK | 1 |
| Ying, Y | 1 |
| Hu, YK | 1 |
| Jin, JL | 2 |
| Zhang, JM | 4 |
| Zhang, WH | 1 |
| Huang, YX | 1 |
| Guo, X | 1 |
| Wu, J | 1 |
| Wei, F | 1 |
| Ouyang, Y | 1 |
| Li, Q | 1 |
| Wang, Y | 14 |
| Zhang, Y | 9 |
| Chen, D | 1 |
| Huang, C | 1 |
| Yang, XH | 1 |
| Yang, YL | 1 |
| Huang, AL | 1 |
| Shi, XF | 2 |
| Sheng, QJ | 1 |
| Wang, SJ | 1 |
| Wu, YY | 1 |
| Dou, XG | 1 |
| Ding, Y | 2 |
| Yan, Z | 2 |
| Qiao, B | 1 |
| Gou, W | 1 |
| Fan, Y | 1 |
| Zhou, S | 2 |
| Li, C | 4 |
| Ma, B | 1 |
| Fan, L | 1 |
| Jing, H | 1 |
| Lian, JQ | 3 |
| Li, Y | 10 |
| Wang, JP | 4 |
| Huang, CX | 1 |
| Bai, XF | 3 |
| You, H | 3 |
| Wang, GQ | 2 |
| Ding, YP | 2 |
| Dong, YH | 2 |
| Hou, FQ | 1 |
| Wu, XJ | 1 |
| Chen, J | 3 |
| Liu, YZ | 1 |
| Ren, YY | 1 |
| Song, G | 1 |
| Yu, M | 1 |
| Lu, JJ | 2 |
| Ma, YJ | 1 |
| Wang, J | 9 |
| Chen, EQ | 3 |
| Huang, Z | 4 |
| Zhao, Z | 1 |
| Zheng, Y | 2 |
| Peng, L | 1 |
| Lin, C | 1 |
| Deng, H | 2 |
| Lo, AO | 2 |
| Wong, VW | 4 |
| Wong, GL | 3 |
| Chan, HY | 2 |
| Cheung, CM | 1 |
| Chan, HL | 10 |
| Peveling-Oberhag, J | 1 |
| Herrmann, E | 2 |
| Kronenberger, B | 1 |
| Farnik, H | 1 |
| Susser, S | 1 |
| Sarrazin, C | 1 |
| Zeuzem, S | 6 |
| Hofmann, WP | 1 |
| Thongsawat, S | 3 |
| Gane, EJ | 4 |
| Liaw, YF | 8 |
| Papatheodoridis, G | 4 |
| Bao, W | 8 |
| Trylesinski, A | 6 |
| Naoumov, NV | 9 |
| Amarapurkar, DN | 2 |
| Patel, N | 1 |
| Liu, H | 3 |
| Wan, G | 1 |
| Zeng, H | 2 |
| Huang, L | 2 |
| Yan, J | 2 |
| Zhang, X | 5 |
| Wu, M | 1 |
| Yan, Y | 1 |
| Salpini, R | 1 |
| Alteri, C | 1 |
| Cento, V | 1 |
| Pollicita, M | 1 |
| Micheli, V | 1 |
| Gubertini, G | 1 |
| De Sanctis, GM | 1 |
| Visca, M | 1 |
| Romano, S | 1 |
| Sarrecchia, C | 1 |
| Andreoni, M | 1 |
| Angelico, M | 2 |
| Parruti, G | 1 |
| Svicher, V | 1 |
| Perno, CF | 1 |
| Kim, EH | 1 |
| Park, H | 2 |
| Lee, KH | 2 |
| Ahn, SH | 5 |
| Kim, SM | 1 |
| Han, KH | 5 |
| Zhou, B | 3 |
| Lv, G | 2 |
| Zheng, H | 1 |
| Tsai, MC | 6 |
| Chen, CH | 4 |
| Hung, CH | 4 |
| Lee, CM | 5 |
| Chiu, KW | 4 |
| Wang, JH | 4 |
| Lu, SN | 4 |
| Tseng, PL | 5 |
| Chang, KC | 5 |
| Yen, YH | 5 |
| Hu, TH | 6 |
| Ji, H | 1 |
| Cai, Y | 1 |
| Ayana, DA | 1 |
| Lv, P | 1 |
| Ma, S | 3 |
| Tang, L | 2 |
| Wang, W | 1 |
| Huang, X | 7 |
| Lai, Q | 3 |
| Zhang, M | 5 |
| Li, CK | 1 |
| Abbott, WG | 5 |
| Singal, AK | 2 |
| Salameh, H | 1 |
| Kuo, YF | 1 |
| Fontana, RJ | 2 |
| Tse, CH | 1 |
| Chim, AM | 1 |
| Stein, DS | 1 |
| Ke, J | 1 |
| Uy, G | 1 |
| Bosheva, M | 1 |
| Qi, Y | 1 |
| Praestgaard, J | 1 |
| Yang, HH | 1 |
| Fan, YM | 1 |
| Li, T | 3 |
| Zhang, LF | 1 |
| Mui, C | 1 |
| Fan, HW | 1 |
| Zhou, BT | 1 |
| Liu, ZY | 1 |
| Ng, H | 1 |
| Liu, XQ | 1 |
| Goel, V | 1 |
| Bose, PD | 1 |
| Sarma, MP | 1 |
| Hazam, RK | 1 |
| Das, BC | 1 |
| Gondal, R | 1 |
| Kar, P | 1 |
| Wang, L | 4 |
| Chen, H | 2 |
| Fan, C | 1 |
| Gong, Z | 1 |
| Lin, MT | 3 |
| Chou, YP | 2 |
| Yu, HC | 2 |
| Hsu, YC | 3 |
| Cui, SN | 1 |
| Wang, MM | 1 |
| Guo, N | 1 |
| Gong, YX | 1 |
| Chen, YC | 4 |
| Hsu, CW | 5 |
| Chang, MY | 1 |
| Yeh, CT | 2 |
| Hu, P | 4 |
| Lu, JH | 1 |
| Luo, SS | 1 |
| Huang, XY | 1 |
| Weng, XH | 1 |
| Hao, C | 1 |
| Kang, W | 2 |
| Xie, Y | 1 |
| Peng, M | 1 |
| Lian, J | 1 |
| Jia, Z | 1 |
| Lin, KH | 1 |
| Hsu, PI | 1 |
| Tsay, FW | 1 |
| Wang, HM | 1 |
| Tsai, TJ | 1 |
| Lai, KH | 1 |
| Deray, G | 1 |
| Lim, SG | 5 |
| Lai, CL | 13 |
| Rasenack, J | 3 |
| Di Bisceglie, A | 1 |
| Buti, M | 6 |
| Samuel, D | 2 |
| Uddin, A | 1 |
| Bosset, S | 1 |
| Tian, Y | 2 |
| Ni, D | 1 |
| Yang, W | 1 |
| Zhao, K | 2 |
| Song, J | 1 |
| Mao, Q | 2 |
| Tian, Z | 2 |
| van Velkinburgh, JC | 1 |
| Yang, D | 1 |
| Wu, Y | 4 |
| Ni, B | 2 |
| Zhang, W | 1 |
| Sandeep, KK | 1 |
| Zhang, QF | 1 |
| Guo, SH | 3 |
| Zhang, DZ | 4 |
| Wang, N | 1 |
| Hu, HD | 1 |
| Sun, H | 2 |
| Feng, Q | 1 |
| Liu, Q | 2 |
| Yapali, S | 1 |
| Lok, AS | 3 |
| Pipili, C | 1 |
| Cholongitas, E | 2 |
| Chen, DB | 1 |
| Chen, YM | 1 |
| Xie, DY | 2 |
| Lu, CR | 1 |
| Huang, ZL | 1 |
| Zhu, RH | 1 |
| Gao, ZL | 2 |
| Lao, XM | 1 |
| Xia, HH | 1 |
| Lin, XJ | 1 |
| Li, SP | 1 |
| Park, YH | 1 |
| Kim, BK | 2 |
| Kim, JK | 1 |
| Kim, HC | 1 |
| Kim, DY | 3 |
| Park, JY | 3 |
| Kim, SU | 3 |
| Shin, SH | 1 |
| Hahn, KY | 1 |
| Lee, M | 1 |
| Oh, S | 1 |
| Lee, HJ | 2 |
| Yeum, TS | 1 |
| Lee, JH | 1 |
| Yu, SJ | 1 |
| Kim, HY | 1 |
| Yoon, JH | 1 |
| Lee, HS | 1 |
| Kim, YJ | 1 |
| Deng, YR | 1 |
| Yoshida, K | 1 |
| Jin, QL | 1 |
| Murata, M | 1 |
| Yamaguchi, T | 1 |
| Tsuneyama, K | 1 |
| Moritoki, Y | 1 |
| Niu, JQ | 3 |
| Matsuzaki, K | 1 |
| Lian, ZX | 1 |
| Fung, J | 5 |
| Seto, WK | 3 |
| Yuen, MF | 7 |
| Pérez-Cameo, C | 1 |
| Pons, M | 1 |
| Esteban, R | 2 |
| Chon, CY | 1 |
| Huang, K | 1 |
| Qi, TT | 1 |
| Chen, JJ | 2 |
| Wang, YJ | 1 |
| Zhong, CX | 1 |
| Xie, XP | 1 |
| Yin, JH | 1 |
| Ge, J | 2 |
| Jiang, X | 3 |
| Zhou, J | 3 |
| Fu, X | 1 |
| Cho, JH | 1 |
| Lim, JH | 1 |
| Park, GY | 1 |
| Kim, JS | 1 |
| Kang, YJ | 1 |
| Kwon, O | 1 |
| Choi, JY | 1 |
| Park, SH | 2 |
| Kim, YL | 1 |
| Kim, HK | 1 |
| Huh, S | 1 |
| Kim, CD | 1 |
| Sarkar, M | 1 |
| Terrault, NA | 1 |
| Diao, H | 1 |
| He, J | 1 |
| Zheng, Q | 1 |
| Cui, G | 1 |
| Wei, Y | 1 |
| Ye, P | 1 |
| Kohanawa, M | 1 |
| Li, L | 6 |
| Sulaiman, A | 1 |
| Lesmana, LA | 1 |
| Jia, M | 1 |
| Liu, Y | 7 |
| She, W | 1 |
| Jiang, W | 1 |
| Liu, L | 2 |
| Peng, D | 1 |
| Li, W | 3 |
| Du, Y | 1 |
| Jia, T | 1 |
| Chang, L | 1 |
| Li, H | 2 |
| Kim, HR | 1 |
| Yim, HJ | 2 |
| Kang, S | 1 |
| Suh, SJ | 1 |
| Kim, SY | 1 |
| Hyun, JJ | 1 |
| Koo, JS | 1 |
| Kim, JH | 2 |
| Seo, YS | 1 |
| Yeon, JE | 1 |
| Lee, SW | 1 |
| Byun, KS | 1 |
| Um, SH | 2 |
| Panda, C | 1 |
| Yu, MM | 1 |
| Jiang, Q | 2 |
| Ji, Y | 1 |
| Wu, KH | 1 |
| Ju, LL | 1 |
| Tang, X | 2 |
| Yang, YF | 1 |
| van Bömmel, F | 1 |
| Berg, T | 1 |
| Gerlich, WH | 1 |
| Warner, N | 1 |
| Locarnini, S | 2 |
| Neumann-Fraune, M | 1 |
| Beggel, B | 1 |
| Kaiser, R | 2 |
| Obermeier, M | 1 |
| Wang, YH | 2 |
| Wu, BQ | 1 |
| Li, CZ | 1 |
| Hu, JJ | 1 |
| Xue, JY | 1 |
| Yin, W | 1 |
| Liu, YY | 1 |
| Fan, WH | 1 |
| Xu, H | 2 |
| Liang, XS | 1 |
| Guo, H | 1 |
| Wei, X | 1 |
| Liang, Z | 1 |
| Marcellin, P | 3 |
| Wursthorn, K | 3 |
| Wedemeyer, H | 3 |
| Chuang, WL | 1 |
| Lau, G | 1 |
| Avila, C | 5 |
| Peng, CY | 2 |
| Gane, E | 4 |
| Fainboim, H | 1 |
| Foster, GR | 1 |
| Safadi, R | 3 |
| Rizzetto, M | 1 |
| Manns, M | 2 |
| Naoumov, N | 1 |
| Pan, CQ | 2 |
| Pang, Q | 1 |
| Tian, R | 1 |
| Yan, M | 1 |
| Hang, X | 1 |
| Mao, W | 1 |
| Zhang, C | 2 |
| Dunkelberg, JC | 1 |
| Berkley, EM | 1 |
| Thiel, KW | 1 |
| Leslie, KK | 1 |
| Perrella, A | 1 |
| Lanza, AG | 1 |
| Pisaniello, D | 1 |
| DiCostanzo, G | 1 |
| Calise, F | 1 |
| Cuomo, O | 1 |
| Pan, H | 1 |
| Lu, C | 1 |
| Lin, CL | 2 |
| Chien, RN | 3 |
| Yeh, C | 1 |
| Chang, ML | 1 |
| Coffin, CS | 1 |
| Rezaeeaval, M | 1 |
| Pang, JX | 1 |
| Alcantara, L | 1 |
| Klein, P | 1 |
| Burak, KW | 1 |
| Myers, RP | 2 |
| Vasiliadis, T | 1 |
| Goulis, I | 1 |
| Fouzas, I | 1 |
| Antoniadis, N | 1 |
| Papanikolaou, V | 1 |
| Akriviadis, E | 1 |
| Du, X | 1 |
| Ren, S | 1 |
| Shen, C | 1 |
| Shen, Y | 3 |
| Cui, S | 1 |
| Gong, Y | 1 |
| Wang, WZ | 1 |
| Lu, LX | 1 |
| Li, DJ | 1 |
| He, M | 1 |
| Liu, C | 1 |
| Wang, LC | 1 |
| Zhou, TB | 1 |
| Jiang, ZP | 1 |
| Du, LY | 1 |
| Zhu, X | 1 |
| Dai, M | 1 |
| Xiao, GM | 1 |
| Wang, FL | 1 |
| Zhang, JS | 1 |
| Li, YM | 1 |
| Yang, HZ | 1 |
| Hu, YH | 1 |
| Cao, YJ | 1 |
| Cai, HD | 1 |
| Tu, X | 1 |
| Cheng, Q | 1 |
| Chen, F | 1 |
| Dai, Y | 1 |
| Gong, F | 1 |
| Lin, X | 1 |
| Gao, H | 1 |
| Lin, M | 1 |
| Pan, C | 1 |
| Lin, T | 1 |
| Zhou, R | 2 |
| Li, X | 6 |
| Pang, J | 1 |
| Liao, B | 1 |
| Zuo, D | 1 |
| Lu, M | 1 |
| van Campenhout, MJ | 1 |
| Janssen, HL | 4 |
| Meng, N | 1 |
| Gao, X | 2 |
| Yan, W | 1 |
| Liu, P | 1 |
| Lu, XD | 1 |
| Zhang, SJ | 1 |
| Lu, YQ | 1 |
| Tang, WX | 1 |
| Qi, X | 3 |
| Huang, Y | 2 |
| Qin, Y | 1 |
| Mao, R | 1 |
| Lee, S | 1 |
| Song, K | 1 |
| Ku, HJ | 1 |
| Su, F | 1 |
| Dai, J | 2 |
| Yang, S | 2 |
| Cui, X | 1 |
| Ning, H | 1 |
| Huang, M | 2 |
| De Nicolò, A | 1 |
| Simiele, M | 1 |
| Pensi, D | 1 |
| Boglione, L | 3 |
| Allegra, S | 1 |
| Di Perri, G | 3 |
| D'Avolio, A | 3 |
| Wang, G | 1 |
| Qiu, P | 2 |
| Zhou, SF | 2 |
| Xu, L | 1 |
| Wen, P | 2 |
| Wen, J | 1 |
| Xiao, X | 1 |
| Wang, C | 2 |
| Dang, B | 1 |
| Sun, Y | 1 |
| El Agheb, MO | 1 |
| Grange, JD | 1 |
| Zhang, D | 2 |
| Pan, HY | 2 |
| Yang, DH | 1 |
| Huang, HJ | 1 |
| Tong, YX | 1 |
| Chen, CR | 1 |
| Hou, JL | 6 |
| Xu, D | 3 |
| Goodman, Z | 2 |
| Wei, L | 4 |
| Wang, Q | 4 |
| Dong, Y | 2 |
| Njei, B | 1 |
| Gupta, N | 1 |
| Ewelukwa, O | 1 |
| Ditah, I | 1 |
| Foma, M | 1 |
| Lim, JK | 1 |
| Hernández-Laín, A | 1 |
| Guerrero, AM | 1 |
| Domínguez-González, C | 1 |
| Fernández-Vázquez, I | 1 |
| Maya, DG | 1 |
| Delmiro, A | 1 |
| Arenas, J | 1 |
| Morales, JR | 1 |
| Blázquez, A | 1 |
| Moran, M | 1 |
| Martín, MA | 1 |
| Krishnamoorthy, TL | 1 |
| Mutimer, D | 1 |
| Yin, F | 1 |
| Wu, Z | 1 |
| Fang, W | 1 |
| Wu, C | 1 |
| Rayner, S | 1 |
| Han, M | 1 |
| Deng, F | 1 |
| Du, R | 1 |
| Hsieh, TY | 1 |
| Tseng, KC | 1 |
| Yang, SS | 1 |
| Chen, TM | 1 |
| Kao, JH | 2 |
| Khodor, H | 1 |
| Yetim, N | 1 |
| Unal, UK | 1 |
| Demirhan, YE | 1 |
| Gultekin, G | 1 |
| Isal, B | 1 |
| Niederau, C | 1 |
| Amani, A | 1 |
| Thiel, A | 1 |
| Deng, Y | 1 |
| Wu, W | 2 |
| Kang, J | 1 |
| Yang, Y | 3 |
| Zeng, W | 1 |
| Yap, DY | 1 |
| Chan, TM | 1 |
| Mao, RC | 1 |
| Law, ST | 2 |
| Lee, MK | 2 |
| Li, KK | 2 |
| Mok, CK | 1 |
| Jie, Y | 1 |
| Shi, H | 1 |
| Ao, Y | 1 |
| Yang, F | 2 |
| Lin, G | 1 |
| Chong, Y | 1 |
| Dong, H | 2 |
| He, Y | 3 |
| Jin, W | 2 |
| Li, R | 1 |
| Xie, S | 1 |
| Wang, S | 2 |
| Lu, F | 1 |
| Zhuang, H | 3 |
| Zhao, GP | 1 |
| Thu, AM | 1 |
| Poovorawan, K | 1 |
| Kittitrakul, C | 1 |
| Nontprasert, A | 1 |
| Sriboonvorakul, N | 1 |
| Phumratanaprapin, W | 1 |
| Tangkijvanich, P | 1 |
| Leowattana, W | 1 |
| Wilairatana, P | 1 |
| Lu, JF | 1 |
| Liu, YL | 1 |
| Ma, LN | 1 |
| Cao, ZH | 1 |
| He, ZM | 1 |
| Jin, Y | 1 |
| Zhang, SB | 2 |
| Chen, XY | 1 |
| Lin, CC | 1 |
| Bair, MJ | 1 |
| Chen, CJ | 1 |
| Chen, MJ | 1 |
| Liu, CY | 1 |
| Chang, CW | 1 |
| Hu, KC | 1 |
| Liou, TC | 1 |
| Lin, SC | 1 |
| Wang, HY | 1 |
| Chu, CH | 1 |
| Shih, SC | 1 |
| Wang, TE | 1 |
| Wong, DK | 2 |
| Shaikh, J | 2 |
| Taneja, A | 1 |
| Gupta, S | 2 |
| Hamed, K | 2 |
| Jiang, B | 1 |
| Dai, CY | 1 |
| Li, XM | 1 |
| Su, R | 1 |
| Xu, J | 4 |
| Cao, Y | 1 |
| Hou, W | 1 |
| Durante-Mangoni, E | 1 |
| Vitrone, M | 1 |
| Parrella, A | 1 |
| Andini, R | 1 |
| Iossa, D | 1 |
| Ragone, E | 1 |
| Falco, E | 1 |
| Maiello, C | 1 |
| Utili, R | 1 |
| Zampino, R | 1 |
| Wang, GL | 1 |
| Xu, LF | 1 |
| Wen, JB | 1 |
| Xiao, XZ | 1 |
| Demirtürk, N | 1 |
| Aykın, N | 1 |
| Çevik, F | 1 |
| Koca, B | 1 |
| Doğan, N | 1 |
| Köken, T | 1 |
| Wu, X | 2 |
| Li, Z | 1 |
| Zheng, C | 1 |
| Xue, X | 1 |
| Zeng, J | 1 |
| Lee, AS | 1 |
| Tung, Y | 1 |
| Yue-Meng, W | 1 |
| Li, YH | 1 |
| Wu, HM | 1 |
| Yang, J | 1 |
| Xu, Y | 2 |
| Yang, LH | 1 |
| Yang, JH | 1 |
| Jin, D | 1 |
| Qi, C | 1 |
| Yan, T | 1 |
| Cao, F | 1 |
| Guo, D | 1 |
| Yuan, N | 1 |
| Feng, W | 1 |
| Wang, HJ | 1 |
| Jiang, YF | 2 |
| Wang, XR | 1 |
| Zhang, ML | 1 |
| Gao, PJ | 1 |
| Defresne, F | 1 |
| Sokal, E | 1 |
| Ke, W | 1 |
| Gao, Y | 1 |
| Yao, Z | 2 |
| Hua, Z | 1 |
| Xu, W | 1 |
| Fu, DC | 1 |
| Li, YG | 1 |
| Guo, XY | 1 |
| Tu, KW | 1 |
| Dai, YP | 1 |
| Tseng, CM | 1 |
| Chen, TB | 1 |
| Chang, CY | 1 |
| Lin, JT | 1 |
| Mo, LR | 1 |
| Chen, R | 2 |
| Huang, J | 2 |
| Cheng, KL | 1 |
| Xu, MM | 1 |
| Qiu, Q | 1 |
| Yang, LK | 1 |
| Duan, XW | 1 |
| Duan, ZP | 1 |
| Kang, H | 1 |
| Zhao, G | 2 |
| Wong, D | 1 |
| Ip, P | 1 |
| Kopaniszen, M | 1 |
| Huang, FY | 1 |
| Lee, B | 1 |
| Cullaro, G | 1 |
| Chong, CK | 1 |
| Wu, R | 1 |
| Yuen, J | 1 |
| Ngai, V | 1 |
| Tan, Z | 1 |
| Yin, Y | 1 |
| Wu, L | 2 |
| Xu, C | 1 |
| Hou, H | 1 |
| Wu, CK | 1 |
| Madeddu, G | 1 |
| Ortu, S | 1 |
| Garrucciu, G | 1 |
| Maida, I | 1 |
| Melis, M | 1 |
| Muredda, AA | 1 |
| Mura, MS | 1 |
| Babudieri, S | 1 |
| Han, GR | 3 |
| Jiang, HX | 3 |
| Wang, CM | 3 |
| Wang, GJ | 3 |
| Yue, X | 3 |
| Zhao, W | 4 |
| Xing, T | 1 |
| Cao, L | 1 |
| Ye, M | 1 |
| Gao, S | 2 |
| Zhao, M | 1 |
| Bu, Y | 1 |
| Zhao, Q | 1 |
| Ye, L | 1 |
| Zhang, XS | 1 |
| Jin, R | 1 |
| Tao, ML | 1 |
| Evans, A | 1 |
| Riva, A | 2 |
| Cooksley, H | 1 |
| Phillips, S | 1 |
| Puranik, S | 1 |
| Nathwani, A | 1 |
| Brett, S | 1 |
| Chokshi, S | 1 |
| Lui, YY | 3 |
| He, H | 2 |
| Wang, ZY | 1 |
| Zeng, WQ | 1 |
| Leung, N | 4 |
| Heathcote, EJ | 3 |
| Bzowej, N | 3 |
| Han, SH | 2 |
| Hwang, SG | 4 |
| Cakaloglu, Y | 1 |
| Tong, MJ | 1 |
| Brown, NA | 7 |
| Albanis, E | 1 |
| Galil, K | 1 |
| Hadziyannis, SJ | 2 |
| Vassilopoulos, D | 1 |
| Andersen, ES | 1 |
| Weis, NM | 1 |
| García Buey, L | 1 |
| González Mateos, F | 1 |
| Moreno Otero, R | 1 |
| Rodríguez, M | 1 |
| González-Diéguez, ML | 1 |
| Pan, XC | 1 |
| Chen, M | 3 |
| Buster, EH | 2 |
| Schalm, SW | 1 |
| Liang, J | 1 |
| Han, T | 1 |
| Xiao, SX | 1 |
| Lampertico, P | 1 |
| Colombo, M | 1 |
| Nash, K | 1 |
| Nguyen, MH | 1 |
| Keeffe, EB | 2 |
| Low, E | 1 |
| Cox, A | 1 |
| Atkins, M | 1 |
| Nelson, M | 2 |
| Iun', F | 1 |
| Zhang, L | 2 |
| Dusheiko, GM | 1 |
| Jacobs, MG | 1 |
| DiBisceglie, A | 1 |
| Chutaputti, A | 2 |
| O'Brien, C | 1 |
| Nguyen, TT | 1 |
| Poynard, T | 2 |
| Belanger, B | 1 |
| Curtis, M | 1 |
| Miller, MD | 1 |
| Borroto-Esoda, K | 1 |
| Reijnders, JG | 1 |
| Liu, T | 2 |
| Cong, M | 2 |
| Wang, P | 2 |
| Ren, J | 1 |
| Fleischer, RD | 1 |
| Zhang, LJ | 1 |
| Chen, W | 1 |
| Soriano, V | 3 |
| Tuma, P | 1 |
| Vispo, E | 1 |
| Labarga, P | 1 |
| Fernández, JV | 1 |
| Medrano, J | 1 |
| Barreiro, P | 1 |
| Milazzo, L | 1 |
| Caramma, I | 1 |
| Lai, A | 1 |
| Violin, M | 1 |
| De Maddalena, C | 1 |
| Cesari, M | 1 |
| Galli, M | 1 |
| Balotta, C | 1 |
| Hartwell, D | 1 |
| Jones, J | 1 |
| Harris, P | 1 |
| Cooper, K | 1 |
| Lin, Q | 1 |
| Xue, R | 1 |
| Chang, JB | 1 |
| Wang, JF | 1 |
| Suh, DJ | 2 |
| Lee, YS | 1 |
| Lee, MS | 1 |
| Lee, YJ | 1 |
| Lopez, P | 4 |
| Lee, HC | 1 |
| Duong, A | 1 |
| Mousa, SA | 1 |
| Perrillo, RP | 1 |
| Cai, W | 1 |
| An, B | 1 |
| Zhou, X | 3 |
| Guo, Q | 1 |
| Gu, R | 1 |
| Bao, S | 1 |
| Lin, K | 1 |
| Karwowska, S | 1 |
| Lam, E | 1 |
| Limoli, K | 1 |
| Evans, TG | 1 |
| Tsoi, KK | 1 |
| Teo, EK | 2 |
| Mohamed, R | 1 |
| Mihm, U | 1 |
| Dai, ZJ | 1 |
| Ye, C | 1 |
| Chen, YP | 1 |
| Wang, JB | 1 |
| Ji, SW | 1 |
| Zhang, YG | 1 |
| Siqingtu, NL | 1 |
| Zhao, P | 1 |
| Guo, HH | 1 |
| Jiao, J | 1 |
| Zhou, CY | 1 |
| Wu, B | 1 |
| Shen, J | 1 |
| Coppola, N | 1 |
| Masiello, A | 1 |
| Tonziello, G | 1 |
| Macera, M | 1 |
| Iodice, V | 1 |
| Caprio, N | 1 |
| Pasquale, G | 1 |
| But, DY | 1 |
| Hann, HW | 3 |
| Lv, GC | 1 |
| Ma, WJ | 2 |
| Ying, LJ | 1 |
| Jin, X | 2 |
| Zheng, L | 2 |
| Yang, YD | 1 |
| Ying, L | 1 |
| Fan, X | 1 |
| Dai, X | 1 |
| McKeage, K | 1 |
| Keam, SJ | 2 |
| Jung, M | 1 |
| Goodman, ZD | 1 |
| Manns, MP | 2 |
| Lin, BL | 1 |
| Chen, FJ | 1 |
| Chong, YT | 1 |
| Zhang, XH | 1 |
| Yin, YK | 3 |
| Zuckerman, E | 1 |
| Jia, JD | 3 |
| Hu, JG | 1 |
| Jiang, JN | 1 |
| Su, MH | 1 |
| Ge, SF | 1 |
| Jiang, ZC | 1 |
| Zhu, MQ | 1 |
| Liu, ZH | 2 |
| Liang, YX | 1 |
| Guo, WW | 1 |
| Kahloun, A | 1 |
| Bourlière, M | 1 |
| Zoulim, F | 3 |
| Pais, R | 1 |
| Benhamou, Y | 1 |
| Ma, SW | 2 |
| Li, YY | 2 |
| Zhang, GW | 1 |
| Yuen, JC | 1 |
| Hung, IF | 1 |
| Yang, JX | 1 |
| Liu, BM | 1 |
| Li, XG | 1 |
| Yan, CH | 1 |
| Sun, XW | 1 |
| Jiao, XJ | 1 |
| Yan, L | 1 |
| Dong, JP | 1 |
| Hou, CS | 1 |
| Abuduheilili, X | 1 |
| Papatheodoridis, GV | 1 |
| Jaroszewicz, J | 1 |
| Zacher, BJ | 1 |
| Darnedde, M | 1 |
| Raupach, R | 1 |
| Mederacke, I | 1 |
| Cornberg, M | 1 |
| Chen, LB | 1 |
| Cao, H | 2 |
| Zhang, YF | 1 |
| Shu, X | 1 |
| Chen, N | 1 |
| Zhang, K | 1 |
| Li, G | 1 |
| Xu, QH | 1 |
| Zhong, Y | 1 |
| Ren, X | 1 |
| Xu, Z | 1 |
| Ji, D | 1 |
| Yurdaydin, C | 2 |
| Akarca, US | 1 |
| Moon, YM | 4 |
| Chao, YC | 3 |
| Cho, YK | 1 |
| Song, BC | 1 |
| Ye, B | 1 |
| Pan, X | 2 |
| Tornai, I | 1 |
| Chen, WL | 1 |
| Ma, XJ | 1 |
| Cao, MK | 2 |
| Bai, SF | 1 |
| Fang, ZX | 1 |
| Petersen, J | 2 |
| Shi, TD | 1 |
| Wang, XF | 1 |
| Chen, CB | 1 |
| Giles, M | 1 |
| Visvanathan, K | 1 |
| Sasadeusz, J | 1 |
| Razonable, RR | 1 |
| van Maarseveen, NM | 1 |
| Wensing, AM | 1 |
| de Jong, D | 1 |
| Beilhartz, GL | 1 |
| Obikhod, A | 1 |
| Tao, S | 1 |
| Pingen, M | 1 |
| Arends, JE | 1 |
| Hoepelman, AI | 1 |
| Schinazi, RF | 1 |
| Götte, M | 1 |
| Nijhuis, M | 1 |
| Zou, XJ | 1 |
| Jiang, XQ | 1 |
| Tian, DY | 1 |
| Suzuki, F | 2 |
| Tang, LB | 1 |
| Sun, XF | 1 |
| Jiang, XT | 1 |
| Zhang, YX | 1 |
| Tung, WC | 1 |
| Lau, GK | 1 |
| Wang, FS | 1 |
| Nan, XP | 1 |
| Yu, HT | 1 |
| Sun, RL | 1 |
| Peng, MJ | 1 |
| Su, WJ | 1 |
| Yao, W | 1 |
| Fu, J | 1 |
| Hu, XY | 1 |
| Liu, GW | 1 |
| Nie, HM | 1 |
| Fan, XJ | 1 |
| Zhong, S | 1 |
| Da, Y | 1 |
| Lu, Y | 1 |
| Zhou, YJ | 1 |
| Zheng, JL | 1 |
| Pan, HJ | 1 |
| Jiang, S | 1 |
| Tang, J | 1 |
| Zhong, C | 1 |
| Guo, Y | 1 |
| Stroffolini, T | 1 |
| Spadaro, A | 1 |
| Di Marco, V | 1 |
| Scifo, G | 1 |
| Russello, M | 1 |
| Montalto, G | 1 |
| Bertino, G | 2 |
| Surace, L | 1 |
| Caroleo, B | 1 |
| Foti, G | 1 |
| Portelli, V | 1 |
| Madonia, S | 1 |
| Sapienza, M | 1 |
| Cosco, L | 1 |
| Frugiuele, P | 1 |
| Galdieri, A | 1 |
| Brandolino, N | 1 |
| Siciliano, R | 1 |
| Bruno, S | 1 |
| Almasio, PL | 1 |
| Zhou, TY | 1 |
| Wang, JR | 1 |
| Yan, LB | 1 |
| Liang, LB | 1 |
| Piccolo, P | 1 |
| Lenci, I | 1 |
| di Paolo, D | 1 |
| Demelia, L | 1 |
| Sorbello, O | 1 |
| Nosotti, L | 1 |
| Yang, SG | 1 |
| Chen, HZ | 1 |
| Ruan, B | 1 |
| Sarin, SK | 1 |
| Prabhakar, B | 1 |
| Choudhuri, G | 1 |
| Tanwandee, T | 2 |
| Baak, BC | 1 |
| Bakker, CM | 1 |
| Beuers, UH | 1 |
| Brouwer, JT | 1 |
| Drenth, JP | 1 |
| van Erpecum, KJ | 1 |
| van Hoek, B | 1 |
| Honkoop, P | 1 |
| Kerbert-Dreteler, MJ | 1 |
| Koek, GH | 1 |
| van Nieuwkerk, KM | 1 |
| van Soest, H | 1 |
| van der Spek, BW | 1 |
| Tan, AC | 1 |
| Vrolijk, JM | 1 |
| Su, QM | 1 |
| Ye, XG | 1 |
| Cariti, G | 2 |
| Ren, JB | 1 |
| Li, HY | 1 |
| Sun, SJ | 1 |
| Xu, HX | 1 |
| Wang, LJ | 1 |
| Yu, YX | 1 |
| Wu, YP | 1 |
| Xu, YF | 1 |
| Liu, XX | 1 |
| Chang, TT | 1 |
| Cai, YJ | 1 |
| Yu, L | 1 |
| Feng, JY | 1 |
| Ardiri, AM | 1 |
| Calvagno, GS | 1 |
| Bertino, N | 1 |
| Ruggeri, MI | 1 |
| Malaguarnera, M | 1 |
| Malaguarnera, G | 1 |
| Toro, A | 1 |
| Di Carlo, I | 1 |
| Gregori, G | 1 |
| Burdino, E | 1 |
| Baietto, L | 1 |
| Cusato, J | 1 |
| Ghisetti, V | 1 |
| De Rosa, FG | 1 |
| Komolmit, P | 1 |
| Sukeepaisarnjaroen, W | 1 |
| Pessôa, MG | 1 |
| Fassio, E | 1 |
| Ono, SK | 1 |
| Bessone, F | 1 |
| Daruich, J | 1 |
| Cheinquer, H | 1 |
| Pathan, R | 1 |
| Chen, ZT | 1 |
| Wu, JC | 1 |
| Gan, JH | 1 |
| Zhao, WF | 1 |
| Luo, EP | 1 |
| Zhou, XJ | 2 |
| Lloyd, DM | 2 |
| Lee, YM | 1 |
| Chao, GC | 2 |
| Myers, MW | 1 |
| Tong, M | 1 |
| Wong, F | 1 |
| Han, S | 1 |
| Myers, M | 1 |
| Chao, G | 3 |
| Lloyd, D | 1 |
| Kim, JW | 1 |
| Louie, SG | 1 |
| Jones, R | 1 |
| Lu, ZM | 1 |
| Gish, RG | 1 |
| Dienstag, J | 1 |
| Easley, C | 1 |
| Kirkpatrick, P | 1 |
| Ruiz-Sancho, A | 1 |
| Sheldon, J | 2 |
| Xu, DZ | 1 |
| Tan, DM | 1 |
| Zhou, XQ | 1 |
| Wang, YM | 1 |
| Zhu, LM | 1 |
| He, YW | 1 |
| Wan, MB | 1 |
| Chen, CW | 1 |
| Wu, SM | 1 |
| Chen, YG | 1 |
| Xu, JZ | 1 |
| Wang, QH | 1 |
| Pham, PA | 1 |
| Thio, C | 1 |
| Garcia-Gasco, P | 1 |
| Dusheiko, G | 1 |
| Danta, M | 1 |
| Cho, M | 2 |
| Minuk, GY | 1 |
| Jeffers, L | 1 |
| Sievert, W | 1 |
| Harb, G | 2 |
| Qiao, XJ | 1 |
| Gaeta, GB | 1 |
| Stornaiuolo, G | 1 |
| Zhu, L | 1 |
| Wu, S | 1 |
| Constance, BF | 2 |
| Di Bisceglie, AM | 1 |
| Kim, BS | 1 |
| Rim, KS | 1 |
| Kim, DJ | 1 |
| Han, JY | 1 |
| Kim, YS | 1 |
| Choi, HS | 1 |
| Matthews, SJ | 1 |
| Sánchez-Tapias, JM | 1 |
| Kato, N | 1 |
| Goto, T | 1 |
| Omata, M | 1 |
| Tillmann, HL | 1 |
| McHutchison, JG | 1 |
| Mauss, S | 1 |
| Butí, MA | 1 |
| Ayoub, WS | 1 |
| Bridges, EG | 1 |
| Selden, JR | 1 |
| Luo, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Antiviral Therapy on HBV Reactivation and Liver Function After Hepatectomy for HBV-DNA Negative HBV-related Hepatocellular Carcinoma[NCT02829359] | Phase 2/Phase 3 | 200 participants (Actual) | Interventional | 2012-07-31 | Completed | ||
| A Phase I, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics and Safety of Telbivudine (LDT600) in Children and Adolescents With Chronic Hepatitis B[NCT00907894] | Phase 1 | 22 participants (Actual) | Interventional | 2009-02-28 | Completed | ||
| Open Label Study of Nucleus(t)Ide Treated Patients Randomised to Tenofovir, or Tenofovir + Telbivudine[NCT02774837] | Phase 4 | 146 participants (Actual) | Interventional | 2016-04-30 | Active, not recruiting | ||
| The Immunologic Effects of HCV Therapy With Fixed Dose Combination Ledipasvir/Sofosbuvir (HARVONI) in HCV Genotype 1 Chronically Mono-infected Active and Former IDUs.[NCT02347345] | Phase 4 | 34 participants (Actual) | Interventional | 2016-11-15 | Completed | ||
| Chemoembolization With or Without Antiviral Therapy for Unresectable HBV-related Hepatocellular Carcinoma With Low HBV DNA Replication: Effectiveness and Safety. A Prospective and Randomized Clinical Trial[NCT01894269] | Phase 4 | 200 participants (Anticipated) | Interventional | 2013-07-31 | Recruiting | ||
| Antiviral Efficacy of Continuing Lamivudine Plus Adefovir or Switching to Telbivudine Plus Adefovir in HBeAg-positive Lamivudine-refractory Chronic Hepatitis B Patients Who Have Suboptimal Response to Lamivudine Plus Adefovir for at Least 12 Months[NCT01270165] | Phase 3 | 110 participants (Anticipated) | Interventional | 2010-06-30 | Recruiting | ||
| Study the Effect of Nucleoside on Host Immune in Patients With CHB[NCT01480492] | 56 participants (Actual) | Interventional | 2010-01-31 | Completed | |||
| A Randomized, Open-label, Controlled, Multi-center Two-year Study Comparing Efficacy and Safety of Telbivudine, 600 mg PO in Combination With Peginterferon Alpha-2a sq 180 µg With Peginterferon Alpha-2a Monotherapy, and With Telbivudine Monotherapy in Tre[NCT00412750] | Phase 3 | 159 participants (Actual) | Interventional | 2006-12-31 | Terminated (stopped due to Enrollment stopped for safety issues) | ||
| The Efficacy and Safety of Telbivudine and Lamivudine Use in Highly Viremic Mothers to Prevent Hepatitis B Transmission[NCT01743079] | Phase 4 | 700 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| A Prospective, Observational, Single-center Post-marketing Surveillance Study of Telbivudine in Chronic Hepatitis B Adults With HBeAg Positive/Negative.[NCT00970216] | 160 participants (Actual) | Observational | 2009-02-28 | Completed | |||
| A Single Arm, Multicenter, Open-label, 52-week, the Omnibus Extension Study to Evaluate the Safety and Efficacy of Telbivudine in the Fifth Year of Treatment in Chinese Patients With Compensated Chronic Hepatitis B and Are HBV DNA PCR Negative at the End [NCT00646503] | Phase 4 | 150 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| A Single-arm, Multicenter, Open-label, 52-week Treatment, Extension Study to CLDT600ACN04 Study to Evaluate the Efficacy (Including Histological Improvement) and Safety in Fourth to Sixth Year of Telbivudine Treatment in Patients With Chronic Hepatitis B[NCT00877149] | Phase 4 | 80 participants (Anticipated) | Interventional | 2009-03-31 | Completed | ||
| Comparative Study of the Effect of Entecavir Versus Tenofovir on the Presence of HBV DNA in the Peripheral Blood Mononuclear Cells in Chronic Hepatitis B Patients[NCT05168293] | 100 participants (Anticipated) | Observational | 2022-02-01 | Not yet recruiting | |||
| A Study of Efficacy and Safety of Telbivudine in Pregnancy for the Prevention of Perinatal Transmission of Hepatitis B Virus Infection[NCT00939068] | Phase 4 | 180 participants (Anticipated) | Interventional | 2008-02-29 | Enrolling by invitation | ||
| A Randomized, Open-label, Multi-center Clinical Trial to Evaluate Addition of Peginterferon Alfa-2a to CHB Patients Treated With NAs and Achieved HBV DNA<15 IU/ml、HBeAg<100 PEIU/ml、HBsAg Positive and HBsAg<1500 IU/ml.[NCT02894918] | Phase 4 | 114 participants (Anticipated) | Interventional | 2016-09-30 | Active, not recruiting | ||
| A Randomized, Double Blind Trial of LdT (Telbivudine) Versus Lamivudine in Adults With Compensated Chronic Hepatitis B[NCT00057265] | Phase 3 | 0 participants | Interventional | 2003-02-28 | Completed | ||
| A Phase 1 Double-Blinded Study for Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ATI-2173 in Healthy Subjects and Subjects With Chronic Hepatitis B Virus Infection[NCT04248426] | Phase 1 | 88 participants (Actual) | Interventional | 2020-02-05 | Completed | ||
| A Randomized, Open-label, Controlled, Multicenter, Exploratory Trial to Characterize the Results of Daily Oral Administration of Telbivudine (LDT600) 600 mg or Entecavir (ETV) 0.5 mg Given Over 12 Weeks on the Kinetics of Hepatitis B Virus (HBV) DNA in Ad[NCT00412529] | Phase 3 | 44 participants (Actual) | Interventional | 2006-12-31 | Completed | ||
| The Effect of Telbivudine on Renal Function and Proteinuria in Patients With Chronic Hepatitis B Infection and Chronic Kidney Diseases[NCT02049736] | 0 participants (Actual) | Interventional | 2013-12-31 | Withdrawn (stopped due to unable to recruit patients) | |||
| Telbivudine in the Third Trimester of Pregnancy to Prevent Mother-to-infant Transmission of HBV[NCT01637844] | Phase 4 | 335 participants (Actual) | Interventional | 2012-04-30 | Completed | ||
| [NCT01337791] | Phase 4 | 88 participants (Actual) | Interventional | 2008-08-31 | Completed | ||
| An Open Label Trial of Telbivudine (LdT) in Adults With Chronic Hepatitis B Previously Treated in Idenix-Sponsored Telbivudine Studies[NCT00142298] | Phase 3 | 1,869 participants (Actual) | Interventional | 2005-03-31 | Completed | ||
| A Single-arm, Multinational, Two Year Study Evaluating the Efficacy and Safety of lead-in Telbivudine for 24 Weeks With or Without Tenofovir Treatment Intensification in Adult Patients With HBeAg-positive Chronic Hepatitis B.[NCT00651209] | Phase 4 | 105 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| A Randomized, Open-Label Trial of Telbivudine Versus Adefovir Dipivoxil in Adults With HBegAg-Positive, Compensated Chronic Hepatitis B[NCT00115245] | Phase 3 | 0 participants | Interventional | 2004-11-30 | Completed | ||
| HBV Viral Suppression by Entecavir in Adefovir Partial Responders[NCT00704106] | 60 participants (Actual) | Observational | 2008-05-31 | Completed | |||
| A Phase III Randomized, Double Blind Trial of LdT (Telbivudine) Versus Lamivudine in Chinese Adults With Compensated Chronic Hepatitis B[NCT00131742] | Phase 3 | 0 participants | Interventional | 2004-07-31 | Completed | ||
| Prevention of Mother-to-child Transmission of Hepatitis B Virus: a One Arm, Open Label Intervention Study to Estimate the Optimal Timing of Tenofovir (TDF) in Pregnancy[NCT02995005] | Phase 1/Phase 2 | 98 participants (Actual) | Interventional | 2018-05-24 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Gene expression profiles in PBMC will be determined using RNA Seq (NCT02347345)
Timeframe: 24 weeks
| Intervention | RNA seq different from active IDU (Number) |
|---|---|
| baseline | |
| Healthy Volunteers | 12 |
Gene expression profiles in PBMC will be determined using RNA Seq (NCT02347345)
Timeframe: 24 weeks
| Intervention | RNA seq different from active IDU (Number) | |||
|---|---|---|---|---|
| baseline | 4 weeks | 12 weeks | 24 weeks | |
| Active Injection Drug Use (IDU) | 9 | 9 | 9 | 9 |
| Former Injection Drug Use (Former IDU) | 11 | 11 | 11 | 11 |
Marker of immune activation as measured by levels of soluble CD14. Note that the levels of sCD14 were only measured at baseline in the Healthy Volunteers group and therefore there are no data for weeks 4, 12, or 24 entered. (NCT02347345)
Timeframe: 24 weeks
| Intervention | ng/mL (Mean) |
|---|---|
| baseline | |
| Healthy Volunteers | 1542 |
Marker of immune activation as measured by levels of soluble CD14. Note that the levels of sCD14 were only measured at baseline in the Healthy Volunteers group and therefore there are no data for weeks 4, 12, or 24 entered. (NCT02347345)
Timeframe: 24 weeks
| Intervention | ng/mL (Mean) | |||
|---|---|---|---|---|
| baseline | week 4 | week 12 | week 24 | |
| Active Injection Drug Use (IDU) | 1986 | 2060 | 2036 | 1973 |
| Former Injection Drug Use (Former IDU) | 1918 | 1805 | 1782 | 1819 |
HCV RNA levels in plasma (IU/mL) (NCT02347345)
Timeframe: 24 weeks
| Intervention | HCV RNA copies/mL plasma (Mean) | ||
|---|---|---|---|
| baseline | week 12 | week 24 | |
| Active Injection Drug Use (IDU) | 7781148 | 0 | 0 |
| Former Injection Drug Use (Former IDU) | 2320026 | 0 | 0 |
The change from baseline in HBV DNA concentration at Weeks 12 and 24 was analyzed using an analysis of covariance (ANCOVA) model with baseline HBV DNA concentration (log10 copies/ml) as a covariate, treatment and country as factors. (NCT00412750)
Timeframe: Weeks 12 and 24
| Intervention | log 10 copies/ml (Least Squares Mean) | |
|---|---|---|
| Week 12 (n= 37, 52, 50) | Week 24 (n= 17, 48, 42) | |
| LdT + PEG-INF | -6.0569 | -6.9187 |
| LdT Monotherapy | -5.1658 | -5.9633 |
| PEG-INF Monotherapy | -1.8991 | -2.4513 |
The percentage of participants with Virologic breakthrough at Week 48 and 52 by treatment. For the subgroup of patients on treatment who achieve HBV DNA >= 1 log10 copies/mL reduction from baseline on 2 consecutive visits, Virologic Breakthrough is defined as HBV DNA >= 1 log10 copies/mL from nadir on two consecutive visits. (NCT00412750)
Timeframe: Weeks 48 and 52
| Intervention | Percentage of participants (Number) | |
|---|---|---|
| Virologic breakthrough Week 48 | Virologic breakthrough Week 52 | |
| LdT + PEG-INF | 0.0 | 0.0 |
| LdT Monotherapy | 5.7 | 7.5 |
| PEG-INF Monotherapy | 7.5 | 9.4 |
The percentage of participants who achieved HBV DNA non-detectability using the COBAS Amplicor HBV Monitor assay utilizing polymerase chain reaction (PCR) (threshold for detection 300 copies/mL) and Alanine aminotransferase (ALT) normalization defined as ALT within normal limits on two successive visits for a patient with an elevated ALT (>1.0 x upper limit normal) at baseline summarized at Weeks 12 and 24. (NCT00412750)
Timeframe: Weeks 12 and 24
| Intervention | Percentage of participants (Number) | |||
|---|---|---|---|---|
| HBV DNA non-detectability Week 12 (n=37,52,50) | ALT normalization Week 12 (n=37,52,50) | HBV DNA non-detectability Week 24 (n=17,48,42) | ALT normalization Week 24 (n=17,48,41) | |
| LdT + PEG-INF | 13.5 | 13.5 | 70.6 | 11.8 |
| LdT Monotherapy | 9.6 | 28.8 | 35.4 | 54.2 |
| PEG-INF Monotherapy | 0.0 | 20.0 | 7.1 | 31.7 |
HBeAg loss is defined as the loss of detectable serum HBeAg in a patient who was HBeAg positive at baseline. HBeAg seroconversion is defined as HBeAg loss with detectable Hepatitis B 'e' antibody (HBeAb). The efficacy was assessed for 18 weeks, 24 weeks, 48 weeks, 52 weeks and on treatment completion (TC). (NCT00412750)
Timeframe: Weeks 18, 24, 48, 52 and Treatment completion (TC)
| Intervention | Percentage of participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| HBeAg loss Week 18 (n=28,51,45) | HBeAg seroconversion Week 18 (n=28,51,45) | HBeAg loss Week 24 (n=17,48,42) | HBeAg seroconversion Week 24 (n=17,48,42) | HBeAg loss Week 48 (n=0,19,12) | HBeAg seroconversion Week 48 (n=0,19,12) | HBeAg loss Week 52 (n=0,10,6) | HBeAg seroconversion Week 52 (n=0,10,6) | HBeAg loss TC (n=14,24,9) | HBeAg seroconversion TC (n=14,24,9) | |
| LdT + PEG-INF | 17.9 | 17.9 | 17.6 | 7.6 | NA | NA | NA | NA | 7.1 | 7.1 |
| LdT Monotherapy | 7.8 | 7.8 | 6.3 | 4.2 | 36.8 | 36.8 | 50.0 | 50.0 | 29.2 | 25.0 |
| PEG-INF Monotherapy | 8.9 | 8.9 | 11.9 | 11.9 | 25.0 | 25.0 | 16.7 | 16.7 | 33.3 | 33.3 |
(NCT00970216)
Timeframe: 48 weeks
| Intervention | participants (Number) |
|---|---|
| Chronic Hepatitis B | 79 |
Viral kinetic parameters were estimated with a bi-phasic mathematical model of HBV DNA by using compartments of free virus, infected cells, and uninfected target cells. The model parameter of interest was the effectiveness of the drug in blocking virus production from infected cells (efficacy, ε). Blocking efficiency was within the range between 0 and 1. (NCT00412529)
Timeframe: Baseline to 12 weeks
| Intervention | percentage of blocking efficiency (Mean) |
|---|---|
| Telbivudine | 0.991 |
| Entecavir | 0.992 |
"Viral kinetic parameters were estimated with a bi-phasic mathematical model:~V(t) = (1-ε)pI(t) - cV(t)~I(t) = (1- η)TV(t) - δI(t)~V serum viral load, I productively infected cells, ε efficiency factor of blocking virus production, p viral production rate, c viral clearance rate, η efficiency factor of blocking de novo infection, β de novo infection rate, T uninfected target cells, δ rate of infected cell loss. Maximum-likelihood estimation for the viral kinetic parameters entailed fitting a nonlinear differential equation system via the least-squares approach from serum HBV DNA data." (NCT00412529)
Timeframe: Baseline to 12 weeks
| Intervention | infected cell loss per day (Mean) |
|---|---|
| Telbivudine | 0.075 |
| Entecavir | 0.071 |
"Viral kinetic parameters were estimated with a bi-phasic mathematical model:~V(t) = (1-ε)pI(t) - cV(t)~I(t) = (1- η)TV(t) - δI(t)~V serum viral load, I productively infected cells, ε efficiency factor of blocking virus production, p viral production rate, c viral clearance rate, η efficiency factor of blocking de novo infection, β de novo infection rate, T uninfected target cells, δ rate of infected cell loss. Maximum-likelihood estimation for the viral kinetic parameters entailed fitting a nonlinear differential equation system via the least-squares approach from serum HBV DNA data." (NCT00412529)
Timeframe: Baseline to 12 weeks
| Intervention | clearance per day (Mean) |
|---|---|
| Telbivudine | 0.809 |
| Entecavir | 1.002 |
In AUC efficacy analyses, all the visits from baseline to Week 12 visit (including the planned and the repeated) with a non-missing HBV DNA level were included. (NCT00412529)
Timeframe: From Baseline to Week 12
| Intervention | (log10 copies/mL) * days (Mean) |
|---|---|
| Telbivudine | -453.5 |
| Entecavir | -442.6 |
(NCT00412529)
Timeframe: From Baseline to Week 12
| Intervention | IU/L (Mean) | ||
|---|---|---|---|
| Baseline | At Week 12 | Change from Baseline to Week 12 | |
| Entecavir | 170.2 | 54.0 | -116.3 |
| Telbivudine | 163.1 | 55.1 | -108.0 |
Baseline HBV DNA is defined as the last pre-dose assessment of HBV DNA.HBV DNA reductions, considered as the repeated measures, from baseline to Weeks 2, 4, 8. (NCT00412529)
Timeframe: Baseline (day 1) to Weeks 2, 4, 8
| Intervention | log10 copies/mL (Mean) | ||
|---|---|---|---|
| Change from Baseline to week 2 :(N=20, 21) | Change from Baseline to week 4 : (N= 23, 21) | Change from Baseline to week 8 : (N= 23, 21) | |
| Entecavir | -3.974 | -4.875 | -5.976 |
| Telbivudine | -3.999 | -5.273 | -6.161 |
Baseline HBV DNA is defined as the last pre-dose assessment of HBV DNA. (NCT00412529)
Timeframe: Baseline (day 1) to Week 12 (day 85)
| Intervention | log10 copies/mL (Mean) | ||
|---|---|---|---|
| Baseline (day 1) | At Week 12 | Change from Baseline to week 12 | |
| Entecavir | 9.721 | 3.194 | -6.527 |
| Telbivudine | 10.290 | 3.669 | -6.621 |
PCR negative was considered <300 copies/mL. PCR positive was considered =>300 copies/mL. (NCT00412529)
Timeframe: At Week 12
| Intervention | Participants (Number) | |
|---|---|---|
| <300 copies/mL | >= 300 copies/mL | |
| Entecavir | 6 | 15 |
| Telbivudine | 2 | 21 |
The maintained therapeutic response is defined as hepatitis B virus (HBV) DNA < 5 log10 copies/mL and either hepatitis Be antigen (HBeAg) loss or alanine aminotransferase (ALT) normalized. HBeAg loss is loss of detectable serum HBeAg in a patient who was HBeAg-positive at feeder baseline. ALT normalized is defined as ALT within normal limits for a patient with an elevated ALT level (>1.0 × ULN) at either the feeder baseline or feeder screening visit. All efficacy data were analyzed separately for HBeAg-positive and HBeAg-negative patients. (NCT00142298)
Timeframe: 52 weeks, 104 weeks
| Intervention | Percentage of Participants (Number) | |||
|---|---|---|---|---|
| HBeAg Positive: 52 week (n = 103, 79, 43) | HBeAg Positive: 104 week (n = 66, 15, 30) | HBeAg Negative: 52 week (n = 0, 37, 0) | HBeAg Negative: 104 week (n = 0, 10, 0) | |
| Group A: Feeder Study 010 | 69.8 | 76.7 | NA | NA |
| Group A: Feeder Study 2401 | 77.7 | 81.8 | NA | NA |
| Group A: Feeder Study 2402 | 35.4 | 46.7 | 54.1 | 60.0 |
The maintained therapeutic response is defined as hepatitis B virus (HBV) DNA < 5 log10 copies/mL and either hepatitis Be antigen (HBeAg) loss or alanine aminotransferase (ALT) normalized. HBeAg loss is loss of detectable serum HBeAg in a patient who was HBeAg-positive at feeder baseline. ALT normalized is defined as ALT within normal limits for a patient with an elevated ALT level (>1.0 × ULN) at either the feeder baseline or feeder screening visit. All efficacy data were analyzed separately for HBeAg-positive and HBeAg-negative patients. (NCT00142298)
Timeframe: 52 weeks, 104 weeks
| Intervention | Percentage of Participants (Number) | |||
|---|---|---|---|---|
| HBeAg Positive: week 52 (n=338) | HBeAg Positive: week 104 (n=101) | HBeAg Negative: week 52 (n=182) | HBeAg Negative: week 104 (n=79) | |
| Group A : LAM Pool 2302/015 | 60.1 | 65.3 | 80.8 | 81.0 |
The maintained therapeutic response is defined as hepatitis B virus (HBV) DNA < 5 log10 copies/mL and either hepatitis Be antigen (HBeAg) loss or alanine aminotransferase (ALT) normalized. HBeAg loss is loss of detectable serum HBeAg in a patient who was HBeAg-positive at feeder baseline. ALT normalized is defined as ALT within normal limits for a patient with an elevated ALT level (>1.0 × ULN) at either the feeder baseline or feeder screening visit. All efficacy data were analyzed separately for HBeAg-positive and HBeAg-negative patients. (NCT00142298)
Timeframe: 156 weeks, 208 weeks (from feeder study baseline)
| Intervention | Percentage of participants (Number) | |||
|---|---|---|---|---|
| HBeAg Positive: week 156 (n=338) | HBeAg Positive: week 208 (n=252) | HBeAg Negative: week 156 (n=197) | HBeAg Negative: week 208 (n=168) | |
| Group A : LdT Pool 2302/015 | 67.2 | 73.8 | 81.7 | 86.3 |
Maintained clinical response is defined as achievement of serum HBV DNA < 4 log10 copies/mL, normal serum ALT level and improvement or stabilization in Child-Turcotte-Pugh (CTP) score. Total CTP score ranges from 5 to 15; higher scores indicate liver impairment. Improvement is defined as a 2-point or greater reduction in CTP score, and stabilization is defined as a less than 2-point change in CTP score, compared to the patient's baseline value. Analysis was done on the overall per protocol (PP) population and separately for the HBeAg-positive and HBeAg-negative subpopulation. (NCT00142298)
Timeframe: 52 weeks,104 weeks
| Intervention | Percentage of Participants (Number) | |||||
|---|---|---|---|---|---|---|
| HBeAg Positive: week 52 (n=4) | HBeAg Positive: week 104 (n=1) | HBeAg Negative: week 52 (n=11) | HBeAg Negative: week 104 (n=5) | Overall: week 52 (n= 15) | Overall: week 104 (n= 6) | |
| Group B : LAM 2301 | 100 | 100 | 72.7 | 100 | 80.0 | 100 |
Maintained clinical response is defined as achievement of serum HBV DNA < 4 log10 copies/mL, normal serum ALT level and improvement or stabilization in Child-Turcotte-Pugh (CTP) score. Total CTP score ranges from 5 to 15; higher scores indicate liver impairment. Improvement is defined as a 2-point or greater reduction in CTP score, and stabilization is defined as a less than 2-point change in CTP score, compared to the patient's baseline value. Analysis was done on the overall per protocol (PP) population and separately for the HBeAg-positive and HBeAg-negative subpopulation. (NCT00142298)
Timeframe: 156 weeks, 208 weeks (from feeder study baseline)
| Intervention | Percentage of Participants (Number) | |||||
|---|---|---|---|---|---|---|
| HBeAg Positive: week 156 (n= 4) | HBeAg Positive: week 208 (n= 1) | HBeAg Negative: week 156 (n= 11) | HBeAg Negative: week 208 (n= 7) | Overall: Week 156 (n= 15) | Overall: Week 208 (n= 8) | |
| Group B : LdT 2301 | 100 | 100 | 72.7 | 71.4 | 80.0 | 75.0 |
The primary efficacy endpoint for Group C patients was the percentage of patients with sustained therapeutic response (defined as HBV DNA < 5 log10 copies/mL and either HBeAg loss or ALT normalized) at Weeks 52 and 104 of off-treatment follow-up. HBeAg loss is loss of detectable serum HBeAg in a patient who was HBeAg-positive at feeder baseline. ALT normalized is ALT within normal limits for a patient with an elevated ALT level (>1.0 × ULN) at either the feeder baseline or feeder screening visit. All efficacy data were analyzed separately for HBeAg-positive and HBeAg-negative patients. (NCT00142298)
Timeframe: 52 weeks,104 weeks
| Intervention | Percentage of Participants (Number) | |||
|---|---|---|---|---|
| HBeAg Positive: week 52 (n= 53, 42) | HBeAg Positive: week 104 (n= 42, 32) | HBeAg Negative: week 52 (n= 3, 5) | HBeAg Negative: week 104 (n= 3, 6) | |
| Group C : LdT Pool 2302/015 | 69.8 | 57.1 | 0.0 | 0.0 |
| Group C: LAM Pool 2302/015 | 73.8 | 62.5 | 80.0 | 83.3 |
84 reviews available for thymidine and Hepatitis B, Chronic
| Article | Year |
|---|---|
Nucleos(t)ide analogues for preventing HBV reactivation in immunosuppressed patients with hematological malignancies: a network meta-analysis.
Topics: Adenine; Antiviral Agents; Controlled Clinical Trials as Topic; Guanine; Hematologic Neoplasms; Hepa | 2017 |
Efficacy of Nucleot(s)ide Analogs Therapy in Patients with Unresectable HBV-Related Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
Topics: Adenine; Antiviral Agents; Arabinofuranosyluracil; Carcinoma, Hepatocellular; Guanine; Hepatitis B v | 2017 |
Hepatitis B During Pregnancy in Endemic Areas: Screening, Treatment, and Prevention of Mother-to-Child Transmission.
Topics: Antiviral Agents; Endemic Diseases; Female; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Ch | 2017 |
Combination Therapy for Chronic Hepatitis B: Current Updates and Perspectives.
Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Hepatitis B, Chronic; Humans; Interferon-alpha | 2017 |
Telbivudine therapy for gravidas with chronic hepatitis B infection and patients at risk of renal impairment.
Topics: Animals; Antiviral Agents; Female; Hepatitis B, Chronic; Humans; Pregnancy; Pregnancy Complications, | 2017 |
Rhabdomyolysis, lactic acidosis, and multiple organ failure during telbivudine treatment for hepatitis B: a case report and review of the literature.
Topics: Acidosis, Lactic; Adult; Antiviral Agents; Asian People; Hepatitis B, Chronic; Humans; Male; Multipl | 2017 |
Telbivudine treatment in chronic hepatitis B: experience from China.
Topics: Antiviral Agents; China; Clinical Trials as Topic; Female; Hepatitis B e Antigens; Hepatitis B virus | 2013 |
Telbivudine treatment is associated with high hepatitis B e antigen seroconversion and immune modulatory effects in chronic hepatitis B patients.
Topics: Antiviral Agents; China; Clinical Trials as Topic; Hepatitis B e Antigens; Hepatitis B, Chronic; Hum | 2013 |
Telbivudine versus entecavir for nucleos(t)ide-naive HBeAg-positive chronic hepatitis B: a meta-analysis.
Topics: Antiviral Agents; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Telbivudine; Thymid | 2014 |
Meta-analysis: the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B.
Topics: Adenine; Administration, Oral; Age Factors; Antiviral Agents; Carcinoma, Hepatocellular; Guanine; He | 2013 |
Lactic acidosis during telbivudine treatment for HBV: a case report and literature review.
Topics: Acidosis, Lactic; Adult; Antiviral Agents; Hepatitis B, Chronic; Humans; Male; Mitochondrial Disease | 2013 |
Comparison of the forty-eight week efficacy between telbivudine and entecavir in HBeAg-positive Asian patients with chronic hepatitis B: A meta-analysis.
Topics: Alanine Transaminase; Antiviral Agents; Asian People; Creatine Kinase; DNA, Viral; Drug Resistance, | 2013 |
Review article: nucleos(t)ide analogues in patients with chronic hepatitis B virus infection and chronic kidney disease.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Organopho | 2014 |
Extrahepatic effects of nucleoside and nucleotide analogues in chronic hepatitis B treatment.
Topics: Acidosis, Lactic; Adenine; Administration, Oral; Antiviral Agents; Arabinofuranosyluracil; Dose-Resp | 2014 |
HBeAg-positive chronic hepatitis B: why do i treat my patients with Nucleos(t)ide analogs?
Topics: Adenine; Age Factors; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Guanine; Hepatitis B | 2014 |
New therapeutic perspectives in HBV: when to stop NAs.
Topics: Adenine; Algorithms; Antiviral Agents; Biomarkers; DNA, Viral; Drug Therapy, Combination; Guanine; H | 2014 |
Continuous venovenous hemodiafiltration for hyperlactatemia caused by telbivudine in a patient with chronic hepatitis B: a case report and update review.
Topics: Adult; Antiviral Agents; Biomarkers; Creatine Kinase; Hemodiafiltration; Hepatitis B, Chronic; Human | 2015 |
Hepatitis B and C in pregnancy: a review and recommendations for care.
Topics: Antiviral Agents; Breast Feeding; Cesarean Section; Contraindications; DNA, Viral; Female; Hepatitis | 2014 |
Changes in serum alanine aminotransferase levels in telbivudine versus lamivudine treatment for chronic hepatitis B: a meta-analysis.
Topics: Alanine Transaminase; Antiviral Agents; Biomarkers; Hepatitis B, Chronic; Humans; Lamivudine; Telbiv | 2015 |
How to achieve immune control in chronic hepatitis B?
Topics: Antiviral Agents; Biomarkers; DNA, Circular; DNA, Viral; Hepatitis B Surface Antigens; Hepatitis B v | 2015 |
Comparative efficacy of antiviral therapy in preventing vertical transmission of hepatitis B: a network meta-analysis.
Topics: Antiviral Agents; Female; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; H | 2016 |
Hepatitis B: encouraging the use of interferon.
Topics: Adjuvants, Immunologic; Antiviral Agents; Carcinoma, Hepatocellular; Contraindications; Drug Adminis | 2015 |
Monotherapy for hepatitis B infection: a review of treatment options.
Topics: Adenine; Animals; Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans | 2015 |
Effect of Telbivudine Versus Other Nucleos(t)ide Analogs on HBeAg Seroconversion and Other Outcomes in Patients with Chronic Hepatitis B: A Network Meta-Analysis.
Topics: Antiviral Agents; Comparative Effectiveness Research; Hepatitis B e Antigens; Hepatitis B, Chronic; | 2016 |
Potential effects of telbivudine and entecavir on renal function: a systematic review and meta-analysis.
Topics: Antiviral Agents; China; Guanine; Hepatitis B, Chronic; Humans; Kidney; Kidney Diseases; Kidney Func | 2016 |
Renal Function in Nucleos(t)ide Analog-Treated Patients With Chronic Hepatitis B: A Systematic Literature Review and Network Meta-Analysis.
Topics: Antiviral Agents; Glomerular Filtration Rate; Hepatitis B, Chronic; Humans; Kidney; Protective Agent | 2016 |
Chronic hepatitis B in children: Therapeutic challenges and perspectives.
Topics: Adenine; Alanine Transaminase; Antigens, Viral; Antiviral Agents; Child; Guanine; Hepatitis B virus; | 2017 |
HBeAg Seroconversion in HBeAg-Positive Chronic Hepatitis B Patients Receiving Long-Term Nucleos(t)ide Analog Treatment: A Systematic Review and Network Meta-Analysis.
Topics: Antiviral Agents; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Telbivudine; Thymid | 2017 |
[Management of antiviral-resistant chronic hepatitis B virus infection].
Topics: Adenine; Antiviral Agents; Arabinofuranosyluracil; Drug Resistance, Multiple, Viral; Guanine; Hepati | 2008 |
A review of telbivudine for the management of chronic hepatitis B virus infection.
Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Resistance, | 2008 |
Telbivudine in the treatment of chronic hepatitis B.
Topics: Drug Resistance, Viral; Hepatitis B, Chronic; Humans; Nucleosides; Pyrimidinones; Telbivudine; Thymi | 2008 |
[Interferon in hepatitis B].
Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Genotype; Guanine; H | 2008 |
[Nucleoside and nucleotide analogs in the treatment of chronic hepatitis B].
Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Deoxycytidine; Drug Resistance, Viral; Drug The | 2008 |
[Clinical management of patients with chronic hepatitis B virus infection].
Topics: Adenine; Antiviral Agents; Biopsy; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Viral; | 2008 |
Nucleos(t)ide analogues for hepatitis B virus: strategies for long-term success.
Topics: Adenine; Adenine Nucleotides; Alanine Transaminase; Carcinoma, Hepatocellular; DNA, Viral; Drug Admi | 2008 |
Peginterferon for the treatment of chronic hepatitis B in the era of nucleos(t)ide analogues.
Topics: Adenine; Antiviral Agents; DNA, Viral; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens | 2008 |
HBeAg-negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Guanine; Hepatitis B e Antigens; Hepatitis B, Chr | 2009 |
Telbivudine in the treatment of chronic hepatitis B.
Topics: Alanine Transaminase; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; DNA, | 2009 |
Chronic hepatitis B: early viral suppression and long-term outcomes of therapy with oral nucleos(t)ides.
Topics: Adenine; Administration, Oral; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Hepatitis B vir | 2009 |
On-treatment outcome prediction and adjustment during chronic hepatitis B therapy: now and future.
Topics: Adenine; Antiviral Agents; Cost-Benefit Analysis; DNA, Viral; Drug Resistance, Multiple, Viral; Hepa | 2009 |
Treatment of chronic hepatitis B: focus on telbivudine.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, | 2009 |
Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B.
Topics: Animals; Antiviral Agents; Arabinofuranosyluracil; Creatine Kinase; Drug Discovery; Early Terminatio | 2009 |
Telbivudine for the treatment of chronic hepatitis B infection.
Topics: Adult; Antiviral Agents; Cost-Benefit Analysis; Hepatitis B, Chronic; Humans; Nucleosides; Pyrimidin | 2009 |
Current status of nucleoside antivirals in chronic hepatitis B.
Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Resistance, Viral; Guanine; Hepatitis B e Antigens; He | 2009 |
Effect of newer oral antiviral agents on future therapy of chronic hepatitis B.
Topics: Adenine; Administration, Oral; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; | 2010 |
On-treatment monitoring of chronic hepatitis B virus infection: an Asian-Pacific perspective.
Topics: Adenine; Antiviral Agents; Asia; Biomarkers; DNA, Viral; Drug Monitoring; Drug Resistance, Viral; Gu | 2010 |
Safety evaluation of telbivudine.
Topics: Adult; Antiviral Agents; Biomarkers; Creatine Kinase; Double-Blind Method; Drug Resistance, Viral; F | 2010 |
Telbivudine: an effective anti-HBV drug for chronic hepatitis B patients with early on-treatment responses.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Resistance, Viral; Hepatitis B e Antigens; Hepatiti | 2010 |
Comparison of the efficacy of lamivudine and telbivudine in the treatment of chronic hepatitis B: a systematic review.
Topics: Antiviral Agents; Clinical Trials as Topic; Databases, Factual; Hepatitis B, Chronic; Humans; Lamivu | 2010 |
Telbivudine: a review of its use in compensated chronic hepatitis B.
Topics: Antiviral Agents; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Nucleosid | 2010 |
Treatment of HBeAg-positive chronic hepatitis B with nucleos(t)ide analogues.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; | 2011 |
Hepatitis B virus resistance to antiviral drugs: where are we going?
Topics: Adenine; Antiviral Agents; Capsid; Clinical Protocols; Drug Resistance, Viral; Guanine; Hepatitis B | 2011 |
[Interferon-based versus direct antiviral therapy in patients with chronic hepatitis B].
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Guanine; Hepatitis B virus; Hepati | 2011 |
Antiviral therapy for hepatitis B infection during pregnancy and breastfeeding.
Topics: Adenine; Antiviral Agents; Breast Feeding; Female; Guanine; Hepatitis B; Hepatitis B virus; Hepatiti | 2011 |
Antiviral drugs for viruses other than human immunodeficiency virus.
Topics: Acyclovir; Adenine; Amantadine; Antiviral Agents; Comorbidity; Drug Therapy, Combination; Foscarnet; | 2011 |
Meta-analysis: oral anti-viral agents in adults with decompensated hepatitis B virus cirrhosis.
Topics: Adenine; Administration, Oral; Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combin | 2012 |
[New drugs of treatment of patients with chronic hepatitis B].
Topics: Adenine; Antiviral Agents; Arabinofuranosyluracil; Deoxycytidine; Emtricitabine; Hepatitis B, Chroni | 2012 |
Lamivudine versus telbivudine in the treatment of chronic hepatitis B: a systematic review and meta-analysis.
Topics: Antiviral Agents; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Liver Func | 2013 |
The effects of telbivudine in late pregnancy to prevent intrauterine transmission of the hepatitis B virus: a systematic review and meta-analysis.
Topics: Antiviral Agents; Female; Hepatitis B Antibodies; Hepatitis B, Chronic; Humans; Infectious Disease T | 2012 |
Effects of telbivudine and entecavir for HBeAg-positive chronic hepatitis B: a meta-analysis.
Topics: Adult; Antiviral Agents; Biomarkers; Chi-Square Distribution; Drug Resistance, Viral; Guanine; Hepat | 2012 |
[Efficacy and safety of telbivudine treatment to block mother-to-child transmission of hepatitis B virus: a meta-analysis].
Topics: Antiviral Agents; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infant; Infectious Diseas | 2012 |
Considerations for the long-term treatment of chronic hepatitis B with nucleos(t)ide analogs.
Topics: Adenine; Age Factors; Antiviral Agents; Comorbidity; DNA, Viral; Drug Resistance, Viral; Guanine; He | 2012 |
Telbivudine on-treatment HBsAg loss in naive HBeAg negative chronic hepatitis B: a case report and brief review of the literature.
Topics: Antiviral Agents; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans | 2012 |
Entecavir, FTC, L-FMAU, LdT and others.
Topics: Antiviral Agents; Arabinofuranosyluracil; Clinical Trials as Topic; Deoxycytidine; Emtricitabine; Gu | 2003 |
New treatment of chronic hepatitis B.
Topics: Adenine; Animals; Antiviral Agents; Arabinofuranosyluracil; Deoxycytidine; Drug Resistance, Viral; E | 2004 |
Telbivudine: a new nucleoside analogue for the treatment of chronic hepatitis B.
Topics: Animals; Antiviral Agents; Disease Models, Animal; Hepatitis B, Chronic; Humans; Lamivudine; Nucleos | 2005 |
Telbivudine: an upcoming agent for chronic hepatitis B.
Topics: Antiviral Agents; DNA, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Molecular Structure; | 2005 |
Telbivudine: a novel nucleoside analog for chronic hepatitis B.
Topics: Animals; Antiviral Agents; Clinical Trials as Topic; Hepatitis B, Chronic; Humans; Nucleosides; Pyri | 2006 |
Novel anti-hepatitis B agents: A focus on telbivudine.
Topics: Antiviral Agents; Clinical Trials, Phase II as Topic; DNA, Viral; Drug Resistance, Viral; Hepatitis | 2006 |
[Progress in the treatment of chronic hepatitis B with Telbivudine].
Topics: Antiviral Agents; Hepatitis B, Chronic; Humans; Nucleosides; Pyrimidinones; Telbivudine; Thymidine | 2006 |
Improving outcomes for patients with chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Guanine; Hepatitis B Vaccines; Hepatitis B, Chron | 2007 |
Telbivudine: a new option for the treatment of chronic hepatitis B.
Topics: Animals; Antiviral Agents; Hepatitis B, Chronic; Humans; Nucleosides; Pyrimidinones; Telbivudine; Th | 2007 |
Treatment paradigms on hepatitis B e antigen-negative chronic hepatitis B patients.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Guanine; Hepatitis B e Antigens; Hepatitis B, Chr | 2007 |
Treatment of chronic hepatitis B in HIV-infected patients in 2007.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; HIV Infections; Humans; Interferon-alpha; | 2007 |
Telbivudine.
Topics: Antiviral Agents; Hepatitis B virus; Hepatitis B, Chronic; Humans; Nucleic Acid Synthesis Inhibitors | 2007 |
Telbivudine for the treatment of chronic hepatitis B.
Topics: Antiviral Agents; Clinical Trials as Topic; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, | 2007 |
Therapy of chronic hepatitis B: focus on telbivudine.
Topics: Alanine Transaminase; Antiviral Agents; DNA, Viral; Hepatitis B, Chronic; Humans; Nucleosides; Pyrim | 2007 |
Telbivudine: a new treatment for chronic hepatitis B.
Topics: Antiviral Agents; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Hepatitis B, Chronic; Hum | 2007 |
Telbivudine for the management of chronic hepatitis B virus infection.
Topics: Alanine Transaminase; Antiviral Agents; Clinical Trials as Topic; DNA, Viral; Drug Interactions; Dru | 2007 |
Active antiviral therapy for chronic hepatitis B and hepatocellular carcinoma.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; | 2008 |
[Pharmacological agents for the treatment of chronic hepatitis B].
Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Follow-Up Studies; G | 2008 |
Clinical implications of resistance patterns against HBV-polymerase inhibitors for the treatment of chronic hepatitis B.
Topics: Adenine; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B, Chronic; Humans; Lamivudine | 2007 |
[Telbivudine in the treatment of the chronic B hepatitis].
Topics: Adolescent; Adult; Aged; Antiviral Agents; Biomarkers, Pharmacological; Biotransformation; Clinical | 2008 |
Review article: current antiviral therapy of chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Deoxycytidine; Drug Resistance, Viral; Emtrici | 2008 |
64 trials available for thymidine and Hepatitis B, Chronic
| Article | Year |
|---|---|
Entecavir to Telbivudine Switch Therapy in Entecavir-Treated Patients with Undetectable Hepatitis B Viral DNA.
Topics: Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Substitution | 2017 |
Telbivudine treatment started in early and middle pregnancy completely blocks HBV vertical transmission.
Topics: Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Female; Hepatitis B Surface Antigens; Hep | 2017 |
Interpretation of liver stiffness measurement-based approach for the monitoring of hepatitis B patients with antiviral therapy: A 2-year prospective study.
Topics: Adolescent; Adult; Alanine Transaminase; Antiviral Agents; Biopsy; Drug Monitoring; Drug Therapy, Co | 2018 |
Comparison of 208-week sequential therapy with telbivudine and entecavir in HBeAg-positive chronic hepatitis B patients with suboptimal responses to 24 weeks of Peg-IFNα-2a therapy: An open-labelled, randomized, controlled, "real-life" trial.
Topics: Adult; DNA, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon | 2017 |
Rapid downregulation of programmed death-1 and interferon-γ-inducible protein-10 expression is associated with favourable outcome during antiviral treatment of chronic hepatitis B.
Topics: Adult; Antiviral Agents; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Chemokine CXCL10; C | 2013 |
Efficacy and safety of telbivudine plus adefovir dipivoxil combination therapy and entecavir monotherapy for HBeAg-positive chronic hepatitis B patients with resistance to adefovir dipivoxil.
Topics: Adenine; Adult; Antiviral Agents; China; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combinati | 2013 |
Efficacy of telbivudine treatment for hepatitis B e antigen-positive chronic hepatitis B patients with poor response to adefovir dipivoxil.
Topics: Adenine; Adult; Antiviral Agents; China; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B e A | 2013 |
Efficacy of sequential use of telbivudine in hepatitis B e antigen-positive chronic hepatitis B patients with partial responses to pegylated interferon: a pilot study.
Topics: Adult; Antiviral Agents; China; DNA, Viral; Drug Administration Schedule; Drug Therapy, Combination; | 2013 |
Safety of telbivudine treatment for chronic hepatitis B for the entire pregnancy.
Topics: Adult; Antiviral Agents; China; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infant; Inf | 2013 |
Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B.
Topics: Adult; Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis B, Chron | 2013 |
Antiviral therapy decreases viral reactivation in patients with hepatitis B virus-related hepatocellular carcinoma undergoing hepatectomy: a randomized controlled trial.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Female; Hepatectomy; Hepatitis B virus; Hepatiti | 2013 |
Phase I, open-label, single-dose study to evaluate the pharmacokinetics and safety of telbivudine in children and adolescents with chronic hepatitis B.
Topics: Administration, Oral; Adolescent; Adult; Antiviral Agents; Child; Child, Preschool; Drug Administrat | 2013 |
Efficacy and safety of telbivudine therapy in liver failure patients with chronic hepatitis B virus infection.
Topics: Adolescent; Adult; Aged; Antiviral Agents; DNA, Viral; Female; Hepatitis B virus; Hepatitis B, Chron | 2013 |
Telbivudine and adefovir combination therapy for patients with chronic lamivudine-resistant hepatitis B virus infections.
Topics: Adenine; Adult; Aged; Antibodies, Viral; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Com | 2014 |
Telbivudine improves renal function in patients with chronic hepatitis B.
Topics: Adult; Antiviral Agents; Creatinine; Double-Blind Method; Female; Glomerular Filtration Rate; Hepati | 2014 |
Telbivudine improves renal function in patients with chronic hepatitis B.
Topics: Adult; Antiviral Agents; Creatinine; Double-Blind Method; Female; Glomerular Filtration Rate; Hepati | 2014 |
Telbivudine improves renal function in patients with chronic hepatitis B.
Topics: Adult; Antiviral Agents; Creatinine; Double-Blind Method; Female; Glomerular Filtration Rate; Hepati | 2014 |
Telbivudine improves renal function in patients with chronic hepatitis B.
Topics: Adult; Antiviral Agents; Creatinine; Double-Blind Method; Female; Glomerular Filtration Rate; Hepati | 2014 |
[Clinical observations of sequential interferon therapy following complete response to telbivudine treatment in chronic hepatitis B patients].
Topics: Adult; Female; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; I | 2013 |
The 104-week efficacy and safety of telbivudine-based optimization strategy in chronic hepatitis B patients: a randomized, controlled study.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Antiviral Agents; China; Dose-Response Relationshi | 2014 |
Efficacy of switching to telbivudine plus adefovir in suboptimal responders to lamivudine plus adefovir.
Topics: Adenine; Administration, Oral; Adult; Aged; Antiviral Agents; Biomarkers; DNA, Viral; Drug Administr | 2013 |
[Long-term efficacy and safety of telbivudine as monotherapy and as combination therapy with adefovir dipivoxil in HBeAg-positive chronic hepatitis B patients].
Topics: Adenine; Adolescent; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis B e Antig | 2014 |
Viral infection parameters not nucleoside analogue itself correlates with host immunity in nucleoside analogue therapy for chronic hepatitis B.
Topics: Adult; Antiviral Agents; Biomarkers; CD8-Positive T-Lymphocytes; China; Cytokines; DNA, Viral; Femal | 2014 |
Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy.
Topics: Adult; Antiviral Agents; DNA, Viral; Drug Carriers; Drug Therapy, Combination; Female; Global Health | 2015 |
Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice.
Topics: Adult; Antiviral Agents; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B Surface Anti | 2014 |
[Long-term efficacy and safety of telbivudine in the treatment of childbearing patients with chronic hepatitis B].
Topics: Adolescent; Adult; Antiviral Agents; Female; Hepatitis B, Chronic; Humans; Infant; Infant, Newborn; | 2014 |
Significant renoprotective effect of telbivudine during preemptive antiviral therapy in advanced liver cancer patients receiving cisplatin-based chemotherapy: a case-control study.
Topics: Acute Kidney Injury; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoc | 2014 |
Cost-effectiveness analysis of lamivudine, telbivudine, and entecavir in treatment of chronic hepatitis B with adefovir dipivoxil resistance.
Topics: Adenine; Adult; Antiviral Agents; Cost-Benefit Analysis; Double-Blind Method; Drug Resistance, Viral | 2015 |
Long-Term Telbivudine Treatment Results in Resolution of Liver Inflammation and Fibrosis in Patients with Chronic Hepatitis B.
Topics: Adult; Antiviral Agents; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hu | 2015 |
Long-Term Telbivudine Treatment Results in Resolution of Liver Inflammation and Fibrosis in Patients with Chronic Hepatitis B.
Topics: Adult; Antiviral Agents; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hu | 2015 |
Long-Term Telbivudine Treatment Results in Resolution of Liver Inflammation and Fibrosis in Patients with Chronic Hepatitis B.
Topics: Adult; Antiviral Agents; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hu | 2015 |
Long-Term Telbivudine Treatment Results in Resolution of Liver Inflammation and Fibrosis in Patients with Chronic Hepatitis B.
Topics: Adult; Antiviral Agents; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hu | 2015 |
Resistant mutations and quasispecies complexity of hepatitis B virus during telbivudine treatment.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis B virus; Hepati | 2015 |
Cost-effectiveness of Lamivudine, Telbivudine, Adefovir Dipivoxil and Entecavir on decompensated hepatitis B virus-related cirrhosis.
Topics: Adenine; Adult; Antiviral Agents; Cost-Benefit Analysis; Female; Guanine; Hepatitis B virus; Hepatit | 2016 |
[Effect of Telbivudine Tablet Combined Jianpi Bushen Recipe on HBV Specific Cytotoxic T Lymphocyte and HBeAg Seroconversion in Patients with HBeAg Positive Chronic Hepatitis B].
Topics: Drug Therapy, Combination; Drugs, Chinese Herbal; Hepatitis B e Antigens; Hepatitis B virus; Hepatit | 2016 |
[Efficacy of 104-week sequential therapy with telbivudine or entecavir in HBeAg-positive chronic hepatitis B patients with suboptimal responses to 24-week therapy with pegylated interferon-α-2a].
Topics: Antiviral Agents; DNA, Viral; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatit | 2016 |
[Short-term results of telbivudine versus entecavir treatments in HBeAg-positive chronic hepatitis B patients in China].
Topics: Adolescent; Adult; Aged; Antiviral Agents; Female; Guanine; Hepatitis B e Antigens; Hepatitis B, Chr | 2008 |
2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind Method; Fe | 2009 |
[Telbivudine treatment on cirrhosis resulting from chronic hepatitis B].
Topics: Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B e Antigens; Hepatit | 2009 |
Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Hepatitis B e Antigens; | 2009 |
[Blocking intrauterine infection by telbivudine in pregnant chronic hepatitis B patients].
Topics: Administration, Oral; Antiviral Agents; DNA, Viral; Female; Hepatitis B Surface Antigens; Hepatitis | 2009 |
Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B.
Topics: Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Female; Guanine; Hepatitis B e Antigens; | 2010 |
A 24-week, parallel-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients.
Topics: Adult; Antiviral Agents; China; DNA, Viral; Female; Guanine; Hepatitis B; Hepatitis B e Antigens; He | 2010 |
[Clinical antiviral effects of telbivudine in patients with chronic hepatitis B].
Topics: Adult; Antiviral Agents; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, | 2010 |
Efficacy of telbivudine in HBeAg-positive chronic hepatitis B patients with high baseline ALT levels.
Topics: Alanine Transaminase; Antiviral Agents; DNA, Viral; Hepatitis B e Antigens; Hepatitis B, Chronic; Hu | 2010 |
Efficacy of switching to telbivudine in chronic hepatitis B patients treated previously with lamivudine.
Topics: Adult; Antiviral Agents; Biomarkers; Chi-Square Distribution; DNA, Viral; Double-Blind Method; Drug | 2011 |
Complementarity-determining region 3 size spectratypes of T cell receptor beta chains in CD8+ T cells following antiviral treatment of chronic hepatitis B.
Topics: Adult; Antiviral Agents; CD8-Positive T-Lymphocytes; Complementarity Determining Regions; Double-Bli | 2011 |
[Efficacy of antiviral treatment on patients with acute-on-chronic hepatitis B liver failure with low viral load].
Topics: Adult; Antiviral Agents; End Stage Liver Disease; Female; Guanine; Hepatitis B, Chronic; Humans; Lam | 2010 |
Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis B.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; Biomarkers; DNA, Viral; Drug Admini | 2011 |
[Study on the efficacy and HBeAg seroconversion related factors of telbivudine and entecavir therapy in HBeAg positive chronic hepatitis B patients].
Topics: Adolescent; Adult; Antiviral Agents; DNA, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatitis | 2011 |
A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection.
Topics: Adult; Antiviral Agents; DNA, Viral; Female; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatit | 2011 |
High serum IL-21 levels after 12 weeks of antiviral therapy predict HBeAg seroconversion in chronic hepatitis B.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Biomarkers; Disease Progression; DNA, Viral; Female; | 2012 |
Inhibition of viral replication downregulates CD4(+)CD25(high) regulatory T cells and programmed death-ligand 1 in chronic hepatitis B.
Topics: Adult; Antiviral Agents; B7-H1 Antigen; CD4-Positive T-Lymphocytes; Cytokines; Down-Regulation; Fema | 2012 |
Telbivudine prevents vertical transmission from HBeAg-positive women with chronic hepatitis B.
Topics: Adult; Antiviral Agents; Case-Control Studies; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis | 2012 |
Telbivudine prevents vertical transmission from HBeAg-positive women with chronic hepatitis B.
Topics: Adult; Antiviral Agents; Case-Control Studies; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis | 2012 |
Telbivudine prevents vertical transmission from HBeAg-positive women with chronic hepatitis B.
Topics: Adult; Antiviral Agents; Case-Control Studies; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis | 2012 |
Telbivudine prevents vertical transmission from HBeAg-positive women with chronic hepatitis B.
Topics: Adult; Antiviral Agents; Case-Control Studies; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis | 2012 |
[Influences of warming kidney prescription on antiviral therapeutic efficacy and creatine kinase in telbivudine-treated HBeAg-positive chronic hepatitis B patients].
Topics: Adult; Antiviral Agents; Creatine Kinase; Female; Hepatitis B, Chronic; Humans; Male; Middle Aged; N | 2012 |
[Efficacy and safety of telbivudine in pregnant chronic hepatitis B patients].
Topics: Adult; Antiviral Agents; Female; Hepatitis B, Chronic; Humans; Nucleosides; Pregnancy; Pregnancy Com | 2011 |
Lamivudine plus adefovir or telbivudine plus adefovir for chronic hepatitis B patients with suboptimal response to adefovir.
Topics: Adenine; Adult; Biomarkers; DNA, Viral; Drug Therapy, Combination; Female; Genotype; Hepatitis B e A | 2012 |
A randomized controlled trial of sequential pegylated interferon-α and telbivudine or vice versa for 48 weeks in hepatitis B e antigen-negative chronic hepatitis B.
Topics: Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Drug Therap | 2013 |
Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-naïve patients with HBV-related decompensated cirrhosis.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind Method; Fe | 2012 |
Efficacy of telbivudine in Taiwanese chronic hepatitis B patients compared with GLOBE extension study and predicting treatment outcome by HBV DNA kinetics at week 24.
Topics: Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis | 2012 |
52-week efficacy and safety of telbivudine with conditional tenofovir intensification at week 24 in HBeAg-positive chronic hepatitis B.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Dr | 2013 |
52-week efficacy and safety of telbivudine with conditional tenofovir intensification at week 24 in HBeAg-positive chronic hepatitis B.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Dr | 2013 |
52-week efficacy and safety of telbivudine with conditional tenofovir intensification at week 24 in HBeAg-positive chronic hepatitis B.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Dr | 2013 |
52-week efficacy and safety of telbivudine with conditional tenofovir intensification at week 24 in HBeAg-positive chronic hepatitis B.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Dr | 2013 |
[Efficacy and safety of telbivudine and adefovir dipivoxil for the treatment of chronic hepatitis B patients with high level hepatitis B virus load and hepatitis B e antigen-positivity].
Topics: Adenine; Adult; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Mal | 2012 |
A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection.
Topics: Adult; Aged; DNA, Viral; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hep | 2004 |
A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B.
Topics: Adolescent; Adult; Age Factors; Aged; DNA, Viral; Dose-Response Relationship, Drug; Double-Blind Met | 2005 |
Pharmacokinetics of telbivudine following oral administration of escalating single and multiple doses in patients with chronic hepatitis B virus infection: pharmacodynamic implications.
Topics: Administration, Oral; Adult; Antiviral Agents; Area Under Curve; Asian People; China; Cohort Studies | 2006 |
[The degree of HBV suppression with 24 week telbivudine- or lamivudine-treatment in hepatitis B patients predicts the efficacy of the treatment at week 52].
Topics: Adolescent; Adult; Aged; Antiviral Agents; DNA, Viral; Double-Blind Method; Female; Hepatitis B, Chr | 2007 |
Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial.
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Biomarkers; DNA, Viral; Drug Therapy, Combinatio | 2007 |
Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial.
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Biomarkers; DNA, Viral; Drug Therapy, Combinatio | 2007 |
Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial.
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Biomarkers; DNA, Viral; Drug Therapy, Combinatio | 2007 |
Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial.
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Biomarkers; DNA, Viral; Drug Therapy, Combinatio | 2007 |
Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial.
Topics: Adolescent; Adult; Antiviral Agents; China; DNA, Viral; Double-Blind Method; Female; Genotype; Hepat | 2008 |
Telbivudine versus lamivudine in patients with chronic hepatitis B.
Topics: Adolescent; Adult; Aged; Antiviral Agents; DNA, Viral; Double-Blind Method; Drug Resistance, Viral; | 2007 |
Telbivudine versus lamivudine in patients with chronic hepatitis B.
Topics: Adolescent; Adult; Aged; Antiviral Agents; DNA, Viral; Double-Blind Method; Drug Resistance, Viral; | 2007 |
Telbivudine versus lamivudine in patients with chronic hepatitis B.
Topics: Adolescent; Adult; Aged; Antiviral Agents; DNA, Viral; Double-Blind Method; Drug Resistance, Viral; | 2007 |
Telbivudine versus lamivudine in patients with chronic hepatitis B.
Topics: Adolescent; Adult; Aged; Antiviral Agents; DNA, Viral; Double-Blind Method; Drug Resistance, Viral; | 2007 |
Telbivudine versus lamivudine in patients with chronic hepatitis B.
Topics: Adolescent; Adult; Aged; Antiviral Agents; DNA, Viral; Double-Blind Method; Drug Resistance, Viral; | 2007 |
Telbivudine versus lamivudine in patients with chronic hepatitis B.
Topics: Adolescent; Adult; Aged; Antiviral Agents; DNA, Viral; Double-Blind Method; Drug Resistance, Viral; | 2007 |
Telbivudine versus lamivudine in patients with chronic hepatitis B.
Topics: Adolescent; Adult; Aged; Antiviral Agents; DNA, Viral; Double-Blind Method; Drug Resistance, Viral; | 2007 |
Telbivudine versus lamivudine in patients with chronic hepatitis B.
Topics: Adolescent; Adult; Aged; Antiviral Agents; DNA, Viral; Double-Blind Method; Drug Resistance, Viral; | 2007 |
Telbivudine versus lamivudine in patients with chronic hepatitis B.
Topics: Adolescent; Adult; Aged; Antiviral Agents; DNA, Viral; Double-Blind Method; Drug Resistance, Viral; | 2007 |
Telbivudine versus lamivudine in patients with chronic hepatitis B.
Topics: Adolescent; Adult; Aged; Antiviral Agents; DNA, Viral; Double-Blind Method; Drug Resistance, Viral; | 2007 |
Telbivudine versus lamivudine in patients with chronic hepatitis B.
Topics: Adolescent; Adult; Aged; Antiviral Agents; DNA, Viral; Double-Blind Method; Drug Resistance, Viral; | 2007 |
Telbivudine versus lamivudine in patients with chronic hepatitis B.
Topics: Adolescent; Adult; Aged; Antiviral Agents; DNA, Viral; Double-Blind Method; Drug Resistance, Viral; | 2007 |
Telbivudine versus lamivudine in patients with chronic hepatitis B.
Topics: Adolescent; Adult; Aged; Antiviral Agents; DNA, Viral; Double-Blind Method; Drug Resistance, Viral; | 2007 |
Telbivudine versus lamivudine in patients with chronic hepatitis B.
Topics: Adolescent; Adult; Aged; Antiviral Agents; DNA, Viral; Double-Blind Method; Drug Resistance, Viral; | 2007 |
Telbivudine versus lamivudine in patients with chronic hepatitis B.
Topics: Adolescent; Adult; Aged; Antiviral Agents; DNA, Viral; Double-Blind Method; Drug Resistance, Viral; | 2007 |
Telbivudine versus lamivudine in patients with chronic hepatitis B.
Topics: Adolescent; Adult; Aged; Antiviral Agents; DNA, Viral; Double-Blind Method; Drug Resistance, Viral; | 2007 |
[The efficacy and safety of telbivudine in korean patients with chronic hepatitis B].
Topics: Adolescent; Adult; Alanine Transaminase; Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis | 2007 |
182 other studies available for thymidine and Hepatitis B, Chronic
| Article | Year |
|---|---|
Efficacy and Long-term Safety of Telbivudine Usage During Second or Third Trimester in Hepatitis B Surface Antigen Positive Mothers With High Viral Load: A 10-year Prospective Study.
Topics: Antiviral Agents; DNA, Viral; Female; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, | 2023 |
Clinical and Immunological Factors Associated with Postpartum Hepatic Flares in Immune-Tolerant Pregnant Women with Hepatitis B Virus Infection Treated with Telbivudine.
Topics: Alanine Transaminase; Antiviral Agents; DNA, Viral; Female; Hepatitis B; Hepatitis B e Antigens; Hep | 2021 |
Telbivudine attenuates gentamicin-induced kidney injury in rats.
Topics: Acute Kidney Injury; Animals; Cystatin C; Gentamicins; Glomerular Filtration Rate; Hepatitis B, Chro | 2017 |
Effectiveness of entecavir or telbivudine therapy in patients with chronic hepatitis B virus infection pre-treated with interferon compared with de novo therapy with entecavir and telbivudine.
Topics: Adult; Antiviral Agents; Drug Resistance, Viral; Female; Follow-Up Studies; Guanine; Hepatitis B e A | 2017 |
Relationship of Treg/Th17 balance with HBeAg change in HBeAg-positive chronic hepatitis B patients receiving telbivudine antiviral treatment: A longitudinal observational study.
Topics: Adult; Antiviral Agents; Biomarkers; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; I | 2017 |
Safety and efficacy of telbivudine for chronic hepatitis B during the entire pregnancy: Long-term follow-up.
Topics: Antiviral Agents; Child Development; Child, Preschool; Female; Follow-Up Studies; Hepatitis B, Chron | 2017 |
Improvement of telbivudine on renal function and massive proteinuria: A case report.
Topics: Antiviral Agents; Biomarkers; Hepatitis B, Chronic; Humans; Kidney Function Tests; Liver Cirrhosis; | 2017 |
Determination of telbivudine in the plasma of chronic hepatitis B patients in long-term treatment by high-performance liquid chromatographic-tandem mass spectrometry.
Topics: Adult; Antiviral Agents; Chromatography, High Pressure Liquid; Creatine Kinase; Drug Monitoring; Fem | 2018 |
Safety and efficacy of lamivudine or telbivudine started in early pregnancy for mothers with active chronic hepatitis B.
Topics: Adult; Antiviral Agents; Case-Control Studies; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis | 2018 |
Motor development delay in offspring is associated with prenatal telbivudine exposure.
Topics: Adult; Antiviral Agents; Developmental Disabilities; DNA, Viral; Female; Hepatitis B virus; Hepatiti | 2018 |
Real World Experience of Telbivudine Versus Entecavir in Patients with Chronic Hepatitis B, Including Long-Term Outcomes after Treatment Modification.
Topics: Adult; Aged; Antiviral Agents; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Inc | 2018 |
Case report: lactic acidosis and rhabdomyolysis during telbivudine and tenofovir treatment for chronic hepatitis B.
Topics: Acidosis, Lactic; Antiviral Agents; DNA Polymerase gamma; Drug Therapy, Combination; Hepatitis B, Ch | 2018 |
Trends in hepatitis B virus resistance to nucleoside/nucleotide analogues in North China from 2009-2016: A retrospective study.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Chin | 2018 |
Clinical-features analysis on 926 patients with virological breakthrough in chronic hepatitis B receiving nucleos(t)ide analogues.
Topics: Adenine; Adult; DNA, Viral; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Comb | 2018 |
Hepatitis B virus serosurvey and awareness of mother-to-child transmission among pregnant women in Shenyang, China: An observational study.
Topics: Adult; Antiviral Agents; China; Female; Health Knowledge, Attitudes, Practice; Hepatitis B e Antigen | 2018 |
Effectiveness of telbivudine antiviral treatment in patients with hepatitis B virus-associated glomerulonephritis: A 104-week pilot study.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; DNA, Viral; Female; Glom | 2018 |
The use of tenofovir and telbivudine combination therapy for immune-tolerant chronic hepatitis B patients awaiting assisted reproduction.
Topics: Antiviral Agents; Hepatitis B, Chronic; Humans; Telbivudine; Tenofovir; Thymidine; Viral Load | 2019 |
Telbivudine plus adefovir therapy for chronic hepatitis B patients with virological breakthrough or genotypic resistance to telbivudine.
Topics: Adenine; Antiviral Agents; Biomarkers; Chi-Square Distribution; DNA, Viral; Drug Resistance, Viral; | 2013 |
A different look at the management of chronic hepatitis B in a resource-constrained country.
Topics: Adenine; Antiviral Agents; China; Drug Therapy, Combination; Health Resources; Hepatitis B virus; He | 2013 |
Efficacy of entecavir switch therapy in chronic hepatitis B patients with incomplete virological response to telbivudine.
Topics: Adult; Antiviral Agents; Drug Resistance, Viral; Drug Substitution; Female; Follow-Up Studies; Guani | 2013 |
Dynamics of hepatitis B virus quasispecies heterogeneity and virologic response in patients receiving low-to-moderate genetic barrier nucleoside analogs.
Topics: Adult; Antiviral Agents; DNA, Viral; Female; Genetic Variation; Genotype; Hepatitis B virus; Hepatit | 2013 |
Increased eGFR with telbivudine in combination therapy of chronic hepatitis B infection.
Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Glomerular Filtration Rate; Guanine; Hepatitis | 2014 |
Snapshot on drug-resistance rate and profiles in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice.
Topics: Adenine; Adult; Antiviral Agents; Cohort Studies; DNA, Viral; Drug Resistance, Viral; Female; Guanin | 2013 |
Two cases of telbivudine-induced myopathy in siblings with chronic hepatitis B.
Topics: Adult; Antiviral Agents; Creatine Kinase; Electromyography; Hepatitis B, Chronic; Humans; Male; Musc | 2013 |
Quantification of hepatitis B surface antigen and E antigen: correlation between Elecsys and architect assays.
Topics: Antiviral Agents; Genotype; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; | 2013 |
A comparison of efficacy and safety of 2-year telbivudine and entecavir treatment in patients with chronic hepatitis B: a match-control study.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Drug Res | 2014 |
Serum interleukin-37 concentrations and HBeAg seroconversion in chronic HBV patients during telbivudine treatment.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Coinfection; Female; Hepatitis B e Antigens; Hepatiti | 2013 |
Circulating chemokine (C-X-C Motif) receptor 5(+) CD4(+) T cells benefit hepatitis B e antigen seroconversion through IL-21 in patients with chronic hepatitis B virus infection.
Topics: Adolescent; Adult; Antibodies, Viral; Antiviral Agents; Biomarkers; CD4-Positive T-Lymphocytes; Cell | 2013 |
Serum hepatitis B surface antigen kinetics in severe reactivation of hepatitis B e antigen negative chronic hepatitis B patients receiving nucleoside/nucleotide analogues.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Female; Guanine; Hepatitis B e Anti | 2013 |
Serum HBV DNA level at week 12 is superior to viral response at week 24 in predicting long-term treatment outcome of telbivudine for chronic hepatitis B patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug | 2013 |
Chemokine receptor 5 (CCR5) polymorphism in chronic hepatitis B patients treated with three different nucleos(t)ide analogues.
Topics: Adenine; Alanine Transaminase; Genotype; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Homozyg | 2013 |
[Clinical efficacy of telbivudine in retreatment and native treatment of chronic hepatitis B for 24 months].
Topics: Adult; Aged; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Male; Middle Aged; Telbiv | 2013 |
On-treatment mortality predictors in chronic hepatitis B patients experiencing severe acute exacerbation: a prospective observational study.
Topics: Adult; Aged; alpha-Fetoproteins; Antiviral Agents; Bilirubin; Biomarkers; Disease Progression; Femal | 2013 |
Kinetics of Th17 cytokines during telbivudine therapy in patients with chronic hepatitis B.
Topics: Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis | 2013 |
Real-world application of the roadmap model in chronic hepatitis B patients with telbivudine therapy.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Drug Resistance, Viral; | 2013 |
Telbivudine treatment corrects HBV-induced epigenetic alterations in liver cells of patients with chronic hepatitis B.
Topics: Antiviral Agents; Case-Control Studies; Chromatin; Enhancer of Zeste Homolog 2 Protein; Epigenesis, | 2014 |
Potential benefit of telbivudine on renal function does not outweigh its high rate of antiviral drug resistance and other adverse effects.
Topics: Antiviral Agents; Female; Glomerular Filtration Rate; Hepatitis B, Chronic; Humans; Male; Renal Insu | 2014 |
Durability of efficacy after telbivudine off-treatment in chronic hepatitis B patients.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Female; Follow-Up Studies; Hepatitis B, Chronic; Humans; | 2014 |
Antiviral therapy in patients with hepatitis B virus-related hepatocellular carcinoma: is it ready for universal application?
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Hepatectomy; Hepatitis B, Chronic; Humans; Liver Neopla | 2013 |
Long-term outcomes of chronic hepatitis B virus infection in the era of antiviral therapy in Korea.
Topics: Adult; Age Factors; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Follow | 2014 |
Telbivudine protects renal function in patients with chronic hepatitis B infection in conjunction with adefovir-based combination therapy.
Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Glomerular Fi | 2014 |
Reversible phospho-Smad3 signalling between tumour suppression and fibrocarcinogenesis in chronic hepatitis B infection.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; DNA, Viral; Female; Hepatit | 2014 |
[Clinical observations of changes in serum creatine kinase during telbivudine treatment].
Topics: Adolescent; Adult; Aged; Creatine Kinase; Female; Hepatitis B, Chronic; Humans; Male; Middle Aged; R | 2013 |
TCRγδ(+)CD4(-)CD8(-) T cells suppress the CD8(+) T-cell response to hepatitis B virus peptides, and are associated with viral control in chronic hepatitis B.
Topics: Adult; Antiviral Agents; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cohort Studies; Cro | 2014 |
Telbivudine decreases proportion of peripheral blood CD4+CD25+CD127low T cells in parallel with inhibiting hepatitis B virus DNA.
Topics: Adult; Antiviral Agents; Case-Control Studies; Female; Forkhead Transcription Factors; Gene Expressi | 2014 |
Successful withdrawal of antiviral treatment in kidney transplant recipients with chronic hepatitis B viral infection.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Female; Follow-Up Studies; Guani | 2014 |
Ending vertical transmission of hepatitis B: the third trimester intervention.
Topics: Female; Hepatitis B, Chronic; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Male; P | 2014 |
A possible role for NKT-like cells in patients with chronic hepatitis B during telbivudine treatment.
Topics: Adult; Antiviral Agents; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunophenotyping; | 2014 |
An observational study to evaluate the safety and efficacy of telbivudine in adults with chronic hepatitis B.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Female; Hepatitis B Ant | 2014 |
Telbivudine therapy may shape CD4(+) T-cell response to prevent liver fibrosis in patients with chronic hepatitis B.
Topics: Adolescent; Adult; Antiviral Agents; Case-Control Studies; CD4-Positive T-Lymphocytes; Cells, Cultur | 2015 |
Efficacy of telbivudine compared with entecavir in hepatitis B virus-related cirrhosis: 2 year follow-up data.
Topics: Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug-Related Side Effects and Adverse R | 2015 |
Telbivudine plus tenofovir in combination therapy in patients with chronic hepatitis B infection--an Indian experience.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Femal | 2013 |
Comparison of telbivudine versus lamivudine in interrupting perinatal transmission of hepatitis B virus.
Topics: Adult; Antiviral Agents; DNA, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infant | 2014 |
Antiviral therapy of chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Arabinofuranosyluracil; Carcinoma, Hepatocellular; Gene Products, pol; Gu | 2014 |
Reduction of infectivity in chronic hepatitis B virus carriers among healthcare providers and pregnant women by antiviral therapy.
Topics: Adenine; Antiviral Agents; DNA, Viral; Female; Guanine; Health Personnel; Hepatitis B e Antigens; He | 2014 |
Mechanisms of hepatitis B virus resistance development.
Topics: Adenine; Amino Acid Substitution; Antiviral Agents; Deoxycytidine; Drug Resistance, Multiple, Viral; | 2014 |
Hepatitis B virus drug resistance tools: one sequence, two predictions.
Topics: Adenine; Antiviral Agents; Base Sequence; Drug Resistance, Multiple, Viral; Genotype; Guanine; Hepat | 2014 |
Antiviral efficacy analysis of telbivudine concurrent with the first cycle of chemotherapy in HBsAg-positive lymphoma patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antiviral Agents; Female; Hepatitis B Surface Antige | 2014 |
[Predictive value of HBeAg levels in telbivudine-treated chronic hepatitis B patients].
Topics: Adolescent; Adult; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Male; Middle Aged; | 2014 |
Telbivudine prophylaxis for hepatitis B virus recurrence after liver transplantation improves renal function.
Topics: Adult; Antiviral Agents; Creatinine; Female; Hepatitis B, Chronic; Humans; Lamivudine; Liver Transpl | 2014 |
The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long-term nucleos(t)ide analogue therapy.
Topics: Adenine; Adult; Antiviral Agents; Canada; Carcinoma, Hepatocellular; Female; Guanine; Hepatitis B e | 2014 |
Telbivudine is associated with improvement of renal function in patients transplanted for HBV liver disease.
Topics: Adult; Aged; Antiviral Agents; Chemoprevention; DNA, Viral; Female; Glomerular Filtration Rate; Hepa | 2015 |
Effect of Peg-interferon α-2a combined with Adefovir in HBV postpartum women with normal levels of ALT and high levels of HBV DNA.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B e Antig | 2015 |
Growth and development of children prenatally exposed to telbivudine administered for the treatment of chronic hepatitis B in their mothers.
Topics: Adult; Ankyloglossia; Antiviral Agents; Body Mass Index; Body Weight; Child Development; China; Deli | 2015 |
[Promotion of HBeAg seroconversion/loss in patients with chronic hepatitis B following the switch from nucleoside drugs to telbivudine and adefovir].
Topics: Adenine; Drug Combinations; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Nucleic Acid Synth | 2014 |
[Effect of human concentration nucleoside transporters 1 and multi-drug resistance protein 4 gene polymorphism on response of chronic hepatitis B to nucleoside analogues treatment].
Topics: Antiviral Agents; Drug Resistance, Multiple, Viral; Guanine; Hepatitis B e Antigens; Hepatitis B, Ch | 2014 |
Is there an association of hepatitis B virus infection with minimal change disease of nephrotic syndrome? A clinical observational report.
Topics: Adult; Antiviral Agents; Biopsy; Drug Monitoring; Drug Therapy, Combination; Female; Hepatitis B vir | 2015 |
The predictive value of early indicators for HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients with Telbivudine treatment for 104 weeks.
Topics: Adult; Antiviral Agents; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Male; Middle | 2015 |
Tenofovir rescue therapy in pregnant females with chronic hepatitis B.
Topics: Adenine; Adult; Antiviral Agents; Apgar Score; Biomarkers; Birth Weight; China; DNA, Viral; Drug Res | 2015 |
[Clinical observation of telbivudine's antiviral efficacy and protection against mother-to-infant transmission of chronic hepatitis B during the first trimester of pregnancy].
Topics: Antiviral Agents; DNA, Viral; Female; Hepatitis A Vaccines; Hepatitis B e Antigens; Hepatitis B Vacc | 2015 |
[Nucleoside analogues for acute-on-chronic liver failure associated with hepatitis B virus infection: a 24-month survival analysis].
Topics: Acute-On-Chronic Liver Failure; Antiviral Agents; Cohort Studies; Guanine; Hepatitis B virus; Hepati | 2015 |
Aberrant expression and dysfunction of TLR2 and its soluble form in chronic HBV infection and its regulation by antiviral therapy.
Topics: Adolescent; Adult; Antiviral Agents; Cross-Sectional Studies; Female; Gene Expression Profiling; Hep | 2015 |
Efficacy of telbivudine in the treatment of chronic hepatitis b and liver cirrhosis and its effect on immunological responses.
Topics: Adult; Aged; Antiviral Agents; Female; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Male; Middle A | 2015 |
Impact of nucleos(t)ide analogue combination therapy on the estimated glomerular filtration rate in patients with chronic hepatitis B.
Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Glomerular Filtration Rat | 2015 |
Comparison of the Effects of Telbivudine and Entecavir Treatment on Estimated Glomerular Filtration Rate in Patients with Chronic Hepatitis B.
Topics: Adult; Antiviral Agents; Diabetes Complications; Diabetes Mellitus; Drug Administration Schedule; Fe | 2015 |
Prevalence and types of drug-resistant variants in Chinese patients with acute hepatitis B.
Topics: Adenine; Adult; Antiviral Agents; China; DNA, Viral; Drug Resistance, Viral; Female; Genetic Variati | 2015 |
UPLC-MS/MS method for the simultaneous quantification of anti-HBV nucleos(t)ides analogs: Entecavir, lamivudine, telbivudine and tenofovir in plasma of HBV infected patients.
Topics: Antiviral Agents; Calibration; Chemistry Techniques, Analytical; Chromatography; Chromatography, Hig | 2015 |
Comparison of renal safety and efficacy of telbivudine, entecavir and tenofovir treatment in chronic hepatitis B patients: real world experience.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; F | 2016 |
[Efficacy and safety of telbivudine alone and combined with adefovir for the treatment of nucleos(t)ide-naive chronic hepatitis B in patients with high-level hepatitis B virus load].
Topics: Adenine; Alanine Transaminase; Drug Therapy, Combination; Hepatitis B e Antigens; Hepatitis B virus; | 2015 |
[Prevention of mother to child transmission of hepatitis B].
Topics: Adult; Antiviral Agents; Female; Hepatitis B Surface Antigens; Hepatitis B Vaccines; Hepatitis B, Ch | 2015 |
[Influence of monotherapy with telbivudine or entecavir on renal function in patients with chronic hepatitis B].
Topics: Alanine Transaminase; Antiviral Agents; Creatinine; Guanine; Hepatitis B, Chronic; Humans; Kidney; K | 2015 |
Ten-year follow-up of hepatitis B relapse after cessation of lamivudine or telbivudine treatment in chronic hepatitis B patients.
Topics: Adolescent; Adult; Antiviral Agents; DNA, Viral; Feasibility Studies; Female; Follow-Up Studies; Hep | 2015 |
A novel RRM2B gene variant associated with Telbivudine-induced mitochondrial myopathy.
Topics: Aged; Antiviral Agents; Cell Cycle Proteins; Female; Hepatitis B, Chronic; Humans; Liver Transplanta | 2015 |
Efficacy and resistance to telbivudine treatment in chronic hepatitis B patients with favorable predictors: a multicenter study in Taiwan.
Topics: Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B e Antigens; H | 2016 |
Long-term follow-up of HBsAg-positive patients in Germany.
Topics: Adenine; Adult; Age Factors; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Drug Therapy, | 2016 |
[The safety of telbivudine in preventing mother-to-infant transmission of hepatitis B virus in pregnant women after discontinuation].
Topics: Adult; Antiviral Agents; DNA, Viral; Female; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, C | 2015 |
Use of telbivudine in kidney transplant recipients with chronic hepatitis B virus infection: A preliminary experience.
Topics: Allografts; Antiviral Agents; Biomarkers; DNA, Viral; Hepatitis B Surface Antigens; Hepatitis B viru | 2016 |
A comparison of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive patients: a prospective cohort study in China.
Topics: Adult; Aged; Antiviral Agents; Biomarkers; China; Female; Follow-Up Studies; Guanine; Hepatitis B; H | 2016 |
Cumulative incidence and risk factors of creatine kinase elevation associated with telbivudine.
Topics: Adult; Aged; Antiviral Agents; Creatine Kinase; Female; Glomerular Filtration Rate; Hepatitis B, Chr | 2016 |
Comparison of efficacy and renal safety of telbivudine and entecavir in treatment-naive elderly patients with chronic hepatitis B.
Topics: Age Factors; Aged; Biomarkers; DNA, Viral; Drug Resistance, Neoplasm; Female; Glomerular Filtration | 2016 |
Comprehensive analysis of hospital-based prospective cohort reveals the unique effectiveness and safety for nucleos(t)ide analogues in HBV patients.
Topics: Adenine; Adult; Antiviral Agents; Female; Guanine; Hepatitis B, Chronic; Hospitalization; Humans; La | 2016 |
Composition and Interactions of Hepatitis B Virus Quasispecies Defined the Virological Response During Telbivudine Therapy.
Topics: Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B Surface Antigens; H | 2015 |
Nephrotoxicity caused by oral antiviral agents in patients with chronic hepatitis B treated in a hospital for tropical diseases in Thailand.
Topics: Adenine; Adult; Antiviral Agents; Creatinine; Female; Follow-Up Studies; Guanine; Hepatitis B, Chron | 2015 |
[Efficacy of combination antiviral therapy following childbirth in pregnant HBV carriers receiving telbivudine for prevention of mother-to-child transmission].
Topics: Adenine; Alanine Transaminase; Antiviral Agents; Carrier State; DNA, Viral; Drug Therapy, Combinatio | 2015 |
Off-treatment efficacy of 3-year nucleos(t)ide analogues in chronic hepatitis B patients.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; Female; Guanine; Hepatitis B, Chronic; Human | 2016 |
COLD-PCR for early detection of hepatitis B virus antiviral drug resistance mutations.
Topics: Antiviral Agents; Cold Temperature; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; | 2015 |
[Drug-resistant mutations in hepatitis B virus found in chronic HBV carriers using PCR sequencing technology].
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Genotype; Guanine; Hepatitis B virus; | 2016 |
Efficacy and safety of tenofovir, entecavir, and telbivudine for chronic hepatitis B in heart transplant recipients.
Topics: Adult; Aged; Antiviral Agents; Cohort Studies; DNA, Viral; Female; Follow-Up Studies; Guanine; Heart | 2016 |
[Effect of IL-28B polymorphisms on the natural course of HBV infection].
Topics: Adult; Antiviral Agents; Carrier State; Female; Guanine; Hepatitis B, Chronic; Humans; Interferons; | 2016 |
Comparison of clinical efficacy and renal safety of telbivudine and entecavir in chronic hepatitis B patients receiving cytotoxic chemotherapy.
Topics: Aged; Antineoplastic Agents; Antiviral Agents; DNA, Viral; Female; Glomerular Filtration Rate; Guani | 2016 |
Telbivudine versus lamivudine and entecavir for treatment-naïve decompensated hepatitis B virus-related cirrhosis.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug-Related Side Effects and Adver | 2017 |
Hepatic flare after telbivudine withdrawal and efficacy of postpartum antiviral therapy for pregnancies with chronic hepatitis B virus.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Drug Administration Schedule; Female; Follow-Up Studi | 2017 |
Elevated serum interleukin-38 level at baseline predicts virological response in telbivudine-treated patients with chronic hepatitis B.
Topics: Administration, Oral; Adult; Antiviral Agents; Biomarkers; Case-Control Studies; DNA, Viral; Drug Ad | 2016 |
Cost-effectiveness analysis of tenofovir disoproxil fumarate for treatment of chronic hepatitis B in China.
Topics: Adenine; Antiviral Agents; Cost-Benefit Analysis; Female; Guanine; Hepatitis B, Chronic; Humans; Lam | 2016 |
Comparative effectiveness of nucleos(t)ide analogues in chronic hepatitis B patients undergoing cytotoxic chemotherapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antiviral Agents; Cytotoxins; Fem | 2016 |
[HBsAg clearance rate in patients with HBeAg-positive chronic hepatitis B: a comparative effect analysis based on the real world].
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis | 2016 |
Small surface antigen variants of HBV associated with responses to telbivudine treatment in chronic hepatitis B patients.
Topics: Adult; Antiviral Agents; DNA Mutational Analysis; DNA, Viral; Drug Resistance, Viral; Female; Geneti | 2017 |
Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Biopsy; DNA, Circular; DNA, Viral; Female; Hepatitis B virus; Hepatitis B | 2017 |
Long-term outcomes of hepatitis B virus-related cirrhosis treated with nucleos(t)ide analogs.
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Female; Guanine; Hepatitis B, Chronic; Hum | 2017 |
Telbivudine treatment of hepatitis B virus-infected pregnant women at different gestational stages for the prevention of mother-to-child transmission: Outcomes of telbivudine treatment during pregnancy.
Topics: Adult; Antiviral Agents; Cohort Studies; Drug Administration Schedule; Female; Hepatitis B, Chronic; | 2016 |
Comparison of the Efficacies and Safety of Combined Therapy between Telbivudine Plus Adefovir and Lamivudine Plus Adefovir in Patients with Hepatitis B Virus Infection in Real-World Practice.
Topics: Adenine; Adult; Biomarkers; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Hepatitis | 2016 |
DNMT1 modulation in chronic hepatitis B patients and hypothetic influence on mitochondrial DNA methylation status during long-term nucleo(t)side analogs therapy.
Topics: Adenine; Aged; Antiviral Agents; Cross-Sectional Studies; Cytosine; DNA (Cytosine-5-)-Methyltransfer | 2017 |
Long-term safety and efficacy of telbivudine in infants born to mothers treated during the second or third trimesters of pregnancy.
Topics: Adult; Antiviral Agents; Child, Preschool; Drug-Related Side Effects and Adverse Reactions; Female; | 2017 |
Anti-HBV drugs suppress the growth of HBV-related hepatoma cells via down-regulation of hepatitis B virus X protein.
Topics: Animals; Antiviral Agents; Carcinoma, Hepatocellular; Cell Proliferation; DNA Replication; DNA, Vira | 2017 |
[Chinese roadmap for treating chronic hepatitis B with telbivudine].
Topics: Antiviral Agents; Hepatitis B, Chronic; Humans; Nucleosides; Pyrimidinones; Telbivudine; Thymidine | 2008 |
Clinical features of adverse reactions associated with telbivudine.
Topics: Adult; Arrhythmias, Cardiac; Creatine Kinase; Drug Synergism; Hepatitis B, Chronic; Humans; Interfer | 2008 |
Programmed death 1 expression during antiviral treatment of chronic hepatitis B: Impact of hepatitis B e-antigen seroconversion.
Topics: Adult; Alanine Transaminase; Antigens, CD; Antiviral Agents; Apoptosis Regulatory Proteins; Biopsy; | 2008 |
[New treatment of chronic hepatitis B].
Topics: Antiviral Agents; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Pyrimidinones; Reverse Tran | 2008 |
[The effect of telbivudine on peripheral blood CD4+CD25+ regulatory T cells and its significance in patients with chronic hepatitis B].
Topics: Adolescent; Adult; Antiviral Agents; Case-Control Studies; Female; Hepatitis B e Antigens; Hepatitis | 2008 |
Telbivudine has activity against HIV-1.
Topics: Anti-HIV Agents; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nucleosides | 2009 |
[Methodical recommendations of Asian-Pacific Association for Studying the Liver (APASL) concerning treatment of the viral hepatitis B (HBV)].
Topics: Antiviral Agents; Asia; Drug Therapy, Combination; Guanine; Hepatitis B, Chronic; Humans; Interferon | 2008 |
[Dynamic changes of Th1/Th2 type cytokines in peripheral blood of patients with hepatitis B e antigen-positive chronic hepatitis B treated with telbivudine].
Topics: Adult; Antiviral Agents; DNA, Viral; Female; Flow Cytometry; Hepatitis B e Antigens; Hepatitis B vir | 2009 |
Perspectives on the management of chronic hepatitis B and C.
Topics: Antiviral Agents; Enzyme Inhibitors; Hepacivirus; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis | 2009 |
Anti-hepatitis B virus activity in vitro of combinations of tenofovir with nucleoside/nucleotide analogues.
Topics: Adenine; Antiviral Agents; Cell Line; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug | 2009 |
Treatment with nucleos(t)ide analogues in chronic hepatitis B: where does the road map lead us?
Topics: Antiviral Agents; DNA, Viral; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Nucleosides; Pyr | 2009 |
[Symposium on clinical application of telbivudine].
Topics: Antiviral Agents; Congresses as Topic; DNA, Viral; Hepatitis B e Antigens; Hepatitis B, Chronic; Hum | 2009 |
Different models of HBeAg seroconversion predicated by on-treatment ALT and HBV DNA profiles.
Topics: Adenine; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Female; Follow-Up Studies; | 2009 |
[Pharmacoeconomic evaluation of telbivudine vs. lamivudine in treating the patients with HBeAg-positive and negative chronic hepatitis B].
Topics: Adult; Antifungal Agents; China; Cost-Benefit Analysis; DNA, Viral; Drug Costs; Economics, Pharmaceu | 2009 |
Hepatitis B in HIV patients: what is the current treatment and what are the challenges?
Topics: Adenine; Antiviral Agents; Deoxycytidine; DNA, Viral; Drug Therapy, Combination; Emtricitabine; Guan | 2009 |
[Telbivudine in the management of HIV/HBV coinfection. Treating hepatitis B without HIV trouble].
Topics: Adenine; AIDS-Related Opportunistic Infections; Algorithms; Anti-HIV Agents; Antiviral Agents; Comor | 2009 |
Telbivudine in the treatment of chronic hepatitis B: experience in HIV type-1-infected patients naive for antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Antiviral Agents; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Male; | 2009 |
[The efficacy of nucleoside/nucleotide analogue on chronic hepatitis B].
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Guanine; Hepatitis B e Antigens; Hepa | 2009 |
[Preliminary clinical study of efficacy on re-treatment for interferon suboptimal CHB patients].
Topics: Administration, Oral; Adult; Alanine Transaminase; DNA, Viral; Female; Hepatitis B e Antigens; Hepat | 2009 |
On-treatment serum HBsAg level is predictive of sustained off-treatment virologic response to telbivudine in HBeAg-positive chronic hepatitis B patients.
Topics: Adolescent; Adult; Antiviral Agents; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B Surface | 2010 |
Telbivudine exhibits no inhibitory activity against HIV-1 clinical isolates in vitro.
Topics: Anti-HIV Agents; Antiviral Agents; Drug Resistance, Viral; Guanine; Hepatitis B virus; Hepatitis B, | 2010 |
Cost-effectiveness analysis of roadmap models in chronic hepatitis B using tenofovir as the rescue therapy.
Topics: Adenine; Antiviral Agents; Asia; Cost-Benefit Analysis; Decision Support Techniques; DNA, Viral; Dru | 2010 |
Cost-effectiveness of nucleoside analog therapy for hepatitis B in China: a Markov analysis.
Topics: Adenine; Antiviral Agents; China; Cost-Benefit Analysis; Guanine; Hepatitis B e Antigens; Hepatitis | 2010 |
[Icteric hepatitis in a patient with non-Hodgkin's lymphoma treated by rituximab-based chemotherapy].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Antiviral Ag | 2010 |
Dynamic analysis of CD127 expression on memory CD8 T cells from patients with chronic hepatitis B during telbivudine treatment.
Topics: Adult; Antiviral Agents; CD8-Positive T-Lymphocytes; DNA, Viral; Female; Gene Expression Profiling; | 2010 |
Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients.
Topics: Adult; Antiviral Agents; Body Weight; Enzyme-Linked Immunosorbent Assay; Genotype; Hepatitis B Core | 2010 |
Telbivudine: rhabdomyolysis and neuropathy.
Topics: Antiviral Agents; Hepatitis B, Chronic; Humans; Nucleosides; Peripheral Nervous System Diseases; Pyr | 2010 |
[Programmed death-1 (PD-1) and PD-L1 expression during antiviral treatment of chronic hepatitis B].
Topics: Adult; Antiviral Agents; B7-H1 Antigen; CD8-Positive T-Lymphocytes; Female; Hepatitis B e Antigens; | 2010 |
[A study on the factors correlated to virological response in chronic hepatitis B patients with telbivudine treatment].
Topics: Adolescent; Adult; Antiviral Agents; DNA, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Hu | 2010 |
[Analogs combination therapy in chronic hepatitis B: when and how?].
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; Hepatitis B, | 2010 |
[Long-term therapy for chronic hepatitis B in HIV co-infected patients].
Topics: Adenine; Antiretroviral Therapy, Highly Active; Antiviral Agents; Deoxycytidine; Drug Resistance, Vi | 2010 |
Significance of HBV DNA levels at 12 weeks of telbivudine treatment and the 3 years treatment outcome.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug | 2011 |
Profile of HBV antiviral resistance mutations with distinct evolutionary pathways against nucleoside/nucleotide analogue treatment among Chinese chronic hepatitis B patients.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; China; Cross-Sectional Studie | 2010 |
Treatment of HBeAg-negative chronic hepatitis B patients with nucleos(t)ide analogues.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; | 2011 |
Correlation between the Elecsys HBsAg II assay and the Architect assay for the quantification of hepatitis B surface antigen (HBsAg) in the serum.
Topics: Clinical Laboratory Techniques; Drug Resistance, Viral; Genotype; Hepatitis B e Antigens; Hepatitis | 2011 |
Genotypic resistance profile of hepatitis B virus (HBV) in a large cohort of nucleos(t)ide analogue-experienced Chinese patients with chronic HBV infection.
Topics: Adenine; Adult; Amino Acid Substitution; Antiviral Agents; China; DNA, Viral; Drug Resistance, Viral | 2011 |
Treatment of chronic hepatitis B with telbivudine: wise hepatologists needed in hepatitis B endemic countries where treatment options are limited.
Topics: Antiviral Agents; Biomarkers; DNA, Viral; Drug Resistance, Viral; Drug Substitution; Endemic Disease | 2011 |
[New insight for HBV DNA and HBsAg quantitation during antiviral therapy in patients with chronic hepatitis B].
Topics: Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Hepatitis B Surface Antigens; Hepatitis B v | 2011 |
Effect of telbivudine therapy on the cellular immune response in chronic hepatitis B.
Topics: Adult; Alanine Transaminase; Antiviral Agents; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Cytokines; | 2011 |
Two patterns of alanine aminotransferase increase to predict long-term viral response in chronic hepatitis B patients: virus- or host-induced?
Topics: Adenine; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Female; Guanine; Hepacivir | 2011 |
HBV treatment and pregnancy.
Topics: Female; Hepatitis B, Chronic; Humans; Infectious Disease Transmission, Vertical; Male; Nucleosides; | 2011 |
Effects of antiviral therapy with Telbivudine on peripheral iNKT cells in HBeAg(+) chronic hepatitis B patients.
Topics: Adult; Antiviral Agents; Female; Gene Expression Profiling; Hepatitis B e Antigens; Hepatitis B, Chr | 2012 |
Telbivudine exerts no antiviral activity against HIV-1 in vitro and in humans.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Cell Line; Coinfection; DNA, Viral; Drug Resistance, | 2011 |
Clinical features and risk factors of creatine kinase elevations and myopathy associated with telbivudine.
Topics: Adolescent; Adult; Age Distribution; Aged; Antiviral Agents; Creatine Kinase; Female; Hepatitis B, C | 2011 |
[New drugs of treatment of patients with chronic hepatitis B].
Topics: Adenine; Antiviral Agents; Arabinofuranosyluracil; Deoxycytidine; Emtricitabine; Hepatitis B, Chroni | 2011 |
A comparison of telbivudine and entecavir for chronic hepatitis B in real-world clinical practice.
Topics: Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Guanine; | 2012 |
Restored circulating invariant NKT cells are associated with viral control in patients with chronic hepatitis B.
Topics: Adult; Case-Control Studies; CD4-Positive T-Lymphocytes; Cell Movement; Cytokines; Female; Hepatitis | 2011 |
Uncover the immune biomarkers underlying hepatitis B e antigen (HBeAg) seroconversion: a need for more translational study.
Topics: Antiviral Agents; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interleukins; Male; | 2012 |
Telbivudine improves the function of myeloid dendritic cells in patients with chronic hepatitis B.
Topics: Adult; Antigens, CD; Antiviral Agents; B7-H1 Antigen; Cells, Cultured; Dendritic Cells; Down-Regulat | 2012 |
Telbivudine myopathy in a patient with chronic hepatitis B.
Topics: Adult; Antiviral Agents; Hepatitis B, Chronic; Humans; Male; Muscular Diseases; Telbivudine; Thymidi | 2012 |
Effects of telbivudine treatment on the circulating CD4⁺ T-cell subpopulations in chronic hepatitis B patients.
Topics: Adult; Antiviral Agents; Case-Control Studies; CD4-Positive T-Lymphocytes; Cytokines; Female; Hepati | 2012 |
[Influence of adefovir dipivoxil or telbivudine monotherapy on renal function of patients with chronic hepatitis B].
Topics: Adenine; Adolescent; Adult; Creatinine; Female; Glomerular Filtration Rate; Hepatitis B, Chronic; Hu | 2012 |
Current practice of chronic hepatitis B treatment in Southern Italy.
Topics: Adenine; Adult; Age Factors; Aged; Aged, 80 and over; Antiviral Agents; Female; Guanine; Hepatitis B | 2012 |
Acute liver failure resulting from discontinuation of nucleoside analogues in chronic hepatitis B patients: a report of two cases.
Topics: Adenine; Adult; Antiviral Agents; Guanine; Hepatitis B, Chronic; Histocytochemistry; Humans; Lamivud | 2013 |
The 2012 revised Dutch national guidelines for the treatment of chronic hepatitis B virus infection.
Topics: Adenine; Antiviral Agents; Drug Approval; Drug Resistance, Viral; Female; Guanine; Hepatitis B, Chro | 2012 |
Telbivudine in the treatment of hepatitis B-associated cryoglobulinemia.
Topics: Aged; Alanine Transaminase; Antiviral Agents; CD4-CD8 Ratio; Cryoglobulinemia; Cryoglobulins; DNA, V | 2013 |
[Telbivudine-associated creatine kinase elevation in chronic hepatitis B patients].
Topics: Adolescent; Adult; Aged; Antiviral Agents; Creatine Kinase; Hepatitis B, Chronic; Humans; Middle Age | 2012 |
Treatment with telbivudine positively regulates antiviral immune profiles in Chinese patients with chronic hepatitis B.
Topics: Administration, Oral; Adult; Alanine Transaminase; Antigens, CD; Antiviral Agents; Asian People; Asp | 2013 |
Kinetics and prediction of HBsAg loss during therapy with analogues in patients affected by chronic hepatitis B HBeAg negative and genotype D.
Topics: Adenine; Aged; Antiviral Agents; Biomarkers; Chi-Square Distribution; DNA, Viral; Female; Genotype; | 2013 |
Telbivudine (Tyzeka) for chronic Hepatitis B.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Resistance, Viral; Hepatitis B, Chronic; Humans; Nu | 2007 |
Telbivudine.
Topics: Antiviral Agents; Enzyme Inhibitors; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepat | 2007 |
Drug profile: telbivudine (Tyzeka).
Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Resistance, Viral; Hepatitis B, Chronic; Hu | 2007 |
[New first line therapy of chronic hepatitis B. Primary therapy goal: effective virus suppression].
Topics: Antiviral Agents; Clinical Trials as Topic; DNA, Viral; Hepatitis B virus; Hepatitis B, Chronic; Hum | 2007 |
[Treatment in every detected virus replication. New guideline for therapy of hepatitis B publicized].
Topics: Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; Human | 2007 |
Summaries for patients. Antiviral therapy for chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Biomarkers; DNA, Viral; Drug Therapy, Combinatio | 2007 |
[Anti-viral therapy of type B chronic hepatitis. 3. Future of anti-viral agents].
Topics: Adenine; Antiviral Agents; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Hepatitis B, Chroni | 2008 |
Telbivudine versus lamivudine in patients with chronic hepatitis B.
Topics: Antiviral Agents; Drug Resistance, Viral; Genotype; Hepatitis B virus; Hepatitis B, Chronic; Humans; | 2008 |
Nonclinical safety profile of telbivudine, a novel potent antiviral agent for treatment of hepatitis B.
Topics: Administration, Oral; Animals; Antiviral Agents; Carcinogenicity Tests; Dose-Response Relationship, | 2008 |